<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002907" GROUP_ID="LIVER" ID="846100020911394125" MERGED_FROM="" MODIFIED="2010-08-04 18:02:03 +0200" MODIFIED_BY="[Empty name]" REVIEW_NO="01" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.2">
<COVER_SHEET MODIFIED="2010-08-05 00:49:20 +0200" MODIFIED_BY="Norberto Chavez-Tapia">
<TITLE MODIFIED="2010-07-09 14:23:25 +0200" MODIFIED_BY="[Empty name]">Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding</TITLE>
<CONTACT>
<PERSON ID="4DD5730482E26AA201BA4B54069A499E" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Norberto</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Chavez-Tapia</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>khavez@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Medica Sur Clinic &amp; Foundation</ORGANISATION>
<ADDRESS_1>Puente de Piedra 150</ADDRESS_1>
<ADDRESS_2/>
<CITY>Mexico City</CITY>
<ZIP>14050</ZIP>
<REGION/>
<COUNTRY CODE="MX">Mexico</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-08-05 00:49:20 +0200" MODIFIED_BY="Norberto Chavez-Tapia">
<PERSON ID="4DD5730482E26AA201BA4B54069A499E" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Norberto</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Chavez-Tapia</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>khavez@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Medica Sur Clinic &amp; Foundation</ORGANISATION>
<ADDRESS_1>Puente de Piedra 150</ADDRESS_1>
<ADDRESS_2/>
<CITY>Mexico City</CITY>
<ZIP>14050</ZIP>
<REGION/>
<COUNTRY CODE="MX">Mexico</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="BAF0B2F882E26AA2004627991531378C" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tonatiuh</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Barrientos-Gutierrez</LAST_NAME>
<SUFFIX/>
<POSITION>Medical Sciences Researcher</POSITION>
<EMAIL_1>tonatiuhb@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Tobacco Research Department</DEPARTMENT>
<ORGANISATION>National Institute of Public Health</ORGANISATION>
<ADDRESS_1>7a Cerrada de Fray Pedro de Gante #50</ADDRESS_1>
<ADDRESS_2>Col Seccion XVI, Tlalpan</ADDRESS_2>
<CITY>Mexico City</CITY>
<ZIP>14000</ZIP>
<REGION>Mexico City</REGION>
<COUNTRY CODE="MX">Mexico</COUNTRY>
<PHONE_1/>
<PHONE_2>(52)5554871015</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="BAF0AE0682E26AA2004627994FFA88F2" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Felix</FIRST_NAME>
<MIDDLE_INITIALS>I</MIDDLE_INITIALS>
<LAST_NAME>Tellez-Avila</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>felixtelleza@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Gastroenterology</DEPARTMENT>
<ORGANISATION>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Mexico City</CITY>
<ZIP>1400</ZIP>
<REGION>Distrito Federal</REGION>
<COUNTRY CODE="MX">Mexico</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12341" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Karla</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Soares-Weiser</LAST_NAME>
<SUFFIX>MD, PhD</SUFFIX>
<POSITION>Director</POSITION>
<EMAIL_1>karla@enhance-reviews.com</EMAIL_1>
<EMAIL_2>ksoares@netvision.net.il</EMAIL_2>
<URL>www.enhance-reviews.com</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Enhance Reviews Ltd</ORGANISATION>
<ADDRESS_1>5 Percy Street, Office 4</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>W1T 1DG</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 20 8123 6785</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="BAF0B1B082E26AA2004627999AF29DE3" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Misael</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Uribe</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>muribe@medicasur.org.mx</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Gastroenterology</DEPARTMENT>
<ORGANISATION>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán</ORGANISATION>
<ADDRESS_1>Vasco de Quiroga #15. Seccion XVI. Del. Tlalpan</ADDRESS_1>
<ADDRESS_2/>
<CITY>Mexico City</CITY>
<ZIP>14000</ZIP>
<REGION/>
<COUNTRY CODE="MX">Mexico</COUNTRY>
<PHONE_1>+52 5555733418</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2010-08-04 21:40:56 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UP_TO_DATE>
<DATE DAY="30" MONTH="6" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="21" MONTH="6" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="29" MONTH="9" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2002"/>
</DATES>
<WHATS_NEW MODIFIED="2010-08-04 11:39:59 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2010-08-04 11:39:59 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="8" YEAR="2010"/>
<DESCRIPTION>
<P>Six new trials were added to the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-08-03 12:21:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="29" MONTH="6" YEAR="2010"/>
<DESCRIPTION>
<P>This review was updated: the list of authors was changed, six new trials were included, the Background section was changed, the Methods section was modified according the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>), the discussion was modified.</P>
<P>The primary outcomes were arranged to include quality of life and adverse events as primary outcomes in concordance with the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-08-03 09:58:45 +0200" MODIFIED_BY="Dimitrinka Nikolova"/>
<SOURCES_OF_SUPPORT MODIFIED="2010-07-07 17:41:21 +0200" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2010-07-07 17:41:21 +0200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-07-07 17:41:21 +0200" MODIFIED_BY="[Empty name]">
<NAME>Medica Sur Clinic &amp; Foundation</NAME>
<COUNTRY CODE="MX">Mexico</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-08-04 21:41:53 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SUMMARY MODIFIED="2010-08-04 21:36:46 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2010-07-27 17:43:24 +0200" MODIFIED_BY="[Empty name]">Antibiotic prophylaxis for prevention of bacterial infections and death in cirrhotic patients with upper gastrointestinal bleeding</TITLE>
<SUMMARY_BODY MODIFIED="2010-08-04 21:36:46 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Patients with liver cirrhosis have an impaired immune response. Often, liver cirrhosis patients experience complications from portal hypertension, such as gastroesophageal varices. These varices can bleed, increasing the risk of infection and death in a short period of time, despite proper endoscopic management. Patients who develop bacterial infections during hospitalisation for gastroesophageal haemorrhage are at increased risk of dying. Twelve trials (1241 patients) assessing several antibiotic prophylaxis regimens versus no intervention or placebo were analysed, showing that antibiotic prophylaxis successfully reduced the incidence of bacterial infections. Antibiotic prophylaxis was also associated with a reduction in mortality, mortality from bacterial infections, rebleeding rate, and days of hospitalisation. The prophylactic treatment was not associated with important adverse effects. Five trials (650 patients) assessed one antibiotic regimen compared with another. All antibiotic regimens provided similar benefits and none seemed superior. Thus, to this point there is no evidence to recommend one specific antibiotic regimen over the other. All trials analysed were subject to bias; thus, results should be interpreted carefully.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-08-04 11:41:50 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-07-27 17:42:27 +0200" MODIFIED_BY="[Empty name]">
<P>Bacterial infections are a frequent complication in patients with cirrhosis and upper gastrointestinal bleeding. Antibiotic prophylaxis seems to decrease the incidence of bacterial infections. Oral antibiotics, active against enteric bacteria, have been commonly used as antibiotic prophylaxis in patients with cirrhosis and upper gastrointestinal bleeding. This is an update of a Cochrane review first published in 2002.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-07-09 14:20:50 +0200" MODIFIED_BY="[Empty name]">
<P>To assess the benefits and harms of antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-08-04 11:41:50 +0200" MODIFIED_BY="[Empty name]">
<P>We searched <I>The Cochrane Hepato-Biliary Group Controlled Trials Register</I>, <I>The Cochrane Central Register of Controlled Trials </I>(<I>CENTRAL</I>) in <I>The Cochrane Library</I>, <I>MEDLINE</I>, <I>EMBASE</I>, and <I>Science Citation Index EXPANDED</I> until June 2010. In addition, we handsearched the references of all identified studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-07-26 18:57:22 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trials comparing different types of antibiotic prophylaxis with no intervention, placebo, or another antibiotic to prevent bacterial infections in cirrhotic patients with upper gastrointestinal bleeding.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-07-06 16:18:43 +0200" MODIFIED_BY="[Empty name]">
<P>Three authors independently assessed trial quality, risk of bias, and extracted data. We contacted study authors for additional information. Association measures were relative risk (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-08-04 16:08:33 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Twelve trials (1241 patients) evaluated antibiotic prophylaxis compared with placebo or no antibiotic prophylaxis. All trials were at risk of bias. Antibiotic prophylaxis compared with no intervention or placebo was associated with beneficial effects on mortality (RR 0.79, 95% CI 0.63 to 0.98), mortality from bacterial infections (RR 0.43, 95% CI 0.19 to 0.97), bacterial infections (RR 0.36, 95% CI 0.27 to 0.49), rebleeding (RR 0.53, 95% CI 0.38 to 0.74), days of hospitalisation (MD -1.91, 95% CI -3.80 to -0.02), bacteraemia (RR 0.25, 95% CI 0.15 to 0.40), pneumonia (RR 0.45, 95% CI 0.27 to 0.75), spontaneous bacterial peritonitis (RR 0.29, 95% CI 0.15 to 0.57), and urinary tract infections (RR 0.23, 95% CI 0.12 to 0.41). No serious adverse events were reported. The trials showed no significant heterogeneity of effects. Another five trials (650 patients) compared different antibiotic regimens. Data could not be combined as each trial used different antibiotic regimen. None of the examined antibiotic regimen was superior to the control regimen regarding mortality or bacterial infections.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-08-03 10:11:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Prophylactic antibiotic use in patients with cirrhosis and upper gastrointestinal bleeding significantly reduced bacterial infections, and seems to have reduced all-cause mortality, bacterial infection mortality, rebleeding events, and hospitalisation length. These benefits were observed independently of the type of antibiotic used; thus, no specific antibiotic can be preferred. Therefore, antibiotic selection should be made considering local conditions such as bacterial resistance profile and treatment cost.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-08-04 11:40:57 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-08-04 16:10:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<CONDITION MODIFIED="2010-08-04 16:10:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Chronic liver diseases are characterised by important changes on hepatic physiology with portal hypertension being their haemodynamic expression. The presence of clinically significant portal hypertension (portal pressure gradient &#8805;10 mmHg) promotes the formation of collateral portosystemic circulation, portal hypertensive gastropathy, gastric varices, and oesophageal varices (<LINK REF="REF-Bosch-2009" TYPE="REFERENCE">Bosch 2009</LINK>).</P>
<P>Bleeding, secondary to oesophageal or gastro-oesophageal varices, is observed in up to 30% of the patients with liver cirrhosis during the course of their illness, recurring in 70% of the patients and being fatal in 20% (<LINK REF="REF-NIEC-1988" TYPE="REFERENCE">NIEC 1988</LINK>). The highest mortality peak is observed during the first six weeks after the bleeding episode (<LINK REF="REF-Burroughs-2009" TYPE="REFERENCE">Burroughs 2009</LINK>). Hepatic functional status (assessed by Child-Pugh score), renal dysfunction (assessed by creatinine serum levels), and bacterial infections are the most important mortality risk factors (<LINK REF="REF-Augustin-2009" TYPE="REFERENCE">Augustin 2009</LINK>). Consequently, guidelines for treatment of patients suffering variceal gastrointestinal bleeding include volume expansion, haemorrhage control, use of vasoconstrictors, and short-term antibiotic prophylaxis (<LINK REF="REF-Garcia_x002d_Tsao-2009" TYPE="REFERENCE">Garcia-Tsao 2009</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2010-08-03 10:15:23 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The prophylactic use of oral or intravenous antibiotics has been recommended in several consensus guidelines. The recommended drugs are mainly oral quinolones (norfloxacin 400 mg b.i.d for 7 days) or intravenous cephalosporins (ceftriaxone 1 g/day for 7 days) (<LINK REF="REF-Garcia_x002d_Tsao-2009" TYPE="REFERENCE">Garcia-Tsao 2009</LINK>). However, other groups of antibiotics have been assessed such as beta-lactams or aminoglycosides (<LINK REF="REF-Bernard-1999" TYPE="REFERENCE">Bernard 1999</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2010-08-03 10:15:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Cirrhosis is characterised by cellular and humoral immune dysfunction as well as increased bacterial translocation from the gut into the bloodstream, facilitating the development of infections (<LINK REF="REF-Chavez_x002d_Tapia-2007" TYPE="REFERENCE">Chavez-Tapia 2007</LINK>). The  most  common  bacterial infections are caused by gram-negative bacteria, producing spontaneous bacterial peritonitis (25%), urinary tract infections (20%), pneumonia (15%), and bacteraemia (12%) (<LINK REF="REF-Fernandez-2002" TYPE="REFERENCE">Fernandez 2002</LINK>). Considering the increased mortality associated with infections, the vulnerability of the immune system and the bacteriological profile, the use of antibiotics is recommended.</P>
</THEORY>
<IMPORTANCE MODIFIED="2010-08-03 10:17:08 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Prophylactic use of antibiotics during an episode of upper gastrointestinal bleeding in cirrhotic patients is considered standard of care. However, differences in the antibiotics used, schedules of administration, duration of therapy, and changes in the bacteriological profile across clinical trials make the evaluation of this intervention difficult. This review systematically assesses these issues and updates the information from a previous published review (<LINK REF="REF-Soares_x002d_Weiser-2002" TYPE="REFERENCE">Soares-Weiser 2002</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-08-04 16:10:56 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>To assess the benefits and harms of antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding.</LI>
</UL>
<P>Specifically this review was designed to:</P>
<UL>
<LI>Compare the all-cause mortality and infection mortality between cirrhotic patients with gastrointestinal bleeding receiving antibiotic prophylaxis or no intervention/placebo.</LI>
<LI>Compare the proportion of bacterial infections in patients with gastrointestinal bleeding receiving antibiotic prophylaxis versus no intervention/placebo.</LI>
<LI>Determine the most effective antibiotic regimen.</LI>
</UL>
</OBJECTIVES>
<METHODS MODIFIED="2010-08-04 11:40:28 +0200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-08-04 16:11:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<CRIT_STUDIES MODIFIED="2010-08-03 10:28:31 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trials comparing different types of antibiotic therapy against no intervention, or placebo, or another antibiotic, in the prophylaxis of bacterial infections in cirrhotic patients with upper gastrointestinal bleeding were identified. Trials were included irrespective of publication status, language, or blinding.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-07-09 14:21:41 +0200" MODIFIED_BY="[Empty name]">
<P>Adult patients with cirrhosis and upper gastrointestinal bleeding were included, regardless of the aetiology of cirrhosis or severity of the disease.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-08-04 16:11:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The following interventions, used alone or in combination, and regardless of the mode of administration (intravenous or oral), were considered.</P>
<UL>
<LI>Aminoglycosides (eg, gentamicin, neomycin, tobramycin);</LI>
<LI>Amoxicillin with or without clavulanic acid;</LI>
<LI>Cephalosporins (eg, cefotaxime, ceftriaxone, ceftazidime, cefonicid);</LI>
<LI>Quinolones (eg, ciprofloxacin, ofloxacin, norfloxacin);</LI>
<LI>Trimethoprim/sulphamethoxazole;</LI>
<LI>Non-absorbable antibiotics (eg, colistin, nystatin);</LI>
<LI>Other antibiotics.</LI>
</UL>
<P>Control groups received no intervention, placebo, or any antibiotic.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-08-04 14:57:39 +0200" MODIFIED_BY="[Empty name]">
<P>Primary outcome measures:</P>
<UL>
<LI>Number of deaths;</LI>
<LI>Number of patients that developed bacterial infections (bacteraemia, pneumonia, urinary tract infection, spontaneous bacterial peritonitis, and/or other bacterial infections);</LI>
<LI>Quality of life score (measured by any scale) between groups;</LI>
<LI>Adverse events (<LINK REF="REF-ICH_x002d_GCP-1997" TYPE="REFERENCE">ICH-GCP 1997</LINK>):</LI>
</UL>
<UL>
<OL>
<LI>Any serious adverse events that were fatal, life-threatening, or requiring inpatient hospitalisation or prolongation of existing hospitalisation;</LI>
<LI>Any adverse events that resulted in significant disability or incapacity;</LI>
<LI>Any important medical events that might not be immediately life-threatening or resulted in death or hospitalisation, but might jeopardise the patient or required intervention to prevent one of the above outcomes;</LI>
<LI>Any adverse events that required discontinuation of medication.</LI>
</OL>
</UL>
<P>Secondary outcome measures:</P>
<UL>
<LI>Number of patients who developed bacterial infections after an invasive procedure to stop upper gastrointestinal bleeding;</LI>
<LI>Number of patients who developed superinfection or antibiotic resistance in at least one of the follow-up cultures;</LI>
<LI>Number of patients who developed rebleeding during the follow-up (overall rebleeding rate and up to seven days rate);</LI>
<LI>Number of patients who dropped out from the trial after randomisation;</LI>
<LI>Cost of different types of antibiotics used for prophylaxis;</LI>
<LI>Number of days of hospitalisation.</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-08-04 11:40:23 +0200" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2010-08-04 11:40:23 +0200" MODIFIED_BY="[Empty name]">
<P>Relevant randomised trials were identified by searching <I>The Cochrane Hepato-Biliary Group Controlled Trials Register</I> (<LINK REF="REF-Gluud-2010" TYPE="REFERENCE">Gluud 2010</LINK>), the <I>Cochrane Central Register of Controlled Trials</I> (<I>CENTRAL</I>) (Issue 2, 2010) in <I>The Cochrane Library</I>, <I>MEDLINE</I> (1950 to 21 June 2010), <I>EMBASE</I> (1980 to 21 June 2010), and <I>Science Citation Index EXPANDED</I> (1945 to 21 June 2010) (<LINK REF="REF-Royle-2003" TYPE="REFERENCE">Royle 2003</LINK>).</P>
<P>Search strategies and time span of the searches are given in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-07-23 18:12:34 +0200" MODIFIED_BY="[Empty name]">
<P>The references of all identified studies were inspected for more trials. Additionally, the first or corresponding author of each included trial, as well as researchers active in the field, were contacted for information regarding unpublished trials and complementary information on their own trial.</P>
<P>References from an existing review on this topic (<LINK REF="REF-Bernard-1999" TYPE="REFERENCE">Bernard 1999</LINK>) were also checked for any missing trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-08-04 11:40:28 +0200" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2010-08-03 10:32:28 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Three authors (NC, FT, TB) independently inspected each identified reference and applied the inclusion criteria. For potentially relevant articles, or in cases of disagreement between the three reviewers, the full text article was obtained and inspected independently. If resolving disagreement by discussion was not possible, the article was added to those 'awaiting assessment' and the authors of the original study were contacted for clarification. In the event of no reply from the authors within three months, a fourth reviewer (MU or KSW) reviewed the article to solve the disagreement. Justification for study exclusion was documented.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-08-03 10:34:09 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Two authors (NC and TB) independently extracted the data from the included trials. In case of disagreement between the two authors, a third author (FT) extracted the data. The data extraction was discussed, decisions documented, and, when necessary, the authors of the original studies were contacted for clarification. Justification for study exclusion was documented. Trials were identified with the last name of the first author and the year in which the trial was first published, and ordered chronologically.</P>
<P>The following data were extracted, verified, and recorded:</P>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of trials</HEADING>
<UL>
<LI>Date, location, and setting of trial;</LI>
<LI>Publication status;</LI>
<LI>Case definitions used (clinical, serological, bacteriological);</LI>
<LI>Sponsor of trial (known or unknown; industry or not industry).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of participants</HEADING>
<UL>
<LI>Number of participants in each group;</LI>
<LI>Age, sex, nationality;</LI>
<LI>Severity of liver disease and cirrhosis according to the aetiology of liver disease, regardless of the criteria used.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of interventions</HEADING>
<UL>
<LI>Type of antibiotic, dose, mode of administration, schedule, length of follow-up (in months).</LI>
<LI>Number of days that antibiotic prophylaxis was provided.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of outcome measures</HEADING>
<P>Whenever possible, the number of events previously listed under <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK> were recorded in each group of the randomised trials.</P>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-08-04 11:40:28 +0200" MODIFIED_BY="[Empty name]">
<P>Two authors (NC and TB) independently assessed bias risk of the trials, without masking the trial names. For this purpose, instructions given in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>) and the <I>Cochrane Hepato-Biliary Group Module</I> (<LINK REF="REF-Gluud-2010" TYPE="REFERENCE">Gluud 2010</LINK>) were followed. The risk of overestimation of intervention effects in randomised trials due to inadequate methodological quality (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>) was assessed using the domains below. Whenever information was not available in the published trial, authors were contacted directly.</P>
<SUBSECTION>
<HEADING LEVEL="4">Sequence generation</HEADING>
<UL>
<LI>Low risk of bias, if the allocation sequence was generated by a computer or random number table. Drawing of lots, tossing of a coin, shuffling of cards, or throwing dice were also considered as adequate if a person who was not otherwise involved in the recruitment of participants performed the procedure.</LI>
<LI>Unclear, if the trial was described as randomised, but the method used for the allocation sequence generation was not described or insufficient to permit judgement.</LI>
<LI>High risk of bias, if a system involving dates, names, or admittance numbers were used for the allocation of patients.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<UL>
<LI>Low risk of bias, if the allocation of patients involved a central independent unit, on-site locked computer, identically appearing numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed envelopes.</LI>
<LI>Unclear, if the trial was described as randomised, but the method used to conceal the allocation was not described or insufficient to permit judgement.</LI>
<LI>High risk of bias, if the allocation sequence was known to the investigators who assigned participants or if the study was quasi-randomised.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding</HEADING>
<UL>
<LI>Low risk of bias, if the trial was described as double blind and the method of blinding involved identical placebo or active drugs.</LI>
<LI>Unclear, if the trial was described as double blind, but the method of blinding was not described.</LI>
<LI>High risk of bias, if the trial was not double blind.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data</HEADING>
<UL>
<LI>Low risk of bias, if there were no post-randomisation drop-outs or withdrawals.</LI>
<LI>Unclear, if it is not clear whether there are any drop-outs or withdrawals or if the reasons for these drop-outs are not clear.</LI>
<LI>High risk of bias, if the reasons for missing data are likely to be related to true outcomes.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective outcome reporting</HEADING>
<UL>
<LI>Low risk of bias, considering that most of the included trials were made before of the obligatory registration on randomised controlled trials databases, and the pre-specified outcomes are not available. The following outcomes were considered fundamental as outcome to avoid selective reporting; a) mortality, b) response rate, and c) adverse events.</LI>
<LI>Unclear, there is insufficient information to assess whether the magnitude and direction of the observed effect is related to selective outcome reporting.</LI>
<LI>High risk of bias, not all of the trial's pre-specified primary outcomes have been reported or similar.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other sources of bias</HEADING>
<UL>
<LI>Low risk of bias, the trial appears to be free of other sources of bias, considering; a) baseline imbalance, b) source of funding, c) early stopping, and d) interim analysis.</LI>
<LI>Unclear, there is insufficient information to assess whether other sources of bias are present.</LI>
<LI>High risk of bias, it is likely that potential sources of bias.</LI>
</UL>
<P>Following the definitions of the above domains, an included trial was judged as a trial with a low risk of bias when the risk of bias was evaluated as 'low' in all domains. If the risk of bias was judged as 'uncertain' or 'high', then the trial was judged as having 'high risk of bias'.</P>
<P>Furthermore, we registered whether or not the randomised clinical trials had used 'intention-to-treat' analysis (<LINK REF="REF-Gluud-2001" TYPE="REFERENCE">Gluud 2001</LINK>), the length of follow-up, and sample size calculation. Any disagreement was resolved by discussion and settled by a third author (FT). We contacted the trial author for clarification as necessary.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-08-03 10:39:33 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Dichotomous data were analysed calculating the relative risk (RR) for each trial, expressing the uncertainty with 95% confidence intervals (CI). Continuous data were analysed calculating mean differences between groups of each trial and its 95% CI. Comparisons were made between trials evaluating antibiotic prophylaxis against no intervention or placebo, and trials comparing different antibiotic regimens.</P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-08-03 10:41:51 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We checked the heterogeneity of effects across trials by visual inspection of the forest plots and Chi<SUP>2</SUP> and I<SUP>2</SUP> tests for heterogeneity (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). Statistical heterogeneity was defined as a P value &#8804; 0.10 (Chi<SUP>2</SUP>) or I<SUP>2</SUP> &gt; 25%. When heterogeneity existed, subgroup analyses were performed in order to assess the impact of potential sources of heterogeneity over the main results.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2010-07-27 17:45:00 +0200" MODIFIED_BY="[Empty name]">
<P>A funnel plot estimating the precision of trials (plot of logarithm of the RR against the sample size) was examined in order to estimate potential asymmetry. In addition, the standard normal deviate (SND), defined as the RR divided by its standard error, was regressed against the estimate's precision (regression equation: SND = a + b x precision) in order to facilitate the prediction of potential heterogeneity or data irregularities in the meta-analyses (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). In this equation, the SND reflects the degree of funnel plot asymmetry as measured by the intercept from the regression analysis.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-08-03 11:11:10 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>For the statistical analyses, we used RevMan Analyses (<LINK REF="REF-RevMan-2010" TYPE="REFERENCE">RevMan 2010</LINK>). Dichotomous data were synthesised poling the RR and 95% CI from all trials to estimate the global effect of the intervention. Continous data were synthesised pooling mean differences and 95% CI from each trial to calculate the average mean difference.</P>
<P>In order to compare the RR from different antibiotic groups and detect differences among the antibiotics tested versus no intervention or placebo, a test for interaction was calculated (<LINK REF="REF-Altman-2003" TYPE="REFERENCE">Altman 2003</LINK>).</P>
</DATA_SYNTHESIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-08-04 16:18:34 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We analysed data using both fixed-effect and random-effects models. When both models produced similar estimates, the fixed-effect result was reported; otherwise, we reported the results from both analyses. Outcomes were analysed as reported in the trial, that is, either per protocol or as intention-to-treat analysis. In order to examine the influence of drop-outs, we performed both worst-best-case (assigning bad outcomes to all of the missing experimental group patients and good outcomes to all of the missing control group patients) and best-worst-case (assigning good outcomes to all of the missing experimental group patients and bad outcomes to all of the missing control group patients) analyses.</P>
<P>To assess the reliability of the meta-analyses on mortality, mortality from bacterial infections, and bacterial infections, the required information size (RIS) was calculated by trial sequential analysis (TSA). We respectively assumed an average event proportion of 22%, 5%, and 36% in the control group of the three meta-analyses; a 20% relative risk reduction of the experimental intervention, and statistical error levels of 5% alpha and 20% beta (80% power). Whenever the cumulative information size in the meta-analysis was smaller than the RIS, the threshold to maintain statistical significance was calculated with the O&#8217;Brien-Fleming boundaries (<LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-08-04 11:40:40 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-08-04 11:40:31 +0200" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2010-08-04 16:19:54 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Forty-one relevant references were initially identified and screened for retrieval. Subsequently, reviews (fourteen references), comments and editorials (four references) were excluded. Twenty-six studies were considered suitable to be included, but nine studies were excluded because they were not randomised trials (six studies), did not include patients with upper gastrointestinal bleeding (two studies), or did not include any of the outcomes assessed in this review (one study) (See '<LINK TAG="EXCLUDED_STUDIES_DESCR" TYPE="SECTION">Excluded studies</LINK>' for additional information). Finally, seventeen trials (twenty-one references) were included for analyses (see '<LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK>' for additional information).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-08-04 11:40:29 +0200" MODIFIED_BY="[Empty name]">
<P>Seventeen trials evaluating th effectiveness of antibiotic prophylaxis against bacterial infections in 1891 patients were included in this review (<LINK REF="STD-Rimola-1985" TYPE="STUDY">Rimola 1985</LINK>; <LINK REF="STD-Soriano-1992" TYPE="STUDY">Soriano 1992</LINK>; <LINK REF="STD-Rolando-1993" TYPE="STUDY">Rolando 1993</LINK>; <LINK REF="STD-Blaise-1994" TYPE="STUDY">Blaise 1994</LINK>; <LINK REF="STD-Selby-1994" TYPE="STUDY">Selby 1994</LINK>; <LINK REF="STD-Pauwels-1996" TYPE="STUDY">Pauwels 1996</LINK>; <LINK REF="STD-Zacharof-1997" TYPE="STUDY">Zacharof 1997</LINK>; <LINK REF="STD-Hsieh-1998" TYPE="STUDY">Hsieh 1998</LINK>; <LINK REF="STD-Sabat-1998" TYPE="STUDY">Sabat 1998</LINK>; <LINK REF="STD-Spanish-Group-1998" TYPE="STUDY">Spanish Group 1998</LINK>; <LINK REF="STD-Gulberg-1999" TYPE="STUDY">Gulberg 1999</LINK>; <LINK REF="STD-Hong-2002" TYPE="STUDY">Hong 2002</LINK>; <LINK REF="STD-Lin-2002" TYPE="STUDY">Lin 2002</LINK>; <LINK REF="STD-Hou-2004" TYPE="STUDY">Hou 2004</LINK>; <LINK REF="STD-Lata-2005" TYPE="STUDY">Lata 2005</LINK>; <LINK REF="STD-Fernandez-2006" TYPE="STUDY">Fernandez 2006</LINK>; <LINK REF="STD-Jun-2006" TYPE="STUDY">Jun 2006</LINK>), in twelve trials (fourteen references) comparison with no intervention or placebo was conducted (<LINK REF="STD-Rimola-1985" TYPE="STUDY">Rimola 1985</LINK>; <LINK REF="STD-Soriano-1992" TYPE="STUDY">Soriano 1992</LINK>; <LINK REF="STD-Rolando-1993" TYPE="STUDY">Rolando 1993</LINK>; <LINK REF="STD-Blaise-1994" TYPE="STUDY">Blaise 1994</LINK>; <LINK REF="STD-Selby-1994" TYPE="STUDY">Selby 1994</LINK>; <LINK REF="STD-Pauwels-1996" TYPE="STUDY">Pauwels 1996</LINK>; <LINK REF="STD-Zacharof-1997" TYPE="STUDY">Zacharof 1997</LINK>; <LINK REF="STD-Hsieh-1998" TYPE="STUDY">Hsieh 1998</LINK>; <LINK REF="STD-Hong-2002" TYPE="STUDY">Hong 2002</LINK>; <LINK REF="STD-Lin-2002" TYPE="STUDY">Lin 2002</LINK>; <LINK REF="STD-Hou-2004" TYPE="STUDY">Hou 2004</LINK>; <LINK REF="STD-Jun-2006" TYPE="STUDY">Jun 2006</LINK>).</P>
<P>Five trials (eight references) were head-to-head antibiotic comparisons (<LINK REF="STD-Sabat-1998" TYPE="STUDY">Sabat 1998</LINK>; <LINK REF="STD-Spanish-Group-1998" TYPE="STUDY">Spanish Group 1998</LINK>; <LINK REF="STD-Gulberg-1999" TYPE="STUDY">Gulberg 1999</LINK>; <LINK REF="STD-Lata-2005" TYPE="STUDY">Lata 2005</LINK>; <LINK REF="STD-Fernandez-2006" TYPE="STUDY">Fernandez 2006</LINK>).</P>
<P>Most trials were retrieved as complete manuscript and two trials as abstracts (<LINK REF="STD-Spanish-Group-1998" TYPE="STUDY">Spanish Group 1998</LINK>; <LINK REF="STD-Zacharof-1997" TYPE="STUDY">Zacharof 1997</LINK>). The only non-English article was written in Korean (<LINK REF="STD-Hong-2002" TYPE="STUDY">Hong 2002</LINK>).</P>
<P>Trials were conducted in Australia (<LINK REF="STD-Selby-1994" TYPE="STUDY">Selby 1994</LINK>), Czech Republic (<LINK REF="STD-Lata-2005" TYPE="STUDY">Lata 2005</LINK>), France (<LINK REF="STD-Blaise-1994" TYPE="STUDY">Blaise 1994</LINK>; <LINK REF="STD-Pauwels-1996" TYPE="STUDY">Pauwels 1996</LINK>), Germany (<LINK REF="STD-Gulberg-1999" TYPE="STUDY">Gulberg 1999</LINK>), Greece (<LINK REF="STD-Zacharof-1997" TYPE="STUDY">Zacharof 1997</LINK>), Korea (<LINK REF="STD-Hong-2002" TYPE="STUDY">Hong 2002</LINK>; <LINK REF="STD-Jun-2006" TYPE="STUDY">Jun 2006</LINK>), Spain (<LINK REF="STD-Rimola-1985" TYPE="STUDY">Rimola 1985</LINK>; <LINK REF="STD-Soriano-1992" TYPE="STUDY">Soriano 1992</LINK>; <LINK REF="STD-Sabat-1998" TYPE="STUDY">Sabat 1998</LINK>; <LINK REF="STD-Spanish-Group-1998" TYPE="STUDY">Spanish Group 1998</LINK>; <LINK REF="STD-Fernandez-2006" TYPE="STUDY">Fernandez 2006</LINK>), Taiwan (<LINK REF="STD-Hsieh-1998" TYPE="STUDY">Hsieh 1998</LINK>; <LINK REF="STD-Lin-2002" TYPE="STUDY">Lin 2002</LINK>; <LINK REF="STD-Hou-2004" TYPE="STUDY">Hou 2004</LINK>), and the United Kingdom (<LINK REF="STD-Rolando-1993" TYPE="STUDY">Rolando 1993</LINK>) (see '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' for details).</P>
<P>The source of the haemorrhage was gastroesophageal varices in six trials (<LINK REF="STD-Rolando-1993" TYPE="STUDY">Rolando 1993</LINK>; <LINK REF="STD-Blaise-1994" TYPE="STUDY">Blaise 1994</LINK>; <LINK REF="STD-Hong-2002" TYPE="STUDY">Hong 2002</LINK>; <LINK REF="STD-Hou-2004" TYPE="STUDY">Hou 2004</LINK>; <LINK REF="STD-Lata-2005" TYPE="STUDY">Lata 2005</LINK>; <LINK REF="STD-Jun-2006" TYPE="STUDY">Jun 2006</LINK>), mixed (variceal and non-variceal gastrointestinal haemorrhage) in seven trials (<LINK REF="STD-Rimola-1985" TYPE="STUDY">Rimola 1985</LINK>; <LINK REF="STD-Soriano-1992" TYPE="STUDY">Soriano 1992</LINK>; <LINK REF="STD-Pauwels-1996" TYPE="STUDY">Pauwels 1996</LINK>; <LINK REF="STD-Hsieh-1998" TYPE="STUDY">Hsieh 1998</LINK>; <LINK REF="STD-Sabat-1998" TYPE="STUDY">Sabat 1998</LINK>; <LINK REF="STD-Lin-2002" TYPE="STUDY">Lin 2002</LINK>; <LINK REF="STD-Fernandez-2006" TYPE="STUDY">Fernandez 2006</LINK>), and not specified in four trials (<LINK REF="STD-Selby-1994" TYPE="STUDY">Selby 1994</LINK>; <LINK REF="STD-Zacharof-1997" TYPE="STUDY">Zacharof 1997</LINK>; <LINK REF="STD-Spanish-Group-1998" TYPE="STUDY">Spanish Group 1998</LINK>; <LINK REF="STD-Gulberg-1999" TYPE="STUDY">Gulberg 1999</LINK>).</P>
<P>While all trials assessed the use of antibiotic prophylaxis, the primary outcome differed between them. The most common was prevention of bacterial infections in fourteen trials (<LINK REF="STD-Rimola-1985" TYPE="STUDY">Rimola 1985</LINK>; <LINK REF="STD-Soriano-1992" TYPE="STUDY">Soriano 1992</LINK>; <LINK REF="STD-Rolando-1993" TYPE="STUDY">Rolando 1993</LINK>; <LINK REF="STD-Blaise-1994" TYPE="STUDY">Blaise 1994</LINK>; <LINK REF="STD-Selby-1994" TYPE="STUDY">Selby 1994</LINK>; <LINK REF="STD-Pauwels-1996" TYPE="STUDY">Pauwels 1996</LINK>; <LINK REF="STD-Zacharof-1997" TYPE="STUDY">Zacharof 1997</LINK>; <LINK REF="STD-Hsieh-1998" TYPE="STUDY">Hsieh 1998</LINK>; <LINK REF="STD-Sabat-1998" TYPE="STUDY">Sabat 1998</LINK>; <LINK REF="STD-Spanish-Group-1998" TYPE="STUDY">Spanish Group 1998</LINK>; <LINK REF="STD-Gulberg-1999" TYPE="STUDY">Gulberg 1999</LINK>; <LINK REF="STD-Hong-2002" TYPE="STUDY">Hong 2002</LINK>; <LINK REF="STD-Lin-2002" TYPE="STUDY">Lin 2002</LINK>; <LINK REF="STD-Fernandez-2006" TYPE="STUDY">Fernandez 2006</LINK>), rebleeding rate in two trials (<LINK REF="STD-Hou-2004" TYPE="STUDY">Hou 2004</LINK>; <LINK REF="STD-Jun-2006" TYPE="STUDY">Jun 2006</LINK>), and early and late mortality in one trial (<LINK REF="STD-Lata-2005" TYPE="STUDY">Lata 2005</LINK>).</P>
<P>All trials were performed on hospitalised patients, but four specifically described critical care settings (<LINK REF="STD-Rimola-1985" TYPE="STUDY">Rimola 1985</LINK>; <LINK REF="STD-Blaise-1994" TYPE="STUDY">Blaise 1994</LINK>; <LINK REF="STD-Pauwels-1996" TYPE="STUDY">Pauwels 1996</LINK>; <LINK REF="STD-Lata-2005" TYPE="STUDY">Lata 2005</LINK>). Eleven trials reported the Child-Pugh score as a categorical variable, from them nine included patients with Child-Pugh score A/B/C (overall distribution 17/51/32%, respectively), two trials reported only patients with Child Pugh score B/C. Diagnostic and management of the gastrointestinal haemorrhage was done by endoscopy.</P>
<P>The antibiotics compared versus no intervention or placebo were: quinolones (five trials), quinolones plus beta-lactams (two trials), cephalosporins (three trials), carbapenems (one trial) and non-absorbable antibiotics (one trial) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>The head-to-head antibiotic comparisons were explored in five trials (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>), as follows: combination of antibiotics versus a single antibiotic (<LINK REF="STD-Sabat-1998" TYPE="STUDY">Sabat 1998</LINK>), two antibiotics from the same group (<LINK REF="STD-Spanish-Group-1998" TYPE="STUDY">Spanish Group 1998</LINK>; <LINK REF="STD-Gulberg-1999" TYPE="STUDY">Gulberg 1999</LINK>), and different groups of antibiotics in each intervention group (<LINK REF="STD-Lata-2005" TYPE="STUDY">Lata 2005</LINK>; <LINK REF="STD-Fernandez-2006" TYPE="STUDY">Fernandez 2006</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-08-04 11:40:31 +0200" MODIFIED_BY="[Empty name]">
<P>Nine studies were excluded from this review. The main reason was the retrospective or non-interventional study design, one study used inadequate allocation concealment (<LINK REF="STD-Henrion-1992" TYPE="STUDY">Henrion 1992</LINK>); another trial did not measure any of the outcomes analysed in this review (<LINK REF="STD-Pulanic-1989" TYPE="STUDY">Pulanic 1989</LINK>); two studies were excluded because the patients did not have upper gastrointestinal haemorrhage (<LINK REF="STD-Gines-1990" TYPE="STUDY">Gines 1990</LINK>; <LINK REF="STD-Novella-1997" TYPE="STUDY">Novella 1997</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-08-04 11:40:37 +0200" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> for more information. None of the trials was of low risk of bias.</P>
<ALLOCATION MODIFIED="2010-08-04 11:40:32 +0200" MODIFIED_BY="[Empty name]">
<P>Allocation sequence was generated by random table number or software in eleven trials (<LINK REF="STD-Rimola-1985" TYPE="STUDY">Rimola 1985</LINK>; <LINK REF="STD-Soriano-1992" TYPE="STUDY">Soriano 1992</LINK>; <LINK REF="STD-Rolando-1993" TYPE="STUDY">Rolando 1993</LINK>; <LINK REF="STD-Selby-1994" TYPE="STUDY">Selby 1994</LINK>; <LINK REF="STD-Pauwels-1996" TYPE="STUDY">Pauwels 1996</LINK>; <LINK REF="STD-Zacharof-1997" TYPE="STUDY">Zacharof 1997</LINK>; <LINK REF="STD-Sabat-1998" TYPE="STUDY">Sabat 1998</LINK>; <LINK REF="STD-Hou-2004" TYPE="STUDY">Hou 2004</LINK>; <LINK REF="STD-Lata-2005" TYPE="STUDY">Lata 2005</LINK>; <LINK REF="STD-Fernandez-2006" TYPE="STUDY">Fernandez 2006</LINK>; <LINK REF="STD-Jun-2006" TYPE="STUDY">Jun 2006</LINK>). In six trials no clear information about the sequence generation was reported and authors did not provide further information, being classified as unclear. The allocation concealment information was properly indicated in only one trial (<LINK REF="STD-Jun-2006" TYPE="STUDY">Jun 2006</LINK>), was clarified by direct communication in four trials (<LINK REF="STD-Rimola-1985" TYPE="STUDY">Rimola 1985</LINK>; <LINK REF="STD-Rolando-1993" TYPE="STUDY">Rolando 1993</LINK>; <LINK REF="STD-Zacharof-1997" TYPE="STUDY">Zacharof 1997</LINK>; <LINK REF="STD-Fernandez-2006" TYPE="STUDY">Fernandez 2006</LINK>), and was unclear in twelve trials. Considering both sequence generation process and allocation concealment, only five trials were classified as having low risk of bias (<LINK REF="STD-Rimola-1985" TYPE="STUDY">Rimola 1985</LINK>; <LINK REF="STD-Rolando-1993" TYPE="STUDY">Rolando 1993</LINK>; <LINK REF="STD-Selby-1994" TYPE="STUDY">Selby 1994</LINK>; <LINK REF="STD-Zacharof-1997" TYPE="STUDY">Zacharof 1997</LINK>; <LINK REF="STD-Jun-2006" TYPE="STUDY">Jun 2006</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-08-04 11:40:36 +0200" MODIFIED_BY="[Empty name]">
<P>The risk of bias was high or unclear in all trials included in this review. Only one trial used placebo (<LINK REF="STD-Hsieh-1998" TYPE="STUDY">Hsieh 1998</LINK>), but blinding procedures were not reported. Most trials were designed to compare antibiotic prophylaxis versus no intervention, complicating the blinding process. The <I>Cochrane Handbook for Systematic Reviews or Interventions</I> (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>) allows considering a trial with a low risk of bias if the outcome is not directly affected by the lack of blinding. Thus, when mortality was the outcome, the trials were considered to be at low risk of bias. Mortality secondary to infections and overall infections as the outcomes could have been affected by the lack of blinding, therefore, considering these outcomes, all trials were considered at high risk of bias.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-08-03 11:40:58 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Common exclusion criteria from the trials included bacterial infections at admission, positivity of biological cultures during follow-up and death, or surgery during the first twelve to twenty-four hours. The trial by <LINK REF="STD-Rimola-1985" TYPE="STUDY">Rimola 1985</LINK> was considered at high risk of bias because patients excluded were not balanced across groups; similarly, <LINK REF="STD-Jun-2006" TYPE="STUDY">Jun 2006</LINK> reported a higher proportion of missing outcomes in the non-prophylaxis group.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2010-08-03 11:41:14 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Except for the trials reported only in abstract form (<LINK REF="STD-Zacharof-1997" TYPE="STUDY">Zacharof 1997</LINK>; <LINK REF="STD-Spanish-Group-1998" TYPE="STUDY">Spanish Group 1998</LINK>), all the trials reported at least the primary outcome in their methods.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2010-08-04 11:40:37 +0200" MODIFIED_BY="[Empty name]">
<P>Lack of sample size calculation was the most frequently observed source of other bias. Sample size calculation was described in four trials (<LINK REF="STD-Sabat-1998" TYPE="STUDY">Sabat 1998</LINK>; <LINK REF="STD-Hou-2004" TYPE="STUDY">Hou 2004</LINK>; <LINK REF="STD-Fernandez-2006" TYPE="STUDY">Fernandez 2006</LINK>; <LINK REF="STD-Jun-2006" TYPE="STUDY">Jun 2006</LINK>).</P>
<P>Intention-to-treat analysis was performed in one trial (<LINK REF="STD-Hsieh-1998" TYPE="STUDY">Hsieh 1998</LINK>). There was a clear rule to exclude some patients from the analysis in certain trials (<LINK REF="STD-Blaise-1994" TYPE="STUDY">Blaise 1994</LINK>; <LINK REF="STD-Lin-2002" TYPE="STUDY">Lin 2002</LINK>; <LINK REF="STD-Fernandez-2006" TYPE="STUDY">Fernandez 2006</LINK>), without considering the intention-to-treat analysis (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>).</P>
<P>Three other trials could have been subjected to other forms of bias. In <LINK REF="STD-Rimola-1985" TYPE="STUDY">Rimola 1985</LINK>, the antibiotic used was changed over the course of the trial; <LINK REF="STD-Gulberg-1999" TYPE="STUDY">Gulberg 1999</LINK> used surrogates for infection in several analysis; and <LINK REF="STD-Sabat-1998" TYPE="STUDY">Sabat 1998</LINK> stopped the trial prematurely due to differences in economical outcomes.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-08-04 11:40:40 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Mortality</HEADING>
<P>Twelve trials reported overall mortality in 1241 patients. No significant heterogeneity of effects was observed and a slight asymmetry towards the left side of the funnel plot suggested a potential overestimation of effects from small sized trials. The effect of antibiotic prophylaxis on overall mortality was significant (RR 0.79, 95% CI 0.79 to 0.98).</P>
<P>To explore the impact of dropouts on mortality, best-worst-case and worst-best-case analyses were performed (worst-best-case analysis RR 1.45, 95% CI 1.04 to 2.02; best-worst-case analysis RR 0.48, 95% CI 0.38 to 0.60).</P>
<P>The TSA showed a trend towards beneficial effects of the intervention to reduce mortality, but the cumulative Z-score did not cross the O'Brien-Fleming boundaries (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>); therefore, no clear conclusion can be drawn and more trials are needed to confirm the result of this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Mortality from bacterial infections</HEADING>
<P>Six trials reported mortality from bacterial infections, comparing prophylaxis with no intervention or placebo (<LINK REF="STD-Rimola-1985" TYPE="STUDY">Rimola 1985</LINK>; <LINK REF="STD-Soriano-1992" TYPE="STUDY">Soriano 1992</LINK>; <LINK REF="STD-Pauwels-1996" TYPE="STUDY">Pauwels 1996</LINK>; <LINK REF="STD-Lin-2002" TYPE="STUDY">Lin 2002</LINK>; <LINK REF="STD-Hou-2004" TYPE="STUDY">Hou 2004</LINK>; <LINK REF="STD-Jun-2006" TYPE="STUDY">Jun 2006</LINK>). Antibiotic prophylaxis was associated with a significant decrease in mortality from bacterial infections (RR 0.43, 95% CI 0.19 to 0.97).</P>
<P>The sensitivity analysis showed this estimation could have been biased by differential drop-out rates (worst-best-case analysis RR 3.30, 95% CI 1.43 to 7.62; best-worst-case analysis RR 0.14, 95% CI 0.06 to 0.31).</P>
<P>The TSA demonstrated that the few number of trials included in the analysis were not enough to conclude a beneficial effect of prophylaxis over mortality from bacterial infections (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Bacterial infections</HEADING>
<P>All trials comparing antibiotic prophylaxis versus no intervention or placebo reported incidence of bacterial infections. For this review, only confirmed bacterial infections were considered. A total of 1241 patients were included in the trials, showing antibiotic prophylaxis to be significantly beneficial to reduce bacterial infections (RR 0.36, 95% CI 0.27 to 0.49). Heterogeneity of effects across trials was significant. However, all estimators remained statistically significant independently of the type of analyses used (random or fixed-effects), strengthening the evidence for the proposed effect.</P>
<P>Bacterial infections were not affected by the sensitivity analysis (worst-best-case analysis RR 0.77, 95% CI 0.63 to 0.93; best-worst-case analysis RR 0.26, 95% CI 0.26 to 0.43), and also the TSA showed significant benefit of antibiotic prophylaxis over no intervention or placebo (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
<P>Bacteremia was reported in nine trials with a significant risk reduction in patients under antibiotic prophylaxis (RR 0.25, 95% CI 0.15 to 0.40). Similarly, other infectious outcomes were significantly reduced with the use of antibiotic prophylaxis: pneumonia in nine trials (RR 0.45, 95% CI 0.27 to 0.75), spontaneous bacterial peritonitis in eight trials (RR 0.29, 95% CI 0.15 to 0.57), and urinary tract infections in nine trials (RR 0.23, 95% CI 0.12 to 0.41).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Drop-outs and sensitivity analysis</HEADING>
<P>There was no significant difference in drop-out rates across eight trials reporting this outcome (RR 1.07, 95% CI 0.76 to 1.51).</P>
<P>We analysed overall mortality and bacterial infections stratifying by sample size (larger than 100 versus smaller than 101 patients), RR were homogeneous across strata.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>No significant adverse events were reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life</HEADING>
<P>No information regarding this outcome was reported in the trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Antibiotic regimens</HEADING>
<P>Although a beneficial effect of antibiotic prophylaxis was observed when pooling all trials, stratifying by group of antibiotic diluted the effect and no beneficial effects on mortality or mortality from bacterial infections was observed.</P>
<P>Regarding bacterial infections, all the antibiotics showed a risk reduction, the beneficial effect seemed to be higher in trials using cephalosporins (RR 0.16, 95% CI 0.05 to 0.48), followed by quinolones (RR 0.27, 95% CI 0.18 to 0.39), quinolones plus beta-lactams (RR 0.38, 95% CI 0.23 to 0.62), and other antibiotics (RR 0.57, 95%CI 0.41 to 0.81). However, the test for interaction demonstrated that only the group of 'other antibiotics' significantly differed from all other drugs (quinolones versus other antibiotics P value = 0.004, and cephalosporins versus other antibiotics P value 0.03). No significant difference between quinolones and cephalosporins was observed (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Rebleeding</HEADING>
<P>In three trials (<LINK REF="STD-Hong-2002" TYPE="STUDY">Hong 2002</LINK>; <LINK REF="STD-Hou-2004" TYPE="STUDY">Hou 2004</LINK>; <LINK REF="STD-Jun-2006" TYPE="STUDY">Jun 2006</LINK>) rebleeding was reported. A significant reduction was observed among patients under antibiotic prophylaxis in overall rebleeding (RR 0.53, 95% CI 0.38 to 0.74), and rebleeding after up to seven days of follow-up (RR 0.24, 95% CI 0.12 to 0.50).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Days of hospitalisation</HEADING>
<P>Seven trials reported hospitalisation length of stay, two trials during intensive care hospitalisation only (<LINK REF="STD-Blaise-1994" TYPE="STUDY">Blaise 1994</LINK>; <LINK REF="STD-Pauwels-1996" TYPE="STUDY">Pauwels 1996</LINK>), and five trials during full-length of hospitalisation (<LINK REF="STD-Soriano-1992" TYPE="STUDY">Soriano 1992</LINK>; <LINK REF="STD-Hsieh-1998" TYPE="STUDY">Hsieh 1998</LINK>; <LINK REF="STD-Hong-2002" TYPE="STUDY">Hong 2002</LINK>; <LINK REF="STD-Lin-2002" TYPE="STUDY">Lin 2002</LINK>; <LINK REF="STD-Jun-2006" TYPE="STUDY">Jun 2006</LINK>). The overall effect of the intervention was not significant (MD -0.79 days, 95% CI -1.84 to 0.26) - however, this estimate is highly influenced by the intensive care hospitalisation trials. When full-length hospitalisation trials were considered alone, a beneficial effect from the intervention was observed (MD -1.91 days, 95% CI -3.80 to -0.02).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Antibiotic regimens versus other antibiotic regimens</HEADING>
<P>Five trials compared different antibiotic regimens. No significant differences between regimens were observed for the outcomes under study. See <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK> for more information.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-08-04 11:40:52 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2010-08-04 11:40:48 +0200" MODIFIED_BY="[Empty name]">
<P>This systematic review is an update of a previous systematic review and meta-analysis published in 2002 (<LINK REF="REF-Soares_x002d_Weiser-2002" TYPE="REFERENCE">Soares-Weiser 2002</LINK>). From that date, new trials supporting the use of antibiotic prophylaxis on cirrhotic patients with upper gastrointestinal haemorrhage became available. Six new trials - four comparing antibiotics against no-intervention, and two comparing different antibiotic regimens - were included in this update.</P>
<P>The most clinically relevant outcomes assessed in this review were mortality, mortality from bacterial infections, bacterial infections, and rebleeding. The inclusion of new trials did not modify a previously observed beneficial effect of antibiotic prophylaxis on mortality and bacterial infections. Rebleedingwas included as a new secondary outcome as it is an important outcome in clinical practice. We observed a statistically significant beneficial effect of the intervention on rebleeding. However, studies assessing rebleeding are still scarce and our presented results are based on only three trials. To confirm this observation, more data are required. In this updated review, antibiotic prophylaxis reduced the hospitalisation length of stay, but not the time in critical care.</P>
<P>The effects observed were more robust for prevention of bacterial infections, which remained significant after sensitivity analysis and TSA. This could be explained by the fact that all the trials included were designed and powered to evaluate this outcome.</P>
<P>The evolution of the intervention goes from non-absorbable antibiotics (one trial), to quinolones (five trials), and to more recent cephalosporins (three trials), but there is no solid evidence to prefer one antibiotic regimen over the other. This was also observed in trials exploring several antibiotic regimens simultaneously. Use of quinolones was first explored by <LINK REF="STD-Soriano-1992" TYPE="STUDY">Soriano 1992</LINK> and quinolones have been broadly used since then, despite rising concerns of a potential reduction of their effects due to bacterial resistance. However, considering that bacterial resistance pattern vary by location, use of quinolones for antibiotic prophylaxis will have to be assessed in specific local settings.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-08-04 11:40:49 +0200" MODIFIED_BY="[Empty name]">
<P>The current evidence to support antibiotic prophylaxis is based on twelve randomised trials, and, except for America and Africa, the intervention has been assessed in heterogeneous populations, providing external validity to this review. This review aimed to evaluate the effects of antibiotic prophylaxis on bacterial infections and mortality, and although a beneficial effect was observed, caution should be exerted when interpreting mortality results, since all included trials were not specifically designed to evaluate this outcome. Moreover, the significance of the observation could not be confirmed in trial sequential analysis (<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>).</P>
<P>Several issues were not answered in this review. Adverse events, quality of life, and the economic impact of the intervention were not explored in the trials included, remaining important areas of uncertainty and requiring further data to establish an evidence-based conclusion.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-08-04 11:40:50 +0200" MODIFIED_BY="[Empty name]">
<P>This review included 1891 cirrhotic patients with upper gastrointestinal bleeding; 1241 of them participated in randomised trials comparing antibiotic prophylaxis versus no intervention or placebo, and the remaining 650 participants in trials comparing different antibiotic prophylactic regimens. All trials presented methodological weaknesses and should be considered at risk of bias. Lack of blinding and lack of proper sample size calculations were the most common sources of bias. Although less subjective outcomes were considered in this review (mortality, mortality from bacterial infections, confirmed bacterial infections, and rebleeding) the influence of these sources of bias cannot be determined precisely.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2010-08-04 11:40:51 +0200" MODIFIED_BY="[Empty name]">
<P>All trials included in this review presented incomplete data to adequately assess their methodological strength and usefulness. Several attempts were made to contact original authors, but only in few cases an answer was obtained.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2010-08-04 11:40:52 +0200" MODIFIED_BY="[Empty name]">
<P>The current treatment guidelines consider antibiotic prophylaxis as standard of care (<LINK REF="REF-Garcia_x002d_Tsao-2007" TYPE="REFERENCE">Garcia-Tsao 2007</LINK>; <LINK REF="REF-Bosch-2008" TYPE="REFERENCE">Bosch 2008</LINK>; <LINK REF="REF-Garcia_x002d_Tsao-2009" TYPE="REFERENCE">Garcia-Tsao 2009</LINK>) based on the beneficial effects reported on mortality. However, this effect is less well-supported compared to the effect of prophylaxis to prevent bacterial infections. The information provided in this review will help the practitioner to weight the most important effects from antibiotic prophylaxis.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-08-04 11:40:57 +0200" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-08-04 11:40:57 +0200" MODIFIED_BY="[Empty name]">
<P>The use of prophylactic antibiotics in patients with cirrhosis and upper gastrointestinal bleeding significantly reduce bacterial infections and seems to reduce all-cause mortality, bacterial infection mortality, incidence of rebleeding events, and length of hospitalisation. These benefits were observed indistinctly of the antibiotic assessed. No specific antibiotic regimen can be recommended over another.Thus, antibiotic selection should be made considering local conditions such as bacterial resistance profile and treatment cost.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-08-04 16:48:16 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The sensitivity analysis and the TSA, in addition to the meta-analysis, demonstrate the robustness of data regarding antibiotic prophylaxis to prevent bacterial infections. However, data are not as conclusive concerning the other outcomes. Considering the benefits of antibiotic prophylaxis for bacterial infection prevention it will seem unwise to further conduct trials with placebo or no intervention as comparators, although specific conditions in clinical settings could justify their conduct.</P>
<P>The information regarding the benefits and harms from different antibiotic regimens is still scarce. Critical information such as the differential impact of each regimen over quality of life or their pharmaco-economical advantages are still unclear and require further investigation.</P>
<P>Future research must include adequate sample size calculations and proper blinding processes. Additionaly, information about other significant outcomes, particularly adverse events, should also be considered in the future. Finally, trials should follow the recommended guidelines for the reporting of clinical trials (CONSORT - Consolidated Standards of Reporting Trials: www.consort-statement.org).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-08-04 21:41:31 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We thank Dimitrinka Nikolova and Christian Gluud of The Cochrane Hepato-Biliary Group for ongoing support for this review.<BR/>Thanks to J. Fernandez, P. Gines, A. Rimola, N. Rolando, and A. Zacharof, who kindly supplied additional information on their own trials.</P>
<P>We would like thank M Brezis, R Tur-Kaspa, and L Leibovici who participated in the previous version of this review (<LINK REF="REF-Soares_x002d_Weiser-2002" TYPE="REFERENCE">Soares-Weiser 2002</LINK>). Their work was supported by the Tel Aviv University, Hadassah University Hospital - Mount Scopus, and Rabin Medical Center - Beilinson Campus, (Israel). The Danish Medical Research Council's Grant on Getting Research into Practice (GRIP), Copenhagen Hospital Corporation's Research Grant on Getting Research into Practice (GRIP), and The 1991 Pharmacy Foundation (Denmark</P>
<P>Peer Reviewers: Wolfgang Fleig, Germany; Gennaro D'Amico, Italy.<BR/>Contact Editor: Christian Gluud, Denmark.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-08-04 21:41:53 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Norberto C. Chavez-Tapia: update co-ordination, data collection, data management, data interpretation, and review writing.<BR/>Tonatiuh Barrientos-Gutierrez: data collection, data management, data analysis, and review writing.<BR/>Felix I Tellez-Avila: data analysis and interpretation.<BR/>Karla Soares-Weiser: conception and co-ordination of the previous version of this review, provided general advice on this updated review.<BR/>Misael Uribe: data interpretation, provided general advice on the review, and secured funding for the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-08-04 11:43:13 +0200" MODIFIED_BY="[Empty name]">
<P>During the update process, the condition assessed changed from gastrointestinal bleeding to upper gastrointestinal bleeding. Rebleeding was included as a secondary outcome, and quality of life and adverse events were included as primary outcomes.</P>
<P>Test of interaction and TSA were included.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-08-04 15:15:24 +0200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-07-28 12:33:25 +0200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-07-28 11:57:18 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Blaise-1994" NAME="Blaise 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blaise M, Pateron D, Trinchet JC, Levacher S, Beaugrand M, Pourriat JL</AU>
<TI>Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage</TI>
<SO>Hepatology</SO>
<YR>1994</YR>
<VL>20</VL>
<NO>1 Pt 1</NO>
<PG>34-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94292124"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fernandez-2006" MODIFIED="2010-06-23 14:05:46 +0200" MODIFIED_BY="[Empty name]" NAME="Fernandez 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-06-23 14:05:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez J, Ruiz del Arbol L, Gomez C, Durandez R, Serradilla R, Guarner C, et al</AU>
<TI>Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage</TI>
<SO>Gastroenterology</SO>
<YR>2006</YR>
<VL>131</VL>
<NO>4</NO>
<PG>1049-56; quiz 1285</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gulberg-1999" MODIFIED="2010-07-28 11:56:57 +0200" MODIFIED_BY="[Empty name]" NAME="Gulberg 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Gulberg V, Deibert P, Ochs A, Rossle M, Gerbes AL. Prevention of infectious complications after transjugular intrahepatic portosystemic shunt (TIPS) in patients with cirrhosis of the liver with a single dose of ceftriaxon. Hepatology (AASLD Annual Meeting) 1997;26(4):518A.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gulberg V, Deibert P, Ochs A, Rossle M, Gerbes AL</AU>
<TI>Prevention of infectious complications after transjugular intrahepatic portosystemic shunt (TIPS) in patients with cirrhosis of the liver with a single dose of ceftriaxone (AASLD Abstract)</TI>
<SO>Hepatology</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>4</NO>
<PG>518A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-28 11:56:57 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gulberg V, Deibert P, Ochs A, Rossle M, Gerbes AL</AU>
<TI>Prevention of infectious complications after transjugular intrahepatic portosystemic shunt in cirrhotic patients with a single dose of ceftriaxone</TI>
<SO>Hepato-Gastroenterology</SO>
<YR>1999</YR>
<VL>46</VL>
<NO>26</NO>
<PG>1126-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99298817"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hong-2002" MODIFIED="2010-07-28 11:50:23 +0200" MODIFIED_BY="[Empty name]" NAME="Hong 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-07-28 11:50:23 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hong SN, Kim BJ, Lee SY, Lee CY, Ryu MK, Choi MS, et al</AU>
<TI>[Prospective randomized trial of intravenous ciprofloxacin for prevention of bacterial infection in cirrhotic patients with esophageal variceal bleeding]</TI>
<SO>Taehan Kan Hakhoe Chi</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>3</NO>
<PG>288-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hou-2004" MODIFIED="2010-07-28 11:57:18 +0200" MODIFIED_BY="[Empty name]" NAME="Hou 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-07-28 11:57:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hou MC, Lin HC, Liu TT, Kuo BI, Lee FY, Chang FY, et al</AU>
<TI>Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial</TI>
<SO>Hepatology</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>3</NO>
<PG>746-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hsieh-1998" MODIFIED="2010-07-09 15:24:19 +0200" MODIFIED_BY="[Empty name]" NAME="Hsieh 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-07-09 15:24:19 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Hsieh W, Lin H, Hwang S, Hou M, Lee F, Chang F, et al. The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding. Am J Gastroenterol 1998;93(6):962-6.&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 15:24:19 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hsieh W, Lin H, Hwang S, Hou M, Lee F, Chang F, et al</AU>
<TI>The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1998</YR>
<VL>93</VL>
<NO>6</NO>
<PG>962-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98309244"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jun-2006" MODIFIED="2010-07-28 11:50:45 +0200" MODIFIED_BY="[Empty name]" NAME="Jun 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-07-28 11:50:45 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jun CH, Park CH, Lee WS, Joo YE, Kim HS, Choi SK, et al</AU>
<TI>Antibiotic prophylaxis using third generation cephalosporins can reduce the risk of early rebleeding in the first acute gastroesophageal variceal hemorrhage: a prospective randomized study</TI>
<SO>Journal of Korean Medical Science</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>5</NO>
<PG>883-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lata-2005" MODIFIED="2010-07-28 11:50:53 +0200" MODIFIED_BY="[Empty name]" NAME="Lata 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-07-28 11:50:53 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lata J, Jurankova J, Husova L, Senkyrik M, Dite P, Dastych M, et al</AU>
<TI>Variceal bleeding in portal hypertension: bacterial infection and comparison of efficacy of intravenous and per-oral application of antibiotics - a randomized trial</TI>
<SO>European Journal of Gastroenterology &amp; Hepatology</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>10</NO>
<PG>1105-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2002" MODIFIED="2010-07-28 11:51:03 +0200" MODIFIED_BY="[Empty name]" NAME="Lin 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-07-28 11:51:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin YT, Lo GH, Lai KH, Chen TA, Lin WJ</AU>
<TI>Prophylactic antibiotics in cirrhotics with upper gastrointestinal hemorrhage: a prospective, controlled trial</TI>
<SO>Zhonghua Yi Xue Za Zhi (Taipei)</SO>
<YR>2002</YR>
<VL>65</VL>
<NO>8</NO>
<PG>365-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pauwels-1996" NAME="Pauwels 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pauwels A, Mostefa Kara N, Debenes B, Degoutte E, Levy VG</AU>
<TI>Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection</TI>
<SO>Hepatology</SO>
<YR>1996</YR>
<VL>24</VL>
<NO>4</NO>
<PG>802-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97007920"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rimola-1985" MODIFIED="2010-07-09 15:24:45 +0200" MODIFIED_BY="[Empty name]" NAME="Rimola 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-07-09 15:24:45 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rimola A, Bory F, Teres J, Perez-Ayuso R, Arroyo V, Rodes J</AU>
<TI>Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage</TI>
<SO>Hepatology</SO>
<YR>1985</YR>
<VL>5</VL>
<NO>3</NO>
<PG>463-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="85205789"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rolando-1993" MODIFIED="2010-07-09 15:25:04 +0200" MODIFIED_BY="[Empty name]" NAME="Rolando 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-07-09 15:25:03 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Rolando N, Gimson A, Philpott-Howard J, Sahathevan M, Casewell M, Fagan E, et al. Infectious sequelae after endoscopic sclerotherapy of oesophageal varices: role of antibiotic prophylaxis. J Hepatol 1993;18(3):290-4.&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 15:25:03 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rolando N, Gimson A, Philpott-Howard J, Sahathevan M, Casewell M, Fagan E, et al</AU>
<TI>Infectious sequelae after endoscopic sclerotherapy of oesophageal varices: role of antibiotic prophylaxis</TI>
<SO>Journal of Hepatology</SO>
<YR>1993</YR>
<VL>18</VL>
<NO>3</NO>
<PG>290-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="94044619"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sabat-1998" NAME="Sabat 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Sabat MKLOJPJNMTVCSSTJSGGC, Balanzo J. Parental antibiotic prophylaxis in cirrhotic patients with gastrointestinal bleeding [AASLD abstract]. Hepatology 1996;24(4 Pt.2):448a.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sabat M, Kolle L, Ortiz J, Pamplona J, Novella MT, Villanueva C, et al</AU>
<TI>Parental antibiotic prophylaxis in cirrhotic patients with gastrointestinal bleeding (AASLD abstract)</TI>
<SO>Hepatology</SO>
<YR>1996</YR>
<VL>24</VL>
<NO>4 Pt 2</NO>
<PG>448A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Sabat M, Kolle L, Soriano G, Ortiz J, Pamplona J, Novella MT, et al. Parenteral antibiotic prophylaxis of bacterial infections does not improve cost-efficacy of oral norfloxacin in cirrhotic patients with gastrointestinal bleeding. Am J Gastroenterol 1998;93(12):2457-62.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sabat M, Kolle L, Soriano G, Ortiz J, Pamplona J, Novella MT, et al</AU>
<TI>Parenteral antibiotic prophylaxis of bacterial infections does not improve cost-efficacy of oral norfloxacin in cirrhotic patients with gastrointestinal bleeding</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1998</YR>
<VL>93</VL>
<NO>12</NO>
<PG>2457-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99075752"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Selby-1994" MODIFIED="2010-07-09 15:25:17 +0200" MODIFIED_BY="[Empty name]" NAME="Selby 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-07-09 15:25:17 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Selby WS, Norton ID, Pokorny CS, Benn RA. Bacteremia and bacterascites after endoscopic sclerotherapy for bleeding esophageal varices and prevention by intravenous cefotaxime: a randomized trial. Gastrointest Endosc 1994;40(6):680-4.&lt;/p&gt;" NOTES_MODIFIED="2010-07-09 15:25:17 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Selby WS, Norton ID, Pokorny CS, Benn RA</AU>
<TI>Bacteremia and bacterascites after endoscopic sclerotherapy for bleeding esophageal varices and prevention by intravenous cefotaxime: a randomized trial</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1994</YR>
<VL>40</VL>
<NO>6</NO>
<PG>680-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95163822"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soriano-1992" MODIFIED="2010-07-28 11:47:42 +0200" MODIFIED_BY="[Empty name]" NAME="Soriano 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-07-28 11:47:42 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Soriano G, Guarner C, Tomas A, Villanueva C, Torras X, Gonzalez D, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage [see comments]. Gastroenterology 1992;103(4):1267-72.&lt;/p&gt;" NOTES_MODIFIED="2010-07-28 11:47:42 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Soriano G, Guarner C, Tomas A, Villanueva C, Torras X, Gonzalez D, et al</AU>
<TI>Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage (see comments)</TI>
<SO>Gastroenterology</SO>
<YR>1992</YR>
<VL>103</VL>
<NO>4</NO>
<PG>1267-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Soriano G, Guarner G, Tena F, Villanueva C, Fabrega E, Gonzalez D, et al. Prophylaxis of infections with norfloxacin in cirrhotic patients with gastrointestinal bleeding. EASL abstract 1990;11(Suppl 2):S56.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soriano G, Guarner G, Tena F, Villanueva C, Fabrega E, Gonzalez D, et al</AU>
<TI>Prophylaxis of infections with norfloxacin in cirrhotic patients with gastrointestinal bleeding (EASL abstract)</TI>
<SO>Journal of Hepatology</SO>
<YR>1990</YR>
<VL>11</VL>
<NO>Suppl 2</NO>
<PG>S56</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99075752"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spanish-Group-1998" MODIFIED="2010-07-09 15:25:31 +0200" MODIFIED_BY="[Empty name]" NAME="Spanish Group 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-07-09 15:25:31 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spanish Group for the Study of Bacterial Infections in Cirrhosis</AU>
<TI>Norfloxacin versus ofloxacin in the prophylaxis of infection in cirrhotic patients with gastrointestinal hemorrhage</TI>
<SO>Journal of Hepatology</SO>
<YR>1998</YR>
<VL>28</VL>
<NO>Suppl 1</NO>
<PG>80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Zacharof-1997" NAME="Zacharof 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Zacharof A, Petrogiannopoulos C, Flevaris C, Deliousis A, J P. Ciprofloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage [EASL abstract]. Paper presented at: J Hepatol; 1997, 1997.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zacharof A, Petrogiannopoulos C, Flevaris C, Deliousis A, Poulikakos J</AU>
<TI>Ciprofloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage (EASL abstract)</TI>
<SO>Journal of Hepatology</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>Suppl 1</NO>
<PG>12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Zacharof A, Petrogiannopoulos C, Soutos D, Katsaros D, Zacharof H, J P. Bacterial infection is prevented by ciprofloxacin in cirrhotics with gastrointestinal hemorrhage [abstract]. Paper presented at: Gut; 1997, 1997.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zacharof A, Petrogiannopoulos C, Soutos D, Katsaros D, Zacharof H</AU>
<TI>Bacterial infection is prevented by ciprofloxacin in cirrhotics with gastrointestinal hemorrhage (Abstract)</TI>
<SO>Gut</SO>
<YR>1997</YR>
<VL>41</VL>
<NO>Suppl 3</NO>
<PG>A189</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-07-28 12:33:25 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Gines-1990" NAME="Gines 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Gines P, Rimola A, Planas R, Vargas V, Forne M, Miranda ML, et al. Norfloxacin prevents spontaneous bacterial peritonitis (SBP) in cirrhosis. Final results of a multicenter double-blind placeo controlled study. EASL abstract 1990;11(suppl 2):S26.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gines P, Rimola A, Planas R, Vargas V, Forne M, Miranda ML, et al</AU>
<TI>Norfloxacin prevents spontaneous bacterial peritonitis (SBP) in cirrhosis. Final results of a multicenter double-blind placebo controlled study (EASL abstract)</TI>
<SO>Journal of Hepatology</SO>
<YR>1990</YR>
<VL>11</VL>
<NO>Suppl2</NO>
<PG>S26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Gines P, Rimola A, Planas R, Vargas V, Llach J, Salmeron JM, et al. Norfloxacin for prophylaxis of spontaneous bacterial peritonitis (SBP) in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology (AASLD Annual Meeting) 1989;10(4):587.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gines P, Rimola A, Planas R, Vargas V, Llach J, Salmeron JM, et al</AU>
<TI>Norfloxacin for prophylaxis of spontaneous bacterial peritonitis (SBP) in cirrhosis: results of a double-blind, placebo-controlled trial (AASLD Annual Meeting)</TI>
<SO>Hepatology</SO>
<YR>1989</YR>
<VL>10</VL>
<NO>4</NO>
<PG>587</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Gines P, Rimola A, Planas R, Vargas V, Marco F, Almela M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990;12(4 Pt 1):716-24.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gines P, Rimola A, Planas R, Vargas V, Marco F, Almela M, et al</AU>
<TI>Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial</TI>
<SO>Hepatology</SO>
<YR>1990</YR>
<VL>12</VL>
<PG>716-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="91007687"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goulis-1998" MODIFIED="2010-07-28 12:33:25 +0200" MODIFIED_BY="[Empty name]" NAME="Goulis 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-07-28 12:33:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK</AU>
<TI>Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage</TI>
<SO>Hepatology</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>5</NO>
<PG>1207-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henrion-1992" MODIFIED="2010-07-28 11:56:28 +0200" MODIFIED_BY="[Empty name]" NAME="Henrion 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-07-28 11:56:28 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Henrion J, Schapira M, Derue G, Heller FR. [Prevention of bacterial infection using selective intestinal decontamination in patients with cirrhosis admitted to intensive care. Controlled study in 120 patients]. [French]. Acta Gastroenterologica Belgica 1992;55(4):333-40.&lt;/p&gt;" NOTES_MODIFIED="2010-07-28 11:56:28 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henrion J, Schapira M, Derue G, Heller FR</AU>
<TI>Prevention of bacterial infection using selective intestinal decontamination in patients with cirrhosis admitted to intensive care. Controlled study in 120 patients</TI>
<TO>Prevention de l'infection bacterienne par decontamination intestinale selective chez des patients cirrhotiques admis en soins intensifs Etude controlee chez 120 malades</TO>
<SO>Acta Gastroenterologica Belgica</SO>
<YR>1992</YR>
<VL>55</VL>
<NO>4</NO>
<PG>333-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="93097875"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Husova-2005" MODIFIED="2010-07-28 11:56:42 +0200" MODIFIED_BY="[Empty name]" NAME="Husova 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-07-28 11:56:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Husova L, Lata J, Husa P, Senkyrik M, Jurankova J, Dite P</AU>
<TI>Bacterial infection and acute bleeding from upper gastrointestinal tract in patients with liver cirrhosis</TI>
<SO>Hepato-Gastroenterology</SO>
<YR>2005</YR>
<VL>52</VL>
<NO>65</NO>
<PG>1488-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Novella-1997" NAME="Novella 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Novella M, Sola R, Soriano G, Andreu M, Gana J, Ortiz J, et al</AU>
<TI>Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin</TI>
<SO>Hepatology</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>3</NO>
<PG>532-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97201407"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ortiz J, Vila M, Soriano G, Minana J, Gana J, Mirelis B, et al</AU>
<TI>Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients</TI>
<SO>Hepatology</SO>
<YR>1999</YR>
<VL>29</VL>
<NO>4</NO>
<PG>1064-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99197082"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pohl-2004" MODIFIED="2010-07-28 11:58:25 +0200" MODIFIED_BY="[Empty name]" NAME="Pohl 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-07-28 11:58:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pohl J, Pollmann K, Sauer P, Ring A, Stremmel W, Schlenker T</AU>
<TI>Antibiotic prophylaxis after variceal hemorrhage reduces incidence of early rebleeding</TI>
<SO>Hepato-Gastroenterology</SO>
<YR>2004</YR>
<VL>51</VL>
<NO>56</NO>
<PG>541-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pulanic-1989" MODIFIED="2010-07-09 17:42:31 +0200" MODIFIED_BY="[Empty name]" NAME="Pulanic 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-07-09 17:42:31 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pulanic R, Vrhovac B, Jereb B, Jokic N</AU>
<TI>Controlled trial of the prophylactic administration of antibiotics in sclerotherapy of esophageal varices</TI>
<SO>Journal of Chemotherapy</SO>
<YR>1989</YR>
<VL>1</VL>
<NO>4</NO>
<PG>261-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="90039469"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilbur-2005" MODIFIED="2010-07-09 17:43:00 +0200" MODIFIED_BY="[Empty name]" NAME="Wilbur 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-07-09 17:43:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilbur K, Sidhu K</AU>
<TI>Antimicrobial therapy in patients with acute variceal hemorrhage</TI>
<SO>Canadian Journal of Gastroenterology</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>10</NO>
<PG>607-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2002" MODIFIED="2010-07-28 12:31:29 +0200" MODIFIED_BY="[Empty name]" NAME="Zhao 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-07-28 12:31:29 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao C, Chen SB, Zhou JP, Xiao W, Fan HG, Wu XW, et al</AU>
<TI>Prognosis of hepatic cirrhosis patients with esophageal or gastric variceal hemorrhage: multivariate analysis</TI>
<SO>Hepatobiliary &amp; Pancreatic Diseases International</SO>
<YR>2002</YR>
<VL>1</VL>
<NO>3</NO>
<PG>416-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-06-24 15:33:57 +0200" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-08-04 15:15:24 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-08-04 15:15:24 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-2003" MODIFIED="2010-07-28 12:29:37 +0200" MODIFIED_BY="[Empty name]" NAME="Altman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Interaction revisited: the difference between two estimates</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2003</YR>
<VL>326</VL>
<NO>7382</NO>
<PG>219</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Augustin-2009" MODIFIED="2010-07-28 12:29:43 +0200" MODIFIED_BY="[Empty name]" NAME="Augustin 2009" TYPE="JOURNAL_ARTICLE">
<AU>Augustin S, Muntaner L, Altamirano JT, Gonzalez A, Saperas E, Dot J, et al</AU>
<TI>Predicting early mortality after acute variceal hemorrhage based on classification and regression tree analysis</TI>
<SO>Clinical Gastroenterology and Hepatology</SO>
<YR>2009</YR>
<VL>7</VL>
<NO>12</NO>
<PG>1347-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bernard-1999" MODIFIED="2010-07-28 11:59:24 +0200" MODIFIED_BY="[Empty name]" NAME="Bernard 1999" TYPE="JOURNAL_ARTICLE">
<AU>Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T</AU>
<TI>Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis</TI>
<SO>Hepatology</SO>
<YR>1999</YR>
<VL>29</VL>
<NO>6</NO>
<PG>1655-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bosch-2008" MODIFIED="2010-07-28 12:29:57 +0200" MODIFIED_BY="[Empty name]" NAME="Bosch 2008" TYPE="JOURNAL_ARTICLE">
<AU>Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG</AU>
<TI>The management of portal hypertension: rational basis, available treatments and future options</TI>
<SO>Journal of Hepatology</SO>
<YR>2008</YR>
<VL>48</VL>
<NO>Suppl 1</NO>
<PG>S68-S92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bosch-2009" MODIFIED="2010-07-28 12:30:03 +0200" MODIFIED_BY="[Empty name]" NAME="Bosch 2009" TYPE="JOURNAL_ARTICLE">
<AU>Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC</AU>
<TI>The clinical use of HVPG measurements in chronic liver disease</TI>
<SO>Nature Reviews Gastroenterology &amp; Hepatology</SO>
<YR>2009</YR>
<VL>6</VL>
<NO>10</NO>
<PG>573-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brok-2008" MODIFIED="2010-07-09 17:47:27 +0200" MODIFIED_BY="[Empty name]" NAME="Brok 2008" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Gluud C, Wetterslev J</AU>
<TI>Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>8</NO>
<PG>763-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burroughs-2009" MODIFIED="2010-07-28 11:59:51 +0200" MODIFIED_BY="[Empty name]" NAME="Burroughs 2009" TYPE="JOURNAL_ARTICLE">
<AU>Burroughs AK, Triantos CK, O'Beirne J, Patch D</AU>
<TI>Predictors of early rebleeding and mortality after acute variceal hemorrhage in patients with cirrhosis</TI>
<SO>Nature Clinical Practice Gastroenterology &amp; Hepatology</SO>
<YR>2009</YR>
<VL>6</VL>
<NO>2</NO>
<PG>72-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chavez_x002d_Tapia-2007" MODIFIED="2010-07-28 12:00:06 +0200" MODIFIED_BY="[Empty name]" NAME="Chavez-Tapia 2007" TYPE="JOURNAL_ARTICLE">
<AU>Chavez-Tapia NC, Torre-Delgadillo A, Tellez-Avila FI, Uribe M</AU>
<TI>The molecular basis of susceptibility to infection in liver cirrhosis</TI>
<SO>Current Medicinal Chemistry</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>28</NO>
<PG>2954-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2010-07-28 12:00:20 +0200" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97456606"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fernandez-2002" MODIFIED="2010-06-20 18:17:45 +0200" MODIFIED_BY="[Empty name]" NAME="Fernandez 2002" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V, et al</AU>
<TI>Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis</TI>
<SO>Hepatology</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>1</NO>
<PG>140-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garcia_x002d_Tsao-2007" MODIFIED="2010-06-29 16:01:17 +0200" MODIFIED_BY="[Empty name]" NAME="Garcia-Tsao 2007" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Tsao G, Sanyal A J, Grace N D, Carey W</AU>
<TI>Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis</TI>
<SO>Hepatology</SO>
<YR>2007</YR>
<VL>46</VL>
<NO>3</NO>
<PG>922-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garcia_x002d_Tsao-2009" MODIFIED="2010-07-09 17:50:26 +0200" MODIFIED_BY="[Empty name]" NAME="Garcia-Tsao 2009" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Tsao G, Lim J K</AU>
<TI>Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2009</YR>
<VL>104</VL>
<NO>7</NO>
<PG>1802-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2001" MODIFIED="2010-08-04 15:10:11 +0200" MODIFIED_BY="[Empty name]" NAME="Gluud 2001" TYPE="BOOK_SECTION">
<AU>Gluud C</AU>
<TI>Alcoholic hepatitis: no glucocorticosteroids?</TI>
<SO>FALK Symposium 121</SO>
<YR>2001</YR>
<PG>322-42</PG>
<PB>Steatohepatitis (NASH and ASH)</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2010" MODIFIED="2010-07-28 12:30:41 +0200" MODIFIED_BY="[Empty name]" NAME="Gluud 2010" TYPE="OTHER">
<AU>Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al</AU>
<TI>Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs))</TI>
<SO>2010, Issue 7. Art. No.: LIVER</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2010-08-04 15:10:56 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2009" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]</TI>
<SO>The Cochrane Colloboration, 2009. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH_x002d_GCP-1997" MODIFIED="2010-08-04 14:57:25 +0200" MODIFIED_BY="[Empty name]" NAME="ICH-GCP 1997" TYPE="BOOK">
<AU>International Conference on Harmonisation Expert Working Group</AU>
<SO>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice1997 CFR &amp; ICH Guidelines</SO>
<YR>1997</YR>
<VL>1</VL>
<PB>Barnett International/PAREXEL</PB>
<CY>PA 19063-2043, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2001" MODIFIED="2010-08-04 14:59:14 +0200" MODIFIED_BY="[Empty name]" NAME="Jüni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: assessing the quality of controlled clinical trials</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7303</NO>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2010-06-20 18:35:21 +0200" MODIFIED_BY="[Empty name]" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodological quality and discrepancies between large and small randomised trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2010-06-20 18:32:44 +0200" MODIFIED_BY="[Empty name]" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIEC-1988" MODIFIED="2010-07-09 17:51:16 +0200" MODIFIED_BY="[Empty name]" NAME="NIEC 1988" TYPE="JOURNAL_ARTICLE">
<AU>North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices</AU>
<TI>Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1988</YR>
<VL>319</VL>
<NO>15</NO>
<PG>983-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2010" MODIFIED="2010-07-28 12:06:48 +0200" MODIFIED_BY="[Empty name]" NAME="RevMan 2010" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2010</YR>
<EN>5.0</EN>
<PB>Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Royle-2003" MODIFIED="2010-06-20 14:42:14 +0200" MODIFIED_BY="[Empty name]" NAME="Royle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Royle P, Milne R</AU>
<TI>Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>4</NO>
<PG>591-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2010-07-09 17:52:35 +0200" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment in controlled trials</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2009" MODIFIED="2010-07-09 17:53:22 +0200" MODIFIED_BY="[Empty name]" NAME="Thorlund 2009" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Devereaux P J, Wetterslev J, Guyatt G, Ioannidis J P, Thabane L, et al</AU>
<TI>Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>276-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2008" MODIFIED="2010-08-04 15:15:22 +0200" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>1</NO>
<PG>64-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2010-07-28 12:07:29 +0200" MODIFIED_BY="[Empty name]" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-07-28 12:07:38 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Soares_x002d_Weiser-2002" MODIFIED="2010-07-28 12:07:38 +0200" MODIFIED_BY="[Empty name]" NAME="Soares-Weiser 2002" TYPE="COCHRANE_REVIEW">
<AU>Soares-Weiser K, Brezis M, Tur-Kaspa R, Leibovici L</AU>
<TI>Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD002907"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-08-04 21:35:32 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-08-04 21:35:32 +0200" MODIFIED_BY="Dimitrinka Nikolova" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-08-03 12:16:35 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Blaise-1994">
<CHAR_METHODS MODIFIED="2010-08-03 12:16:35 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Data collection: 09/1990 to 01/1992.<BR/>Exclusion from analysis: patients with no oesophageal varices or infected.<BR/>Follow-up period: 14 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-09 17:24:12 +0200" MODIFIED_BY="[Empty name]">
<P>France<BR/>Hospitalised cirrhotic patients with upper gastrointestinal haemorrhage, without infection, or treatment with antibiotics in the previous two weeks.<BR/>Etiology of bleeding: oesophageal varices.<BR/>Initial infection assessment: chest X-ray, blood count, urine/sputum/blood/ascites culture.<BR/>Endoscopy scheduled within 12 h after enrolment.<BR/>Sclerotherapy performed together with endoscopy to stop bleeding.<BR/>Child-Pugh class A/B/C: 0/20/7.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-09 17:24:23 +0200" MODIFIED_BY="[Empty name]">
<P>Experimental: intravenous + oral ofloxacin, 400 mg/day, 10 days; amoxicillin + clavulanic acid (bolus, 1g) before each endoscopy procedure.</P>
<P>Control: no antibiotic prophylaxis.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-09 17:24:27 +0200" MODIFIED_BY="[Empty name]">
<P>Prevent bacterial infections.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-20 04:43:49 +0200" MODIFIED_BY="[Empty name]">
<P>Authors were contacted for the first version of this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-04 11:41:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fernandez-2006">
<CHAR_METHODS MODIFIED="2010-08-03 12:16:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Data collection 02/2000 to 04/2004.<BR/>Exclusion from analysis: occult infection (positive blood cultures obtained prior to randomisation) and less than two signs of liver failure (Norfloxacin group 6/63; Ceftriaxone group 7/61).<BR/>Follow-up period: 10 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-09 17:25:24 +0200" MODIFIED_BY="[Empty name]">
<P>Spain</P>
<P>Multicenter trial on hospitalised patients in patients with cirrhosis and upper gastrointestinal haemorrhage.</P>
<P>Etiology of bleeding: portal hypertension related in 77% of participants.</P>
<P>Initial infection assessment: blood cultures, ascitic fluid polymorphonuclear count, urine sediment and culture, chest X-ray.</P>
<P>Emergency endoscopy within 24 h after onset of the haemorrhage, plus somatostatin or terlipressin on portal hypertension related haemorrhage.</P>
<P>Sclerotherapy or banding was performed to stop bleeding.</P>
<P>Chil-Pugh class A/B/C: 0/52/59.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-04 11:41:50 +0200" MODIFIED_BY="[Empty name]">
<P>Experimental: intravenous ceftriaxone 1g per day for 7 days.</P>
<P>Control: oral norfloxacin 400 mg b.i.d. for 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-09 17:25:31 +0200" MODIFIED_BY="[Empty name]">
<P>Prevention of bacterial infections.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-20 04:44:19 +0200" MODIFIED_BY="[Empty name]">
<P>The authors were contacted via e-mail and response was received (28-June-2010).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-03 12:16:53 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Gulberg-1999">
<CHAR_METHODS MODIFIED="2010-08-03 12:16:53 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Date of collection: no information provided. <BR/>Exclusion from analysis: no information provided.<BR/>Follow-up period: 7 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-09 17:26:05 +0200" MODIFIED_BY="[Empty name]">
<P>Germany<BR/>Cirrhotic patients with upper gastrointestinal haemorrhage, without infection, or treatment with antibiotics in the previous week, who underwent TIPS.<BR/>Etiology of bleeding: no information provided.<BR/>Initial infection assessment: fever, white blood cells, C-reactive protein.</P>
<P>Child-Pugh class A/B/C: 29/39/14.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-09 17:26:08 +0200" MODIFIED_BY="[Empty name]">
<P>Experimental: intravenous ceftriaxone, 1g, single dose before TIPS.</P>
<P>Control: intravenous ceftriaxone, 2g, single dose before TIPS.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-09 17:26:09 +0200" MODIFIED_BY="[Empty name]">
<P>Bacterial infection after TIPS procedure.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-20 04:44:28 +0200" MODIFIED_BY="[Empty name]">
<P>Authors were contacted for the first version of this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-04 11:41:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hong-2002">
<CHAR_METHODS MODIFIED="2010-08-03 12:17:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Data collection: 12/1998 to 9/2001. <BR/>Exclusion from analysis: death or surgery within 24 h.<BR/>Follow-up period: 30 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-09 17:26:45 +0200" MODIFIED_BY="[Empty name]">
<P>Korea</P>
<P>Hospitalised cirrhotic patients with oesophageal variceal bleeding, without infection or previous use of antibiotics.</P>
<P>Initial infection assessment: physical examination, white blood cells count, liver function test, ascitic fluid analysis and culture.</P>
<P>All patients were enrolled after emergency endoscopic oesophageal variceal ligation.</P>
<P>Child-Pugh class: 8.8 ± 1.6 vs 9.1 ± 1.4.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-04 11:41:49 +0200" MODIFIED_BY="[Empty name]">
<P>Experimental: intravenous ciprofloxacin 200 mg b.i.d. for 3 days.</P>
<P>Control: no antibiotic prophylaxis.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-09 17:26:49 +0200" MODIFIED_BY="[Empty name]">
<P>Prevention of bacterial infections.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-20 04:45:21 +0200" MODIFIED_BY="[Empty name]">
<P>The authors were contacted via e-mail and no response was received (23-June-2010).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-04 11:41:16 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hou-2004">
<CHAR_METHODS MODIFIED="2010-08-03 12:17:09 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Data collection: 01/2001 to 02/2003. <BR/>Exclusion from analysis: positive initial bacteriological sample.<BR/>Follow-up period: until death or 3 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-09 17:27:25 +0200" MODIFIED_BY="[Empty name]">
<P>Taiwan</P>
<P>Hospitalised patients with endoscopy-proven gastroesophageal variceal bleeding without signs of infection.</P>
<P>Etiology of bleeding: endoscopy-proven gastroesophageal variceal bleeding.</P>
<P>Endoscopic procedure was completed within 24 h of admission or bleeding onset.</P>
<P>Endoscopic variceal ligation or sclerotherapy was preceded by vasoactive agent or balloon tamponade.</P>
<P>Child-Pugh class (A/B/C): 20/64/27.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-04 11:41:16 +0200" MODIFIED_BY="[Empty name]">
<P>Experimental: intravenous ofloxacin 200 mg b.i.d. for 2 days followed by oral ofloxacin 200 mg b.i.d. for 5 days.</P>
<P>Control: no antibiotic prophylaxis.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-09 17:27:31 +0200" MODIFIED_BY="[Empty name]">
<P>Rebleeding rate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-20 04:45:46 +0200" MODIFIED_BY="[Empty name]">
<P>The authors were contacted via e-mail and no response was received (23-June-2010).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-20 04:46:12 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hsieh-1998">
<CHAR_METHODS MODIFIED="2010-07-09 17:28:02 +0200" MODIFIED_BY="[Empty name]">
<P>Data collection: 07/95 to 07/96.<BR/>Exclusion from analysis: no information.<BR/>Follow-up period: 30 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-09 17:28:15 +0200" MODIFIED_BY="[Empty name]">
<P>Taiwan<BR/>Hospitalised cirrhotic patients with upper gastrointestinal haemorrhage, without infection, or treatment with antibiotics in the previous two weeks.<BR/>Etiology of bleeding: oesophageal or gastric varices, peptic ulcers, others.<BR/>Initial infection assessment: chest X-ray, blood count, urine/blood/ascites culture.<BR/>Source of bleeding determined by endoscopy scheduled within 24 h after enrolment.<BR/>Sclerotherapy, or band ligation performed within 48 h after enrolment.<BR/>Child-Pugh class A/B/C: 11/64/45.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-09 17:28:18 +0200" MODIFIED_BY="[Empty name]">
<P>Experimental: oral ciprofloxacin, 1 g/day, 7 days.</P>
<P>Control: placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-09 17:28:20 +0200" MODIFIED_BY="[Empty name]">
<P>Prevention of bacterial infections.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-20 04:46:12 +0200" MODIFIED_BY="[Empty name]">
<P>Authors were contacted for the first version of this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-04 21:34:08 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Jun-2006">
<CHAR_METHODS MODIFIED="2010-08-03 12:17:19 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Data collection: 01/2010 to 12/2004. <BR/>Exclusion from the analysis: past history of previous gastroesophageal variceal bleeding, or surgical or endoscopic treatment of gastroesophageal varices; or antibiotics use in the previous two weeks; or terminal illness (or non hepatic malignancy); or other causes of gastrointestinal bleeding.<BR/>Follow-up period: 22 ± 14 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-04 15:18:07 +0200" MODIFIED_BY="[Empty name]">
<P>Korea</P>
<P>Hospitalised cirrhotic patients with endoscopy-proven bleeding from oesophageal or gastric varices, with no signs of infection at admission.</P>
<P>Etiology of the bleeding: oesophageal or gastric varices.</P>
<P>Initial infection assessment: complete blood cell count, chest X-ray, urine analysis and culture, blood culture, and ascitic fluid neutrophil count with culture.</P>
<P>Endoscopy procedure was performed within 12h of admission to emergency room.</P>
<P>Before endoscopy octreotide was used, followed by endoscopic treatment (variceal ligation or sclerotherapy).</P>
<P>Child-Pugh class A/B/C: 8.7 ± 1.9 and 8.3 ± 2.1.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-04 21:34:08 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Experimental: intravenous cefotaxime 2 g t.i.d for 7 days.</P>
<P>Control: no antibiotic prophylaxis.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-09 17:29:04 +0200" MODIFIED_BY="[Empty name]">
<P>Rebleeding rate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-20 04:46:50 +0200" MODIFIED_BY="[Empty name]">
<P>The authors were contacted via e-mail and no response was received (23-June-2010).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-04 11:41:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lata-2005">
<CHAR_METHODS MODIFIED="2010-07-09 17:29:25 +0200" MODIFIED_BY="[Empty name]">
<P>Data collection: 05/2001 to 11/2003.</P>
<P>Exclusion from analysis: Past history of previous variceal bleeding within 3 months.</P>
<P>Follow-up period: 42 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-09 17:29:41 +0200" MODIFIED_BY="[Empty name]">
<P>Czech Republic.</P>
<P>Hospitalised (intensive care unit) patients with endoscopy proven oesophageal varices.</P>
<P>Etiology of bleeding: oesophageal varices.</P>
<P>Initial infection assessment: aerobic blood culture, anaerobic blood culture, perianal smear, urine examination, throat smear, ascites examination (&gt;250 neutrophils/mL).</P>
<P>The endoscopic treatment was performed within 3 h after admission to intensive care unit and was preceded by the administration of terlipressin.</P>
<P>Schlerotherapy performed together with endoscopy to stop bleeding.</P>
<P>Child-Pugh class A/B/C: 4/19/23.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-04 11:41:48 +0200" MODIFIED_BY="[Empty name]">
<P>Experimental:intravenous ampicillin/sulbactam 1.5 g b.i.d. for 7 days.</P>
<P>Control: oral or through nasogastric tube norfloxacin 400 mg b.i.d. for 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-09 17:29:46 +0200" MODIFIED_BY="[Empty name]">
<P>Early and late mortality.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-20 04:47:09 +0200" MODIFIED_BY="[Empty name]">
<P>The authors were contacted via e-mail and no response was received (23-June-2010).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-03 12:17:34 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Lin-2002">
<CHAR_METHODS MODIFIED="2010-08-03 12:17:34 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Data collection: 7/1999 to 8/2000. <BR/>Exclusion from analysis: life expectancy less than 7 days, fever or infection on entry, positive bacterial culture on entry, and previous use of antibiotics within 2 weeks prior to admission. <BR/>Initial infection assessment: blood culture, urine culture cell, chest X-ray, sputum culture, and ascitic fluid culture. <BR/>Follow-up period: 7 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-09 17:30:24 +0200" MODIFIED_BY="[Empty name]">
<P>Taiwan</P>
<P>Hospitalised cirrhotic patients with endoscopy proven upper gastrointestinal bleeding, without infection or previous use of antibiotics.</P>
<P>Endoscopy was performed 12 h within of hospitalisation.</P>
<P>The haemostatic procedure include band ligation plus somastotatin, sandostatin or terlipressin (variceal bleeding) or endoscopic injection of water or diluted epinephrine (peptic ulcer bleeding).</P>
<P>Child-Pugh class A/B/C: 27/50/20.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-09 17:30:28 +0200" MODIFIED_BY="[Empty name]">
<P>Experimental: intravenous cefazolin 1 g tid during 3 days and then shift to oral cephalexin 500 mg qid for 4 days.</P>
<P>Control: no antibiotic prophylaxis.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-09 17:30:29 +0200" MODIFIED_BY="[Empty name]">
<P>Prevention of bacterial infections.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-20 04:47:31 +0200" MODIFIED_BY="[Empty name]">
<P>The authors were contacted via e-mail and no response was received (23-June-2010).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-04 21:35:26 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Pauwels-1996">
<CHAR_METHODS MODIFIED="2010-08-04 21:35:23 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Data collection: 12/89 to 03/92.<BR/>Exclusion from analysis: infection on admission, undergoing surgery within 24 hs after admission, or death in the first 12 h.<BR/>Follow-up period: up to 10 days after stopping bleeding (four weeks).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-04 21:35:26 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>France<BR/>Hospitalised cirrhotic patients with upper gastrointestinal haemorrhage, without infection, or treatment with antibiotics in the previous week.<BR/>Etiology of bleeding: oesophageal or gastric varices, gastric or duodenal ulceration, and others.</P>
<P>Initial infection assessment: chest X-ray, white blood cell count, urine/blood/ascites culture.<BR/>Source of bleeding determined by endoscopy scheduled within 12 hs after enrolment.<BR/>Emergency sclerotherapy performed for patients bleeding from varices.<BR/>Child-Pugh class A/B/C: 16/54/49.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-09 17:31:23 +0200" MODIFIED_BY="[Empty name]">
<P>Experimental (Group III): intravenous + oral ciprofloxacin 400mg per day, amoxicillin-clavulanic acid 3g per day, until three days after cessation of haemorrhage.</P>
<P>Control (Group I and II): no antibiotic prophylaxis.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-09 17:31:25 +0200" MODIFIED_BY="[Empty name]">
<P>Prevention of bacterial infections.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-20 04:48:01 +0200" MODIFIED_BY="[Empty name]">
<P>Two group of patients received no intervention and were combined for the purpose of this review.</P>
<P>Authors were contacted for the first version of this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-04 21:35:32 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Rimola-1985">
<CHAR_METHODS MODIFIED="2010-08-04 21:35:29 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Data collection: no information provided.<BR/>Exclusion from analysis: underwent surgery, or died within 24 hs after admission.<BR/>Follow-up period: up to 10 days after stopping bleeding (four weeks).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-04 21:35:32 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Spain<BR/>Hospitalised cirrhotic patients with upper gastrointestinal haemorrhage, without infection, or treatment with antibiotics in the previous two weeks.<BR/>Etiology of bleeding: oesophageal varices (128 patients), gastric haemorrhage ( 10 patients), peptic ulcers (8 patients).<BR/>Initial infection assessment: chest X-ray, white blood cell count, urine/blood/ascites culture.<BR/>Source of bleeding determined by endoscopy scheduled within 24 hs after enrolment.<BR/>Emergency sclerotherapy performed for patients bleeding from varices.<BR/>Child-Pugh class A/B/C: not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-08-04 11:41:47 +0200" MODIFIED_BY="[Empty name]">
<P>Experimental (non-absorbable antibiotics):<BR/>Group Ia - oral gentamicin (200mg) + vancomycin (500 mg) + nystatin (10^6 UI) every six hs, until two days after cessation of haemorrhage.<BR/>Group Ib - neomycin (1 gm) + colistin (1.5 x 10^6 UI) + nystatin (10^6 UI) every six hs, until two days after cessation of haemorrhage.</P>
<P>Control (Group II): no antibiotic prophylaxis.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-09 17:32:18 +0200" MODIFIED_BY="[Empty name]">
<P>Prevent bacterial infections.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-20 04:48:52 +0200" MODIFIED_BY="[Empty name]">
<P>The antibiotic therapy regimen was modified after inclusion of the first 40 patients in the experimental group because of budget constraints.<BR/>The two group of patients treated with antibiotics were combined for the purpose of this review.</P>
<P>Authors were contacted for the first version of this review, and additional information was received.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-20 04:49:35 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rolando-1993">
<CHAR_METHODS MODIFIED="2010-07-09 17:32:46 +0200" MODIFIED_BY="[Empty name]">
<P>Data collection: no information provided.<BR/>Exclusion from analysis: bleeding not related to variceal bleeding.<BR/>Follow-up period: 7 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-09 17:32:56 +0200" MODIFIED_BY="[Empty name]">
<P>UK<BR/>Hospitalised cirrhotic patients with upper gastrointestinal haemorrhage and high risk of infection, without infection, or treatment with antibiotics in the previous two weeks.<BR/>Etiology of bleeding: all patients had oesophageal varices.<BR/>Endoscopic sclerotherapy was performed after randomisation.<BR/>Initial infection assessment: chest X-ray, white blood cell count, urine/blood/ascites culture.<BR/>Child-Pugh class A/B/C: not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-09 17:33:04 +0200" MODIFIED_BY="[Empty name]">
<P>Experimental: intravenous imipenem + cilastin, 500 mg before and after the sclerotherapy.</P>
<P>Control: intravenous dextrose-saline solution.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-09 17:33:05 +0200" MODIFIED_BY="[Empty name]">
<P>Prevent bacterial infections.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-20 04:49:35 +0200" MODIFIED_BY="[Empty name]">
<P>Authors were contacted for the first version of this review, and additional information was received.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-04 11:41:54 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sabat-1998">
<CHAR_METHODS MODIFIED="2010-08-04 11:41:28 +0200" MODIFIED_BY="[Empty name]">
<P>Data collection: 06/93 to 06/95.<BR/>Exclusion from analysis: occult infection, or underwent surgery, or died within 24 hs after admission.<BR/>Follow-up period: up to three weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-04 11:41:54 +0200" MODIFIED_BY="[Empty name]">
<P>Spain<BR/>Hospitalised cirrhotic patients with upper gastrointestinal haemorrhage and high risk of infection, without infection, or treatment with antibiotics in the previous two weeks.<BR/>Etiology of bleeding: no information.<BR/>Initial infection assessment: chest X-ray, white blood cell count, urine/blood/ascites culture.<BR/>Source of bleeding determined by endoscopy scheduled within four hs after enrolment.<BR/>Emergency sclerotherapy performed for patients bleeding from varices.<BR/>Child-Pugh class A/B/C: 4/31/11.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-09 17:33:50 +0200" MODIFIED_BY="[Empty name]">
<P>Experimental: oral norfloxacin 800 mg/day, during seven days plus intravenous ceftriaxone 2g/day the first three days.</P>
<P>Control: oral norfloxacin 800 mg/day, seven days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-09 17:33:52 +0200" MODIFIED_BY="[Empty name]">
<P>Prevent bacterial infections.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-20 04:50:00 +0200" MODIFIED_BY="[Empty name]">
<P>The initial sample size was calculated to be 152 patients. An interim analysis was done after 1/3 of patients were included, a statistical significant result was found and the trial was stopped.</P>
<P>Authors were contacted for the first version of this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-04 21:35:05 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Selby-1994">
<CHAR_METHODS MODIFIED="2010-08-04 21:35:05 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Data collection: 08/89 to 12/91.<BR/>Exclusion from analysis: no information provided.<BR/>Follow-up period: up to 24 hs.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-09 17:34:46 +0200" MODIFIED_BY="[Empty name]">
<P>Australia<BR/>Hospitalised cirrhotic patients with upper gastrointestinal haemorrhage and high risk of infection, without infection, or treatment with antibiotics in the previous two weeks.<BR/>Etiology of bleeding: no information provided.<BR/>All patients underwent emergency section of sclerotherapy, followed by further sections in weekly intervals.<BR/>Initial infection assessment: chest X-ray, white blood cell count, urine/blood/ascites culture.<BR/>Child-Pugh class A/B/C: 8/18/13.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-09 17:34:50 +0200" MODIFIED_BY="[Empty name]">
<P>Experimental: intravenous cefotaxime, 1 g immediately before sclerotherapy.</P>
<P>Control: no antibiotic prophylaxis.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-09 17:34:51 +0200" MODIFIED_BY="[Empty name]">
<P>Prevent bacterial infections.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-20 04:50:05 +0200" MODIFIED_BY="[Empty name]">
<P>Authors were contacted for the first version of this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-04 21:35:15 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Soriano-1992">
<CHAR_METHODS MODIFIED="2010-08-04 21:35:11 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Data collection: 08/89 to 06/91.<BR/>Exclusion from analysis: underwent surgery, or died within 24 hs after admission.<BR/>Follow-up period: up to four weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-04 21:35:15 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Spain<BR/>Hospitalised cirrhotic patients with upper gastrointestinal haemorrhage, without infection or treatment with antibiotics in the previous two weeks.<BR/>Etiology of bleeding: oesophageal varices, gastric haemorrhage, peptic ulcers, and others.<BR/>Initial infection assessment: chest X-ray, white blood cell count, urine/blood/ascites culture.<BR/>Source of bleeding determined by endoscopy scheduled within four hs after enrolment.<BR/>Emergency sclerotherapy performed for patients bleeding from varices.<BR/>Child-Pugh class A/B/C: 40/55/24.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-09 17:35:32 +0200" MODIFIED_BY="[Empty name]">
<P>Experimental: oral norfloxacin 800 mg/day during seven days.</P>
<P>Control: no antibiotic prophylaxis.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-09 17:35:34 +0200" MODIFIED_BY="[Empty name]">
<P>Prevent bacterial infection.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-20 04:50:14 +0200" MODIFIED_BY="[Empty name]">
<P>Authors were contacted for the first version of this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-20 04:50:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spanish-Group-1998">
<CHAR_METHODS MODIFIED="2010-07-09 17:37:37 +0200" MODIFIED_BY="[Empty name]">
<P>Data collection: no information provided.<BR/>Exclusion from analysis: no information provided.<BR/>Follow-up period: first 10 days of the bleeding episode.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-09 17:37:45 +0200" MODIFIED_BY="[Empty name]">
<P>Spain<BR/>Cirrhotic patients with upper gastrointestinal haemorrhage.<BR/>Etiology of bleeding: no information provided.<BR/>Initial infection assessment: no information provided.<BR/>Source of bleeding determined by: no information.<BR/>Child-Pugh class A/B/C: no information provided.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-09 17:37:52 +0200" MODIFIED_BY="[Empty name]">
<P>Experimental: oral norfloxacin, 800 mg/day, five days.</P>
<P>Control: oral ofloxacin, 400 mg/day, five days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-09 17:37:53 +0200" MODIFIED_BY="[Empty name]">
<P>Prevent bacterial infections.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-20 04:50:33 +0200" MODIFIED_BY="[Empty name]">
<P>Data extracted from an abstract, no publication available.</P>
<P>Authors were contacted for the first version of this review, and additional information was received.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-20 04:50:45 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zacharof-1997">
<CHAR_METHODS MODIFIED="2010-07-09 17:38:17 +0200" MODIFIED_BY="[Empty name]">
<P>Data collection: no information provided.<BR/>Exclusion from analysis: no information provided.<BR/>Follow-up period: no information provided.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-09 17:38:27 +0200" MODIFIED_BY="[Empty name]">
<P>Greece<BR/>Hospitalised cirrhotic patients with upper gastrointestinal haemorrhage.<BR/>Etiology of bleeding: no information provided.<BR/>Source of bleeding determined by emergency endoscopy.<BR/>Child-Pugh class A/B/C: not information provided.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-09 17:38:30 +0200" MODIFIED_BY="[Empty name]">
<P>Experimental: oral ciprofloxacin 500 mg/day during seven days.</P>
<P>Control: no antibiotic prophylaxis.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-09 17:38:32 +0200" MODIFIED_BY="[Empty name]">
<P>Prevent bacterial infections.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-20 04:50:45 +0200" MODIFIED_BY="[Empty name]">
<P>Data extracted from an abstract, and confirmed by the authors.</P>
<P>Authors were contacted for the first version of this review, and additional information was received.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>b.i.d. = twice (two times) a day.<BR/>hs = hours.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-08-03 12:19:12 +0200" MODIFIED_BY="Dimitrinka Nikolova" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-08-03 12:18:22 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Gines-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-03 12:18:22 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Spain<BR/>Randomised clinical trial.<BR/>Through communication with the first author it was clarified that the patients did not have upper gastrointestinal bleeding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-03 12:19:02 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Goulis-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-03 12:19:02 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>UK <BR/>Observational study. Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-03 12:19:12 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Henrion-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-03 12:19:12 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Belgium<BR/>Controlled clinical study.<BR/>Inadequate allocation concealment, alternate method.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-03 12:18:59 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Husova-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-03 12:18:59 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Czech Republic <BR/>Observational study. Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-03 12:18:34 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Novella-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-03 12:18:34 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Spain<BR/>Randomised clinical trial.<BR/>Through communication with the first author it was clarified that the patients did not have upper gastrointestinal bleeding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-03 12:18:53 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Pohl-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-03 12:18:53 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Germany<BR/>Retrospective cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-03 12:18:39 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Pulanic-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-03 12:18:39 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Yugoslavia<BR/>Randomised clinical trial.<BR/>No clinical outcomes, only laboratory variables after antibiotic prophylaxis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-03 12:18:41 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Wilbur-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-03 12:18:41 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Canada<BR/>Retrospective cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-03 12:18:47 +0200" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Zhao-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-03 12:18:47 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>China<BR/>Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT - randomised clinical trial.<BR/>CCT - controlled clinical trial.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-06-24 15:33:57 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-08-04 11:41:49 +0200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-08-04 11:41:27 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:24:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blaise-1994">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:25:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fernandez-2006">
<DESCRIPTION>
<P>The sequence was generated using a random number software.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:26:11 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gulberg-1999">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:26:53 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2002">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:27:36 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hou-2004">
<DESCRIPTION>
<P>The sequence was generated using a random number software.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:28:25 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hsieh-1998">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:29:06 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jun-2006">
<DESCRIPTION>
<P>The sequence was generated using a table of random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:29:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lata-2005">
<DESCRIPTION>
<P>The sequence was generated using a system of accidental numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:30:34 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2002">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:31:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pauwels-1996">
<DESCRIPTION>
<P>The sequence was generated using a table of random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:32:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rimola-1985">
<DESCRIPTION>
<P>The sequence was generated using random number table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-04 11:41:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rolando-1993">
<DESCRIPTION>
<P>The sequence was generated using a computer-based table of random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:34:07 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sabat-1998">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:35:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Selby-1994">
<DESCRIPTION>
<P>The sequence was generated using a table of random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:37:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soriano-1992">
<DESCRIPTION>
<P>The sequence was generated using a table of random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:37:56 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spanish-Group-1998">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:38:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zacharof-1997">
<DESCRIPTION>
<P>The sequence was generated using a table of random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-07-09 17:38:40 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:24:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blaise-1994">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:25:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fernandez-2006">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:26:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gulberg-1999">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:26:55 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2002">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:27:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hou-2004">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:28:26 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hsieh-1998">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:29:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jun-2006">
<DESCRIPTION>
<P>The concealment was done using numbered envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:29:51 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lata-2005">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:30:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2002">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:31:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pauwels-1996">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:32:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rimola-1985">
<DESCRIPTION>
<P>Adequate, this item keeps as the first review.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:33:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rolando-1993">
<DESCRIPTION>
<P>Patients assigned sequentially, sealed opaque envelopes used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:34:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sabat-1998">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:35:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Selby-1994">
<DESCRIPTION>
<P>The treatment was contained in sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:37:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soriano-1992">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:37:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spanish-Group-1998">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:38:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zacharof-1997">
<DESCRIPTION>
<P>Sequentially administered by a pharmacist not involved in the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-08-04 11:41:49 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-04 11:41:09 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Blaise-1994">
<DESCRIPTION>
<P>Not a blinded trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-04 11:41:12 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fernandez-2006">
<DESCRIPTION>
<P>Not a blinded trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-04 11:41:12 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gulberg-1999">
<DESCRIPTION>
<P>Not a blinded trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-04 11:41:49 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hong-2002">
<DESCRIPTION>
<P>Not a blinded trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-04 11:41:16 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hou-2004">
<DESCRIPTION>
<P>Not a blinded trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-09 17:28:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hsieh-1998">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-04 11:41:17 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jun-2006">
<DESCRIPTION>
<P>Not a blinded trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-04 11:41:19 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lata-2005">
<DESCRIPTION>
<P>Not a blinded trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-04 11:41:19 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lin-2002">
<DESCRIPTION>
<P>Not a blinded trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-04 11:41:48 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pauwels-1996">
<DESCRIPTION>
<P>Not a blinded trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-04 11:41:25 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rimola-1985">
<DESCRIPTION>
<P>Not a blinded trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-04 11:41:47 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rolando-1993">
<DESCRIPTION>
<P>Not a blinded trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-04 11:41:29 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sabat-1998">
<DESCRIPTION>
<P>Not a blinded trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-04 11:41:30 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Selby-1994">
<DESCRIPTION>
<P>Not a blinded trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-04 11:41:30 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Soriano-1992">
<DESCRIPTION>
<P>Not a blinded trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-09 17:37:59 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spanish-Group-1998">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-04 11:41:31 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zacharof-1997">
<DESCRIPTION>
<P>Not a blinded trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-07-09 17:38:43 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-09 17:24:53 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blaise-1994">
<DESCRIPTION>
<P>Missing data are balanced in number across the intervention groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-09 17:25:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fernandez-2006">
<DESCRIPTION>
<P>Missing data are balanced in number across the intervention groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-09 17:26:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gulberg-1999">
<DESCRIPTION>
<P>No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-09 17:26:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2002">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-09 17:27:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hou-2004">
<DESCRIPTION>
<P>Missing data are balanced in number across the intervention groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-09 17:28:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hsieh-1998">
<DESCRIPTION>
<P>No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-09 17:29:10 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jun-2006">
<DESCRIPTION>
<P>The proportion of missing outcomes is higher in the no prophylaxis group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-09 17:29:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lata-2005">
<DESCRIPTION>
<P>No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-09 17:30:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2002">
<DESCRIPTION>
<P>Missing data are balanced in number across the intervention groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-09 17:31:38 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pauwels-1996">
<DESCRIPTION>
<P>Missing data are balanced in number across the intervention groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-09 17:32:30 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rimola-1985">
<DESCRIPTION>
<P>The proportion of missing outcomes is not balanced among the groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-09 17:33:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rolando-1993">
<DESCRIPTION>
<P>Reassons for missing data are based on the violation of the protocol.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-09 17:34:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sabat-1998">
<DESCRIPTION>
<P>Reassons for missing data are based on the violation of the protocol.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-09 17:35:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Selby-1994">
<DESCRIPTION>
<P>Reassons for missing data are based on the violation of the protocol.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-09 17:37:22 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soriano-1992">
<DESCRIPTION>
<P>Reassons for missing data are based on the violation of the protocol and are balanced across the groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-09 17:38:01 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spanish-Group-1998">
<DESCRIPTION>
<P>Insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-09 17:38:43 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zacharof-1997">
<DESCRIPTION>
<P>The report include all the expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-07-09 17:38:45 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:24:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blaise-1994">
<DESCRIPTION>
<P>The report include all the expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:25:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fernandez-2006">
<DESCRIPTION>
<P>The report include all the expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:26:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gulberg-1999">
<DESCRIPTION>
<P>The report include all the expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:26:59 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hong-2002">
<DESCRIPTION>
<P>The report include all the expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:27:51 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hou-2004">
<DESCRIPTION>
<P>The report include all the expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:28:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hsieh-1998">
<DESCRIPTION>
<P>The report include all the expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:29:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jun-2006">
<DESCRIPTION>
<P>The report include all the expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:29:59 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lata-2005">
<DESCRIPTION>
<P>The report include all the expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:30:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2002">
<DESCRIPTION>
<P>The report include all the expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:31:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pauwels-1996">
<DESCRIPTION>
<P>The report include all the expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:32:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rimola-1985">
<DESCRIPTION>
<P>The report include all the expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:33:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rolando-1993">
<DESCRIPTION>
<P>The report include all the expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:34:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sabat-1998">
<DESCRIPTION>
<P>The report include all the expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:35:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Selby-1994">
<DESCRIPTION>
<P>The report include all the expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:37:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soriano-1992">
<DESCRIPTION>
<P>The report include all the expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:38:08 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spanish-Group-1998">
<DESCRIPTION>
<P>Insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:38:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zacharof-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-07-09 17:38:47 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:24:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blaise-1994">
<DESCRIPTION>
<P>The trial appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:25:48 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fernandez-2006">
<DESCRIPTION>
<P>The trial appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:26:22 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gulberg-1999">
<DESCRIPTION>
<P>The report support the intervention effects on surrogates of infection.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:27:01 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2002">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:27:53 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hou-2004">
<DESCRIPTION>
<P>The trial appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:28:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hsieh-1998">
<DESCRIPTION>
<P>The trial appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:29:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jun-2006">
<DESCRIPTION>
<P>The trial appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:30:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lata-2005">
<DESCRIPTION>
<P>The trial appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:30:47 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2002">
<DESCRIPTION>
<P>The trial appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:31:42 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pauwels-1996">
<DESCRIPTION>
<P>The trial appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:32:35 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rimola-1985">
<DESCRIPTION>
<P>The antibiotic therapy regimen was modified after inclusion of the first 40 patients in the experimental group because of budget constraints.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:33:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rolando-1993">
<DESCRIPTION>
<P>The trial appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:34:22 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sabat-1998">
<DESCRIPTION>
<P>The trials was stopped due to economical differences and not due to primary outcome differences.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:35:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Selby-1994">
<DESCRIPTION>
<P>The trial appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:37:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soriano-1992">
<DESCRIPTION>
<P>The trial appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:38:09 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spanish-Group-1998">
<DESCRIPTION>
<P>Insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:38:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zacharof-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2010-07-09 17:38:48 +0200" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Intention to treat analysis?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:24:58 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Blaise-1994">
<DESCRIPTION>
<P>The excluded participants are balanced and with a justifiable reason.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:25:50 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fernandez-2006">
<DESCRIPTION>
<P>The excluded participants are balanced and with a justifiable reason.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:26:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gulberg-1999">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:27:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2002">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:27:55 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hou-2004">
<DESCRIPTION>
<P>The exclusion of the patients was not based on an exclusion rule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:28:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hsieh-1998">
<DESCRIPTION>
<P>All randomised participants were included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:29:18 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jun-2006">
<DESCRIPTION>
<P>The exclusion of the patients was not based on an exclusion rule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:30:02 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lata-2005">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:30:48 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lin-2002">
<DESCRIPTION>
<P>The exclusion of the patients was based an exclusion rule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:31:43 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pauwels-1996">
<DESCRIPTION>
<P>The exclusion of the patients was based on an exclusion rule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:32:36 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rimola-1985">
<DESCRIPTION>
<P>The exclusion of the patients was based on an exclusion rule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:33:18 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rolando-1993">
<DESCRIPTION>
<P>The exclusion of the patients was based on an exclusion rule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:34:24 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sabat-1998">
<DESCRIPTION>
<P>The exclusion of the patients was based on an exclusion rule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:35:12 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Selby-1994">
<DESCRIPTION>
<P>The exclusion of the patients was based on an exclusion rule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:37:31 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Soriano-1992">
<DESCRIPTION>
<P>The exclusion of the patients was based on an exclusion rule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:38:11 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spanish-Group-1998">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:38:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zacharof-1997">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2010-07-09 17:38:50 +0200" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Sample calculation?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:25:00 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Blaise-1994">
<DESCRIPTION>
<P>No sample calculation was done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:25:51 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fernandez-2006">
<DESCRIPTION>
<P>The sample was calculated considering the expected incidence of proved and possible infections.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:26:25 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gulberg-1999">
<DESCRIPTION>
<P>No sample calculation procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:27:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2002">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:27:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hou-2004">
<DESCRIPTION>
<P>The sample was calculated considering the expected rebleeding rate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:28:35 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hsieh-1998">
<DESCRIPTION>
<P>No sample calculation procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:29:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jun-2006">
<DESCRIPTION>
<P>The sample was calculated considering the expected rebleeding rate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:30:04 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lata-2005">
<DESCRIPTION>
<P>No sample calculation procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:30:53 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lin-2002">
<DESCRIPTION>
<P>No sample calculation procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:31:45 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pauwels-1996">
<DESCRIPTION>
<P>No sample calculation procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:32:38 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rimola-1985">
<DESCRIPTION>
<P>No sample calculation procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:33:20 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rolando-1993">
<DESCRIPTION>
<P>No sample calculation procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:34:26 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sabat-1998">
<DESCRIPTION>
<P>The was calculated considering the primary outcome, but the trial was stopped considering differences in secondary outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:35:13 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Selby-1994">
<DESCRIPTION>
<P>No sample calculation procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:37:33 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Soriano-1992">
<DESCRIPTION>
<P>No sample calculation procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:38:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spanish-Group-1998">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-09 17:38:50 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zacharof-1997">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2010-07-09 14:32:10 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2010-07-09 14:32:06 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-07-07 11:48:36 +0200" MODIFIED_BY="[Empty name]">Group of antibiotics compared versus no intervention or placebo</TITLE>
<TABLE COLS="2" ROWS="6">
<TR>
<TH>
<P>Group of antibiotics</P>
</TH>
<TH>
<P>Reference</P>
</TH>
</TR>
<TR>
<TD>
<P>Quinolones</P>
</TD>
<TD>
<P>
<LINK REF="STD-Soriano-1992" TYPE="STUDY">Soriano 1992</LINK>; <LINK REF="STD-Zacharof-1997" TYPE="STUDY">Zacharof 1997</LINK>; <LINK REF="STD-Hsieh-1998" TYPE="STUDY">Hsieh 1998</LINK>; <LINK REF="STD-Hong-2002" TYPE="STUDY">Hong 2002</LINK>; <LINK REF="STD-Hou-2004" TYPE="STUDY">Hou 2004</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Quinolones plus beta-lactams</P>
</TD>
<TD>
<P>
<LINK REF="STD-Blaise-1994" TYPE="STUDY">Blaise 1994</LINK>; <LINK REF="STD-Pauwels-1996" TYPE="STUDY">Pauwels 1996</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Cephalosporins</P>
</TD>
<TD>
<P>
<LINK REF="STD-Selby-1994" TYPE="STUDY">Selby 1994</LINK>; <LINK REF="STD-Lin-2002" TYPE="STUDY">Lin 2002</LINK>; <LINK REF="STD-Jun-2006" TYPE="STUDY">Jun 2006</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Carbapenems</P>
</TD>
<TD>
<P>
<LINK REF="STD-Rolando-1993" TYPE="STUDY">Rolando 1993</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Non absorbable</P>
</TD>
<TD>
<P>
<LINK REF="STD-Rimola-1985" TYPE="STUDY">Rimola 1985</LINK>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2010-07-09 14:32:08 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-07-07 11:50:33 +0200" MODIFIED_BY="[Empty name]">Trials comparing different antibiotic regimens</TITLE>
<TABLE COLS="3" ROWS="6">
<TR>
<TH>
<P>Reference</P>
</TH>
<TH>
<P>Intervention 1</P>
</TH>
<TH>
<P>Intervention 2</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sabat-1998" TYPE="STUDY">Sabat 1998</LINK>
</P>
</TD>
<TD>
<P>Quinolone</P>
</TD>
<TD>
<P>Quinolone plus cephalosporin</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Spanish-Group-1998" TYPE="STUDY">Spanish Group 1998</LINK>
</P>
</TD>
<TD>
<P>Quinolone (Norfloxacin)</P>
</TD>
<TD>
<P>Quinolone (Ofloxacin)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gulberg-1999" TYPE="STUDY">Gulberg 1999</LINK>
</P>
</TD>
<TD>
<P>Cephalosporin low dose</P>
</TD>
<TD>
<P>Cephalosporin high dose</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lata-2005" TYPE="STUDY">Lata 2005</LINK>
</P>
</TD>
<TD>
<P>Quinolone</P>
</TD>
<TD>
<P>beta-lactams</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fernandez-2006" TYPE="STUDY">Fernandez 2006</LINK>
</P>
</TD>
<TD>
<P>Quinolone</P>
</TD>
<TD>
<P>Cephalosporin</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2010-07-09 14:32:10 +0200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-07-07 13:24:35 +0200" MODIFIED_BY="[Empty name]">Test of interaction for antibiotic regimens (assessing bacterial infections)</TITLE>
<TABLE COLS="3" ROWS="7">
<TR>
<TH>
<P>Antibiotic regimen 1</P>
</TH>
<TH>
<P>Antibiotic regimen 1</P>
</TH>
<TH>
<P>P-value</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Cephalosporins</P>
</TD>
<TD ALIGN="CENTER">
<P>Quinolones</P>
</TD>
<TD ALIGN="CENTER">
<P>0.39</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Cephalosporins</P>
</TD>
<TD ALIGN="CENTER">
<P>Quinolones + beta-lactams</P>
</TD>
<TD ALIGN="CENTER">
<P>0.17</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Cephalosporins</P>
</TD>
<TD ALIGN="CENTER">
<P>Other antibiotics</P>
</TD>
<TD ALIGN="CENTER">
<P>0.03</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Quinolones</P>
</TD>
<TD ALIGN="CENTER">
<P>Quinolones + beta-lactams</P>
</TD>
<TD ALIGN="CENTER">
<P>0.29</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Quinolones</P>
</TD>
<TD ALIGN="CENTER">
<P>Other antibiotics</P>
</TD>
<TD ALIGN="CENTER">
<P>0.004</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Quinolones + beta-lactams</P>
</TD>
<TD ALIGN="CENTER">
<P>Other antibiotics</P>
</TD>
<TD ALIGN="CENTER">
<P>0.19</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2010-07-07 13:31:13 +0200" MODIFIED_BY="[Empty name]" NO="4">
<TITLE>Data on trials comparing two different regimens of antibiotic prophylaxis</TITLE>
<TABLE COLS="6" ROWS="13">
<TR>
<TH>
<P>Trial ID</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Experimental (n/N)</P>
</TH>
<TH>
<P>Control (n/N)</P>
</TH>
<TH>
<P>Relative Risk</P>
</TH>
<TH>
<P>95% CI</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sabat-1998" TYPE="STUDY">Sabat 1998</LINK>
</P>
</TD>
<TD>
<P>Mortality</P>
</TD>
<TD>
<P>Norfloxacin + ceftriaxone (1/24)</P>
</TD>
<TD>
<P>Norfloxacin (2/22)</P>
</TD>
<TD>
<P>0.46</P>
</TD>
<TD>
<P>0.04 to 4.71</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sabat-1998" TYPE="STUDY">Sabat 1998</LINK>
</P>
</TD>
<TD>
<P>Bacterial infections</P>
</TD>
<TD>
<P>Norfloxacin + ceftriaxone (3/24)</P>
</TD>
<TD>
<P>Norfloxacin (4/22)</P>
</TD>
<TD>
<P>0.69</P>
</TD>
<TD>
<P>0.17 to 2.73</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sabat-1998" TYPE="STUDY">Sabat 1998</LINK>
</P>
</TD>
<TD>
<P>Cost</P>
</TD>
<TD>
<P>Norfloxacin + ceftriaxone - US $99.3 to 220.1</P>
</TD>
<TD>
<P>Norfloxacin - US $1.9 to 745.5</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sabat-1998" TYPE="STUDY">Sabat 1998</LINK>
</P>
</TD>
<TD>
<P>Drop-outs</P>
</TD>
<TD>
<P>Norfloxacin + ceftriaxone (4/28)</P>
</TD>
<TD>
<P>Norfloxacin (6/28)</P>
</TD>
<TD>
<P>0.67</P>
</TD>
<TD>
<P>0.21 to 2.11</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gulberg-1999" TYPE="STUDY">Gulberg 1999</LINK>
</P>
</TD>
<TD>
<P>Mortality</P>
</TD>
<TD>
<P>Ceftriaxone 1g (0/40)</P>
</TD>
<TD>
<P>Ceftriaxone 2g (0/42)</P>
</TD>
<TD>
<P>Risk difference: 0.00</P>
</TD>
<TD>
<P>-0.05 to 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gulberg-1999" TYPE="STUDY">Gulberg 1999</LINK>
</P>
</TD>
<TD>
<P>Bacterial infections</P>
</TD>
<TD>
<P>Ceftriaxone 1g (1/40)</P>
</TD>
<TD>
<P>Ceftriaxone 2g (1/42)</P>
</TD>
<TD>
<P>1.05</P>
</TD>
<TD>
<P>0.11 to 9.80</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Spanish-Group-1998" TYPE="STUDY">Spanish Group 1998</LINK>
</P>
</TD>
<TD>
<P>Bacterial infections (proven)</P>
</TD>
<TD>
<P>Norfloxacin 800mg (26/183)</P>
</TD>
<TD>
<P>Ofloxacin 400mg (27/182)</P>
</TD>
<TD>
<P>0.96</P>
</TD>
<TD>
<P>0.58 to 1.58</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Spanish-Group-1998" TYPE="STUDY">Spanish Group 1998</LINK>
</P>
</TD>
<TD>
<P>Bacterial infections (suspected)</P>
</TD>
<TD>
<P>Norfloxacin 800mg (51/183)</P>
</TD>
<TD>
<P>Ofloxacin 400mg (53/182)</P>
</TD>
<TD>
<P>0.96</P>
</TD>
<TD>
<P>0.69 to 1.32</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lata-2005" TYPE="STUDY">Lata 2005</LINK>
</P>
</TD>
<TD>
<P>Mortality</P>
</TD>
<TD>
<P>Ampicillin and sulbactam 3g (12/21)</P>
</TD>
<TD>
<P>Norfloxacin 800 mg (7/25)</P>
</TD>
<TD>
<P>2.04</P>
</TD>
<TD>
<P>0.98 to 4.23</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fernandez-2006" TYPE="STUDY">Fernandez 2006</LINK>
</P>
</TD>
<TD>
<P>Mortality</P>
</TD>
<TD>
<P>Ceftriaxone 1g (8/54)</P>
</TD>
<TD>
<P>Norfloxacin 800 mg (6/57)</P>
</TD>
<TD>
<P>1.41</P>
</TD>
<TD>
<P>0.52 to 3.79</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fernandez-2006" TYPE="STUDY">Fernandez 2006</LINK>
</P>
</TD>
<TD>
<P>Mortality from bacterial infections</P>
</TD>
<TD>
<P>Ceftriaxone 1g (1/54)</P>
</TD>
<TD>
<P>Norfloxacin 800 mg (1/57)</P>
</TD>
<TD>
<P>1.06</P>
</TD>
<TD>
<P>0.07 to 16.46</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fernandez-2006" TYPE="STUDY">Fernandez 2006</LINK>
</P>
</TD>
<TD>
<P>Bacterial infections</P>
</TD>
<TD>
<P>Ceftriaxone 1g (6/54)</P>
</TD>
<TD>
<P>Norfloxacin 800 mg (5/57)</P>
</TD>
<TD>
<P>1.27</P>
</TD>
<TD>
<P>0.41 to 3.94</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-07-09 15:30:05 +0200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-07-09 15:30:05 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Antibiotics versus no intervention/placebo</NAME>
<DICH_OUTCOME CHI2="3.5847446418465885" CI_END="0.977896908104969" CI_START="0.6332679372777249" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7869375819376646" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="145" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.009706927013061825" LOG_CI_START="-0.19841249999709268" LOG_EFFECT_SIZE="-0.10405971350507726" METHOD="MH" MODIFIED="2010-07-07 15:43:19 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9805311397836415" P_Q="0.0" P_Z="0.030648770102198557" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="588" TOTAL_2="653" WEIGHT="100.00000000000001" Z="2.1616032583072387">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3429873388139972" CI_START="0.46846430725599986" EFFECT_SIZE="0.7931844888366627" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.12807191832088582" LOG_CI_START="-0.32932349282801177" LOG_EFFECT_SIZE="-0.10062578725356298" MODIFIED="2010-07-07 15:34:55 +0200" MODIFIED_BY="[Empty name]" ORDER="598" O_E="0.0" SE="0.2686763286526633" STUDY_ID="STD-Rimola-1985" TOTAL_1="74" TOTAL_2="75" VAR="0.07218696957827392" WEIGHT="16.331185053970493"/>
<DICH_DATA CI_END="1.8570415026877929" CI_START="0.17583377203594702" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2688216098177983" LOG_CI_START="-0.7548977071903873" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2010-07-07 15:34:55 +0200" MODIFIED_BY="[Empty name]" ORDER="595" O_E="0.0" SE="0.6013377943029549" STUDY_ID="STD-Soriano-1992" TOTAL_1="64" TOTAL_2="64" VAR="0.36160714285714285" WEIGHT="5.003944186630795"/>
<DICH_DATA CI_END="1.453646240959568" CI_START="0.35098228665033504" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.1624587295683904" LOG_CI_START="-0.4547148009248664" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2010-07-07 15:34:55 +0200" MODIFIED_BY="[Empty name]" ORDER="592" O_E="0.0" SE="0.3625307868699863" STUDY_ID="STD-Rolando-1993" TOTAL_1="50" TOTAL_2="50" VAR="0.13142857142857145" WEIGHT="10.00788837326159"/>
<DICH_DATA CI_END="1.3759413912904064" CI_START="0.35546226656983415" EFFECT_SIZE="0.6993534482758621" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.1385999353666005" LOG_CI_START="-0.44920649420358616" LOG_EFFECT_SIZE="-0.1553032794184928" MODIFIED="2010-07-07 15:34:55 +0200" MODIFIED_BY="[Empty name]" ORDER="601" O_E="0.0" SE="0.34528040641828084" STUDY_ID="STD-Blaise-1994" TOTAL_1="58" TOTAL_2="59" VAR="0.1192185590563732" WEIGHT="11.339829560911788"/>
<DICH_DATA CI_END="1.8134252939278308" CI_START="0.08823081961840529" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.25849966904069305" LOG_CI_START="-1.0543796863847683" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2010-07-07 15:34:55 +0200" MODIFIED_BY="[Empty name]" ORDER="593" O_E="0.0" SE="0.7711918322345376" STUDY_ID="STD-Selby-1994" TOTAL_1="19" TOTAL_2="19" VAR="0.5947368421052632" WEIGHT="3.5742458475934247"/>
<DICH_DATA CI_END="2.376067966150243" CI_START="0.28511626390864714" EFFECT_SIZE="0.823076923076923" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="0.3758588592476404" LOG_CI_START="-0.5449780084908946" LOG_EFFECT_SIZE="-0.08455957462162715" MODIFIED="2010-07-07 15:34:55 +0200" MODIFIED_BY="[Empty name]" ORDER="597" O_E="0.0" SE="0.5409041343256248" STUDY_ID="STD-Pauwels-1996" TOTAL_1="40" TOTAL_2="107" VAR="0.29257728253055354" WEIGHT="5.057436301356683"/>
<DICH_DATA CI_END="2.0054824979214043" CI_START="0.3663427022237784" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.30221887619583887" LOG_CI_START="-0.43611245545706534" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2010-07-07 15:34:55 +0200" MODIFIED_BY="[Empty name]" ORDER="596" O_E="0.0" SE="0.43369947901195144" STUDY_ID="STD-Zacharof-1997" TOTAL_1="35" TOTAL_2="30" VAR="0.1880952380952381" WEIGHT="6.158700537391747"/>
<DICH_DATA CI_END="1.338725780151369" CI_START="0.3896279178343957" EFFECT_SIZE="0.7222222222222222" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" LOG_CI_END="0.1266916267779052" LOG_CI_START="-0.4093499323708438" LOG_EFFECT_SIZE="-0.14132915279646932" MODIFIED="2010-07-07 15:34:55 +0200" MODIFIED_BY="[Empty name]" ORDER="599" O_E="0.0" SE="0.3148734652924872" STUDY_ID="STD-Hsieh-1998" TOTAL_1="60" TOTAL_2="60" VAR="0.09914529914529915" WEIGHT="12.867285051336328"/>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528007" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-07 15:34:55 +0200" MODIFIED_BY="[Empty name]" ORDER="602" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Hong-2002" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="0.7148491695186849"/>
<DICH_DATA CI_END="4.058163798023074" CI_START="0.12394591057361681" EFFECT_SIZE="0.7092198581560284" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6083295723035174" LOG_CI_START="-0.9067677976142772" LOG_EFFECT_SIZE="-0.14921911265537988" MODIFIED="2010-07-07 15:34:55 +0200" MODIFIED_BY="[Empty name]" ORDER="594" O_E="0.0" SE="0.8899756949426497" STUDY_ID="STD-Lin-2002" TOTAL_1="47" TOTAL_2="50" VAR="0.7920567375886524" WEIGHT="2.078221296951228"/>
<DICH_DATA CI_END="2.409299472677698" CI_START="0.6720755898297837" EFFECT_SIZE="1.272490221642764" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.3818907855724282" LOG_CI_START="-0.17258187813700648" LOG_EFFECT_SIZE="0.10465445371771086" MODIFIED="2010-07-07 15:34:55 +0200" MODIFIED_BY="[Empty name]" ORDER="603" O_E="0.0" SE="0.325699987346873" STUDY_ID="STD-Hou-2004" TOTAL_1="59" TOTAL_2="61" VAR="0.10608048175775323" WEIGHT="9.138155217013855"/>
<DICH_DATA CI_END="1.251337369016956" CI_START="0.48566376446343795" EFFECT_SIZE="0.7795698924731183" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="24" LOG_CI_END="0.0973744142094864" LOG_CI_START="-0.31366429817536934" LOG_EFFECT_SIZE="-0.10814494198294143" MODIFIED="2010-07-07 15:34:55 +0200" MODIFIED_BY="[Empty name]" ORDER="600" O_E="0.0" SE="0.2414461743293054" STUDY_ID="STD-Jun-2006" TOTAL_1="62" TOTAL_2="58" VAR="0.05829625509825733" WEIGHT="17.728259404063387"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.4263788904827033" CI_END="0.9735100628767255" CI_START="0.18697152003076983" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.42663644502235354" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.01165955495109191" LOG_CI_START="-0.7282245412466495" LOG_EFFECT_SIZE="-0.36994204809887066" METHOD="MH" MODIFIED="2010-07-08 10:24:12 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7875394396154639" P_Q="0.0" P_Z="0.04299619861237234" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="346" TOTAL_2="415" WEIGHT="100.00000000000001" Z="2.023746916212577">
<NAME>Mortality from bacterial infections</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1480284022923046" CI_START="0.018260403698457977" EFFECT_SIZE="0.14478764478764478" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.059952632666690105" LOG_CI_START="-1.738489625373756" LOG_EFFECT_SIZE="-0.8392684963535331" MODIFIED="2010-07-07 15:35:18 +0200" MODIFIED_BY="[Empty name]" ORDER="607" O_E="0.0" SE="1.0564138848057119" STUDY_ID="STD-Rimola-1985" TOTAL_1="74" TOTAL_2="75" VAR="1.1160102960102958" WEIGHT="37.34007209221398"/>
<DICH_DATA CI_END="5.377224246500977" CI_START="0.04649238873805159" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.730558148247107" LOG_CI_START="-1.3326181395750694" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-07-07 15:35:18 +0200" MODIFIED_BY="[Empty name]" ORDER="606" O_E="0.0" SE="1.2119199643540823" STUDY_ID="STD-Soriano-1992" TOTAL_1="64" TOTAL_2="64" VAR="1.46875" WEIGHT="10.740677107605952"/>
<DICH_DATA CI_END="5.804577450335185" CI_START="0.07704722115029662" EFFECT_SIZE="0.66875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.7637706103507297" LOG_CI_START="-1.1132430202921602" LOG_EFFECT_SIZE="-0.17473620497071518" MODIFIED="2010-07-07 15:35:18 +0200" MODIFIED_BY="[Empty name]" ORDER="608" O_E="0.0" SE="1.1025670980069544" STUDY_ID="STD-Pauwels-1996" TOTAL_1="40" TOTAL_2="107" VAR="1.2156542056074768" WEIGHT="11.690532906237772"/>
<DICH_DATA CI_END="4.313972048844031" CI_START="0.010467441487503393" EFFECT_SIZE="0.2125" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6348773268879621" LOG_CI_START="-1.9801594581153013" LOG_EFFECT_SIZE="-0.6726410656136697" MODIFIED="2010-07-07 15:35:18 +0200" MODIFIED_BY="[Empty name]" ORDER="609" O_E="0.0" SE="1.5360855521517711" STUDY_ID="STD-Lin-2002" TOTAL_1="47" TOTAL_2="50" VAR="2.3595588235294116" WEIGHT="13.019002554673882"/>
<DICH_DATA CI_END="7.101799877745542" CI_START="0.15051757634100574" EFFECT_SIZE="1.0338983050847457" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8513684301149411" LOG_CI_START="-0.8224127833776955" LOG_EFFECT_SIZE="0.014477823368622805" MODIFIED="2010-07-08 10:24:12 +0200" MODIFIED_BY="[Empty name]" ORDER="604" O_E="0.0" SE="0.9831873701562059" STUDY_ID="STD-Hou-2004" TOTAL_1="59" TOTAL_2="61" VAR="0.9666574048346763" WEIGHT="10.561665822479187"/>
<DICH_DATA CI_END="3.5996908730919825" CI_START="0.10805002783649102" EFFECT_SIZE="0.6236559139784946" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5562652069132014" LOG_CI_START="-0.9663751168951972" LOG_EFFECT_SIZE="-0.20505495499099782" MODIFIED="2010-07-07 15:35:18 +0200" MODIFIED_BY="[Empty name]" ORDER="605" O_E="0.0" SE="0.8944064633962144" STUDY_ID="STD-Jun-2006" TOTAL_1="62" TOTAL_2="58" VAR="0.7999629217649239" WEIGHT="16.648049516789225"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.304623845674648" CI_END="0.486290278900254" CI_START="0.26599598393250495" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.35965436353933666" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="237" I2="32.53447547078419" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.3131044120320184" LOG_CI_START="-0.5751249203956955" LOG_EFFECT_SIZE="-0.4441146662138569" METHOD="MH" MODIFIED="2010-07-07 15:46:03 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.13019337063505254" P_Q="0.0" P_Z="3.050197511166574E-11" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="YEAR" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.08191207050763036" TOTALS="YES" TOTAL_1="588" TOTAL_2="653" WEIGHT="99.99999999999999" Z="6.644126875572875">
<NAME>Bacterial infections</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8413337434821526" CI_START="0.30523251029461934" EFFECT_SIZE="0.5067567567567568" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="32" LOG_CI_END="-0.0750316924296669" LOG_CI_START="-0.5153692115768477" LOG_EFFECT_SIZE="-0.2952004520032573" MODIFIED="2010-07-07 15:35:36 +0200" MODIFIED_BY="[Empty name]" ORDER="612" O_E="0.0" SE="0.25865643845292763" STUDY_ID="STD-Rimola-1985" TOTAL_1="74" TOTAL_2="75" VAR="0.06690315315315315" WEIGHT="15.918363306967938"/>
<DICH_DATA CI_END="0.76601958859545" CI_START="0.23977646540936784" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="28" LOG_CI_END="-0.11576012447948708" LOG_CI_START="-0.6201934461097017" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2010-07-07 15:35:36 +0200" MODIFIED_BY="[Empty name]" ORDER="611" O_E="0.0" SE="0.296306630110801" STUDY_ID="STD-Soriano-1992" TOTAL_1="64" TOTAL_2="64" VAR="0.08779761904761904" WEIGHT="13.958512339796862"/>
<DICH_DATA CI_END="1.045212747193444" CI_START="0.409021793933676" EFFECT_SIZE="0.6538461538461539" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="26" LOG_CI_END="0.01920469765116844" LOG_CI_START="-0.38825355083625657" LOG_EFFECT_SIZE="-0.18452442659254403" MODIFIED="2010-07-07 15:35:36 +0200" MODIFIED_BY="[Empty name]" ORDER="620" O_E="0.0" SE="0.23934299211237242" STUDY_ID="STD-Rolando-1993" TOTAL_1="50" TOTAL_2="50" VAR="0.05728506787330316" WEIGHT="17.018272238881902"/>
<DICH_DATA CI_END="1.255435388862829" CI_START="0.02212601144128878" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.09879436660498035" LOG_CI_START="-1.6550968673722675" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2010-07-07 15:35:36 +0200" MODIFIED_BY="[Empty name]" ORDER="621" O_E="0.0" SE="1.0302443927398635" STUDY_ID="STD-Selby-1994" TOTAL_1="19" TOTAL_2="19" VAR="1.06140350877193" WEIGHT="2.0719518204525467"/>
<DICH_DATA CI_END="0.5850359155648697" CI_START="0.15918715357909122" EFFECT_SIZE="0.30517241379310345" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="30" LOG_CI_END="-0.2328174716052619" LOG_CI_START="-0.7980919827969994" LOG_EFFECT_SIZE="-0.5154547272011306" MODIFIED="2010-07-07 15:35:36 +0200" MODIFIED_BY="[Empty name]" ORDER="618" O_E="0.0" SE="0.33204504602798507" STUDY_ID="STD-Blaise-1994" TOTAL_1="58" TOTAL_2="59" VAR="0.11025391259172672" WEIGHT="12.32733680349261"/>
<DICH_DATA CI_END="1.1081131921627243" CI_START="0.22702097871000543" EFFECT_SIZE="0.5015625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="32" LOG_CI_END="0.04458412521265791" LOG_CI_START="-0.6439340083706881" LOG_EFFECT_SIZE="-0.2996749415790151" MODIFIED="2010-07-07 15:35:36 +0200" MODIFIED_BY="[Empty name]" ORDER="613" O_E="0.0" SE="0.40443895988658574" STUDY_ID="STD-Pauwels-1996" TOTAL_1="40" TOTAL_2="107" VAR="0.1635708722741433" WEIGHT="9.64993644363272"/>
<DICH_DATA CI_END="0.5716107095247541" CI_START="0.08033153784875025" EFFECT_SIZE="0.21428571428571427" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.24289964299524938" LOG_CI_START="-1.095113918921902" LOG_EFFECT_SIZE="-0.6690067809585756" MODIFIED="2010-07-07 15:35:36 +0200" MODIFIED_BY="[Empty name]" ORDER="610" O_E="0.0" SE="0.5005948842080171" STUDY_ID="STD-Zacharof-1997" TOTAL_1="35" TOTAL_2="30" VAR="0.2505952380952381" WEIGHT="7.124339028196649"/>
<DICH_DATA CI_END="0.49903266505621147" CI_START="0.09895688099659807" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="27" LOG_CI_END="-0.30187102594101783" LOG_CI_START="-1.0045540016096697" LOG_EFFECT_SIZE="-0.6532125137753437" MODIFIED="2010-07-07 15:35:36 +0200" MODIFIED_BY="[Empty name]" ORDER="615" O_E="0.0" SE="0.41275945824459354" STUDY_ID="STD-Hsieh-1998" TOTAL_1="60" TOTAL_2="60" VAR="0.17037037037037037" WEIGHT="9.389852054688175"/>
<DICH_DATA CI_END="1.4119668128919467" CI_START="0.004730931759912724" EFFECT_SIZE="0.08173076923076923" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.1498244891043975" LOG_CI_START="-2.3250533162733724" LOG_EFFECT_SIZE="-1.0876144135844876" MODIFIED="2010-07-07 15:35:36 +0200" MODIFIED_BY="[Empty name]" ORDER="619" O_E="0.0" SE="1.4537554737216178" STUDY_ID="STD-Lin-2002" TOTAL_1="47" TOTAL_2="50" VAR="2.1134049773755654" WEIGHT="1.0790672801107326"/>
<DICH_DATA CI_END="0.9022539539810092" CI_START="0.054732612510581626" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.04467120603944865" LOG_CI_START="-1.2617538215112387" LOG_EFFECT_SIZE="-0.6532125137753437" MODIFIED="2010-07-07 15:35:36 +0200" MODIFIED_BY="[Empty name]" ORDER="617" O_E="0.0" SE="0.7149203529842405" STUDY_ID="STD-Hong-2002" TOTAL_1="20" TOTAL_2="20" VAR="0.5111111111111111" WEIGHT="3.9946074104115232"/>
<DICH_DATA CI_END="0.5377484040431961" CI_START="0.031059648934449815" EFFECT_SIZE="0.1292372881355932" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" LOG_CI_END="-0.2694208698596292" LOG_CI_START="-1.5078034573870123" LOG_EFFECT_SIZE="-0.8886121636233207" MODIFIED="2010-07-07 15:35:36 +0200" MODIFIED_BY="[Empty name]" ORDER="616" O_E="0.0" SE="0.727432062006258" STUDY_ID="STD-Hou-2004" TOTAL_1="59" TOTAL_2="61" VAR="0.5291574048346763" WEIGHT="3.8766374224682782"/>
<DICH_DATA CI_END="0.9221801085097353" CI_START="0.04686318810672564" EFFECT_SIZE="0.2078853046594982" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.035184249778319646" LOG_CI_START="-1.3291681696430009" LOG_EFFECT_SIZE="-0.6821762097106603" MODIFIED="2010-07-07 15:35:36 +0200" MODIFIED_BY="[Empty name]" ORDER="614" O_E="0.0" SE="0.7600925598522208" STUDY_ID="STD-Jun-2006" TOTAL_1="62" TOTAL_2="58" VAR="0.5777406995427018" WEIGHT="3.591123850900064"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.346614741431033" CI_END="0.404675514590629" CI_START="0.15166081104435505" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2477365874323099" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="82" I2="4.152758359751554" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.3928930723563421" LOG_CI_START="-0.8191266258442067" LOG_EFFECT_SIZE="-0.6060098491002744" METHOD="MH" MODIFIED="2010-07-07 15:46:14 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.4003648130522237" P_Q="0.0" P_Z="2.5000070241502882E-8" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="459" TOTAL_2="528" WEIGHT="100.00000000000004" Z="5.573270657805723">
<NAME>Bacteremia</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3375926461698218" CI_START="0.004423738258622547" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.1263238724329746" LOG_CI_START="-2.354210577046648" LOG_EFFECT_SIZE="-1.1139433523068367" MODIFIED="2010-07-07 15:35:45 +0200" MODIFIED_BY="[Empty name]" ORDER="628" O_E="0.0" SE="1.457078214467886" STUDY_ID="STD-Soriano-1992" TOTAL_1="64" TOTAL_2="64" VAR="2.123076923076923" WEIGHT="8.511247200740424"/>
<DICH_DATA CI_END="1.3583113580225423" CI_START="0.184052057375089" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.13299933222130308" LOG_CI_START="-0.7350593235492654" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-07-07 15:35:45 +0200" MODIFIED_BY="[Empty name]" ORDER="623" O_E="0.0" SE="0.5099019513592785" STUDY_ID="STD-Rolando-1993" TOTAL_1="50" TOTAL_2="50" VAR="0.26" WEIGHT="13.094226462677575"/>
<DICH_DATA CI_END="1.255435388862829" CI_START="0.02212601144128878" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.09879436660498035" LOG_CI_START="-1.6550968673722675" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2010-07-07 15:35:45 +0200" MODIFIED_BY="[Empty name]" ORDER="624" O_E="0.0" SE="1.0302443927398635" STUDY_ID="STD-Selby-1994" TOTAL_1="19" TOTAL_2="19" VAR="1.06140350877193" WEIGHT="7.856535877606546"/>
<DICH_DATA CI_END="0.8461031676566987" CI_START="0.15234540973910374" EFFECT_SIZE="0.359026369168357" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.07257667902681847" LOG_CI_START="-0.8171706268040284" LOG_EFFECT_SIZE="-0.44487365291542336" MODIFIED="2010-07-07 15:35:45 +0200" MODIFIED_BY="[Empty name]" ORDER="629" O_E="0.0" SE="0.4373781707238184" STUDY_ID="STD-Blaise-1994" TOTAL_1="58" TOTAL_2="59" VAR="0.19129966422571362" WEIGHT="22.06992699521383"/>
<DICH_DATA CI_END="1.3894338336012249" CI_START="0.08046920833589626" EFFECT_SIZE="0.334375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" LOG_CI_END="0.14283787001509796" LOG_CI_START="-1.0943702712844907" LOG_EFFECT_SIZE="-0.4757662006346964" MODIFIED="2010-07-07 15:35:45 +0200" MODIFIED_BY="[Empty name]" ORDER="627" O_E="0.0" SE="0.7267421864784489" STUDY_ID="STD-Pauwels-1996" TOTAL_1="40" TOTAL_2="107" VAR="0.5281542056074766" WEIGHT="11.401775423283876"/>
<DICH_DATA CI_END="0.565225512613712" CI_START="0.002103692447629089" EFFECT_SIZE="0.034482758620689655" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="14" LOG_CI_END="-0.24777824360817235" LOG_CI_START="-2.67701775218974" LOG_EFFECT_SIZE="-1.462397997898956" MODIFIED="2010-07-07 15:35:45 +0200" MODIFIED_BY="[Empty name]" ORDER="625" O_E="0.0" SE="1.4269473122703158" STUDY_ID="STD-Hsieh-1998" TOTAL_1="60" TOTAL_2="60" VAR="2.036178631995478" WEIGHT="18.986628370882485"/>
<DICH_DATA CI_END="2.13493046249642" CI_START="0.006528134963812313" EFFECT_SIZE="0.11805555555555555" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3293837340468002" LOG_CI_START="-2.1852108754807515" LOG_EFFECT_SIZE="-0.9279135707169758" MODIFIED="2010-07-07 15:35:45 +0200" MODIFIED_BY="[Empty name]" ORDER="622" O_E="0.0" SE="1.4770853210805508" STUDY_ID="STD-Lin-2002" TOTAL_1="47" TOTAL_2="50" VAR="2.181781045751634" WEIGHT="5.713844274622942"/>
<DICH_DATA CI_END="1.1798187507198408" CI_START="0.004022379716757513" EFFECT_SIZE="0.06888888888888889" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.07181529407880412" LOG_CI_START="-2.3955169339609466" LOG_EFFECT_SIZE="-1.161850819941071" MODIFIED="2010-07-07 15:35:45 +0200" MODIFIED_BY="[Empty name]" ORDER="630" O_E="0.0" SE="1.4493231642420548" STUDY_ID="STD-Hou-2004" TOTAL_1="59" TOTAL_2="61" VAR="2.100537634408602" WEIGHT="9.65967525935231"/>
<DICH_DATA CI_END="6.425617500217389" CI_START="0.13619392576840803" EFFECT_SIZE="0.9354838709677419" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8079148695987727" LOG_CI_START="-0.865842261469406" LOG_EFFECT_SIZE="-0.028963695935316617" MODIFIED="2010-07-07 15:35:45 +0200" MODIFIED_BY="[Empty name]" ORDER="626" O_E="0.0" SE="0.9831732240208694" STUDY_ID="STD-Jun-2006" TOTAL_1="62" TOTAL_2="58" VAR="0.9666295884315906" WEIGHT="2.7061401356200325"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.699783044439767" CI_END="0.7523394856609793" CI_START="0.27144395650216435" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4519048645684394" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="45" I2="17.523928490484526" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.12358614414297812" LOG_CI_START="-0.5663198231443457" LOG_EFFECT_SIZE="-0.3449529836436619" METHOD="MH" MODIFIED="2010-07-07 15:46:24 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.2867328111340621" P_Q="0.0" P_Z="0.002256723813642732" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="487" TOTAL_2="554" WEIGHT="100.0" Z="3.0541856487006642">
<NAME>Pneumonia</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6831677421188735" CI_START="0.09570866796267916" EFFECT_SIZE="0.5067567567567568" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.42864782406941077" LOG_CI_START="-1.0190487280759253" LOG_EFFECT_SIZE="-0.2952004520032573" MODIFIED="2010-07-07 15:35:53 +0200" MODIFIED_BY="[Empty name]" ORDER="633" O_E="0.0" SE="0.8503841209436788" STUDY_ID="STD-Rimola-1985" TOTAL_1="74" TOTAL_2="75" VAR="0.7231531531531532" WEIGHT="8.867853389216435"/>
<DICH_DATA CI_END="3.826289779854638" CI_START="0.2613497820434265" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5827778577524814" LOG_CI_START="-0.5827778577524814" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-07 15:35:53 +0200" MODIFIED_BY="[Empty name]" ORDER="632" O_E="0.0" SE="0.6846531968814576" STUDY_ID="STD-Soriano-1992" TOTAL_1="64" TOTAL_2="64" VAR="0.46875" WEIGHT="8.927771317521952"/>
<DICH_DATA CI_END="2.912780519250707" CI_START="0.4484108707633017" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4643077613631941" LOG_CI_START="-0.3483238674078207" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2010-07-07 15:35:53 +0200" MODIFIED_BY="[Empty name]" ORDER="631" O_E="0.0" SE="0.47734384133153207" STUDY_ID="STD-Rolando-1993" TOTAL_1="50" TOTAL_2="50" VAR="0.22785714285714287" WEIGHT="15.623599805663416"/>
<DICH_DATA CI_END="0.4653682847465505" CI_START="0.02745150978423003" EFFECT_SIZE="0.11302681992337164" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="18" LOG_CI_END="-0.3322032175875387" LOG_CI_START="-1.5614337651326975" LOG_EFFECT_SIZE="-0.946818491360118" MODIFIED="2010-07-07 15:35:53 +0200" MODIFIED_BY="[Empty name]" ORDER="639" O_E="0.0" SE="0.7220561084173708" STUDY_ID="STD-Blaise-1994" TOTAL_1="58" TOTAL_2="59" VAR="0.5213650237028379" WEIGHT="39.83159510894409"/>
<DICH_DATA CI_END="5.316797209086882" CI_START="0.016111823018365373" EFFECT_SIZE="0.2926829268292683" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.7256500959632085" LOG_CI_START="-1.79285531730743" LOG_EFFECT_SIZE="-0.5336026106721107" MODIFIED="2010-07-07 15:35:53 +0200" MODIFIED_BY="[Empty name]" ORDER="636" O_E="0.0" SE="1.4793825465580308" STUDY_ID="STD-Pauwels-1996" TOTAL_1="40" TOTAL_2="107" VAR="2.188572719060524" WEIGHT="5.527428886183893"/>
<DICH_DATA CI_END="3.8481017433944946" CI_START="0.11549706168953583" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5852465462167757" LOG_CI_START="-0.9374290643281383" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-07-07 15:35:53 +0200" MODIFIED_BY="[Empty name]" ORDER="634" O_E="0.0" SE="0.8944271909999157" STUDY_ID="STD-Hsieh-1998" TOTAL_1="60" TOTAL_2="60" VAR="0.7999999999999998" WEIGHT="6.695828488141464"/>
<DICH_DATA CI_END="3.919915520931636" CI_START="0.0102043015433387" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5932767075335775" LOG_CI_START="-1.991216716205615" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2010-07-07 15:35:53 +0200" MODIFIED_BY="[Empty name]" ORDER="638" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Hong-2002" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="5.57985707345122"/>
<DICH_DATA CI_END="4.216046909363558" CI_START="0.01013060623596303" EFFECT_SIZE="0.20666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6249054343592355" LOG_CI_START="-1.9943645648020525" LOG_EFFECT_SIZE="-0.6847295652214086" MODIFIED="2010-07-07 15:35:53 +0200" MODIFIED_BY="[Empty name]" ORDER="635" O_E="0.0" SE="1.538572163102943" STUDY_ID="STD-Hou-2004" TOTAL_1="59" TOTAL_2="61" VAR="2.367204301075269" WEIGHT="5.488384006673331"/>
<DICH_DATA CI_END="7.51304006704894" CI_START="0.012970738687746532" EFFECT_SIZE="0.31216931216931215" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8758157049387675" LOG_CI_START="-1.8870352900009673" LOG_EFFECT_SIZE="-0.5056097925310999" MODIFIED="2010-07-07 15:35:53 +0200" MODIFIED_BY="[Empty name]" ORDER="637" O_E="0.0" SE="1.6229123507605943" STUDY_ID="STD-Jun-2006" TOTAL_1="62" TOTAL_2="58" VAR="2.633844498251278" WEIGHT="3.4576819242041985"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8239021329538025" CI_END="0.5722385934465287" CI_START="0.14953928821103096" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2925271815590398" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.24242285545132666" LOG_CI_START="-0.8252446908737531" LOG_EFFECT_SIZE="-0.5338337731625399" METHOD="MH" MODIFIED="2010-07-07 15:46:35 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.9351609163005885" P_Q="0.0" P_Z="3.3011346492288485E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="412" TOTAL_2="478" WEIGHT="100.0" Z="3.5904453317928757">
<NAME>Spontaneous bacterial peritonitis</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.63397241793138" CI_START="0.09491367422759132" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.42061122286459585" LOG_CI_START="-1.0226712141925582" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-07-07 15:36:03 +0200" MODIFIED_BY="[Empty name]" ORDER="643" O_E="0.0" SE="0.8477912478906585" STUDY_ID="STD-Soriano-1992" TOTAL_1="64" TOTAL_2="64" VAR="0.71875" WEIGHT="10.655081567452005"/>
<DICH_DATA CI_END="1.3346052970893525" CI_START="0.020813477841245254" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.12535284424629042" LOG_CI_START="-1.6816553450135776" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2010-07-07 15:36:03 +0200" MODIFIED_BY="[Empty name]" ORDER="647" O_E="0.0" SE="1.0614455552060438" STUDY_ID="STD-Rolando-1993" TOTAL_1="50" TOTAL_2="50" VAR="1.1266666666666667" WEIGHT="15.982622351178007"/>
<DICH_DATA CI_END="1.6045461204669325" CI_START="0.11845196258100081" EFFECT_SIZE="0.43596059113300495" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.20535220480729313" LOG_CI_START="-0.9264577392380681" LOG_EFFECT_SIZE="-0.3605527672153875" MODIFIED="2010-07-07 15:36:03 +0200" MODIFIED_BY="[Empty name]" ORDER="641" O_E="0.0" SE="0.6648307636818249" STUDY_ID="STD-Blaise-1994" TOTAL_1="58" TOTAL_2="59" VAR="0.44199994433775847" WEIGHT="18.487021864895357"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-07 15:36:03 +0200" MODIFIED_BY="[Empty name]" ORDER="646" O_E="0.0" SE="0.0" STUDY_ID="STD-Selby-1994" TOTAL_1="19" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.8233704394716195" CI_START="0.032433012740599135" EFFECT_SIZE="0.2431818181818182" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="0.2608749097273673" LOG_CI_START="-1.489012707329323" LOG_EFFECT_SIZE="-0.6140688988009778" MODIFIED="2010-07-07 15:36:03 +0200" MODIFIED_BY="[Empty name]" ORDER="642" O_E="0.0" SE="1.0278926483425046" STUDY_ID="STD-Pauwels-1996" TOTAL_1="40" TOTAL_2="107" VAR="1.0565632965165677" WEIGHT="15.946380577139056"/>
<DICH_DATA CI_END="1.128971929499989" CI_START="0.05536010096166047" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.05268314386047429" LOG_CI_START="-1.256803126516399" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2010-07-07 15:36:03 +0200" MODIFIED_BY="[Empty name]" ORDER="644" O_E="0.0" SE="0.769198717280955" STUDY_ID="STD-Hsieh-1998" TOTAL_1="60" TOTAL_2="60" VAR="0.5916666666666666" WEIGHT="21.31016313490401"/>
<DICH_DATA CI_END="5.550100334071408" CI_START="0.048149836981098273" EFFECT_SIZE="0.5169491525423728" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7443008343190167" LOG_CI_START="-1.3174051789097336" LOG_EFFECT_SIZE="-0.2865521722953584" MODIFIED="2010-07-07 15:36:03 +0200" MODIFIED_BY="[Empty name]" ORDER="640" O_E="0.0" SE="1.2110563177799274" STUDY_ID="STD-Hou-2004" TOTAL_1="59" TOTAL_2="61" VAR="1.4666574048346763" WEIGHT="5.238748437330568"/>
<DICH_DATA CI_END="1.891296641120713" CI_START="0.00572503642571646" EFFECT_SIZE="0.10405643738977072" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.27675965126605495" LOG_CI_START="-2.24222174576758" LOG_EFFECT_SIZE="-0.9827310472507624" MODIFIED="2010-07-07 15:36:03 +0200" MODIFIED_BY="[Empty name]" ORDER="645" O_E="0.0" SE="1.4796621417765725" STUDY_ID="STD-Jun-2006" TOTAL_1="62" TOTAL_2="58" VAR="2.1894000538068337" WEIGHT="12.379982067100997"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.8594788891894907" CI_END="0.41307128140292815" CI_START="0.12779912352578104" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.22976106658214634" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="58" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-0.3839749981044906" LOG_CI_START="-0.893472124653535" LOG_EFFECT_SIZE="-0.6387235613790128" METHOD="MH" MODIFIED="2010-07-07 15:46:47 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.8695739255642498" P_Q="0.0" P_Z="8.916395448572567E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="514" TOTAL_2="584" WEIGHT="100.00000000000001" Z="4.914159908454431">
<NAME>Urinary tract infections</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1988641623669327" CI_START="0.09520211568390555" EFFECT_SIZE="0.33783783783783783" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.07876997803088454" LOG_CI_START="-1.0213534001487616" LOG_EFFECT_SIZE="-0.4712917110589386" MODIFIED="2010-07-07 15:36:09 +0200" MODIFIED_BY="[Empty name]" ORDER="651" O_E="0.0" SE="0.6462179180412732" STUDY_ID="STD-Rimola-1985" TOTAL_1="74" TOTAL_2="75" VAR="0.4175975975975976" WEIGHT="15.479546173859296"/>
<DICH_DATA CI_END="0.7225120661265672" CI_START="0.002616370378942321" EFFECT_SIZE="0.043478260869565216" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="11" LOG_CI_END="-0.14115489568777567" LOG_CI_START="-2.58230077634741" LOG_EFFECT_SIZE="-1.3617278360175928" MODIFIED="2010-07-07 15:36:09 +0200" MODIFIED_BY="[Empty name]" ORDER="652" O_E="0.0" SE="1.4339411741664647" STUDY_ID="STD-Soriano-1992" TOTAL_1="64" TOTAL_2="64" VAR="2.0561872909698997" WEIGHT="19.91306484152245"/>
<DICH_DATA CI_END="1.8892219341538161" CI_START="0.13232960907368208" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.27628297915888045" LOG_CI_START="-0.8783429704868428" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-07-07 15:36:09 +0200" MODIFIED_BY="[Empty name]" ORDER="655" O_E="0.0" SE="0.6782329983125268" STUDY_ID="STD-Rolando-1993" TOTAL_1="50" TOTAL_2="50" VAR="0.45999999999999996" WEIGHT="10.389425134707365"/>
<DICH_DATA CI_END="0.7694632474263566" CI_START="0.01344807600937754" EFFECT_SIZE="0.10172413793103448" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="-0.1138121189398623" LOG_CI_START="-1.8713398449017242" LOG_EFFECT_SIZE="-0.9925759819207931" MODIFIED="2010-07-07 15:36:09 +0200" MODIFIED_BY="[Empty name]" ORDER="650" O_E="0.0" SE="1.0323804861325512" STUDY_ID="STD-Blaise-1994" TOTAL_1="58" TOTAL_2="59" VAR="1.0658094681472825" WEIGHT="17.167711048804193"/>
<DICH_DATA CI_END="5.316797209086882" CI_START="0.016111823018365373" EFFECT_SIZE="0.2926829268292683" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.7256500959632085" LOG_CI_START="-1.79285531730743" LOG_EFFECT_SIZE="-0.5336026106721107" MODIFIED="2010-07-07 15:36:09 +0200" MODIFIED_BY="[Empty name]" ORDER="654" O_E="0.0" SE="1.4793825465580308" STUDY_ID="STD-Pauwels-1996" TOTAL_1="40" TOTAL_2="107" VAR="2.188572719060524" WEIGHT="4.288252656271832"/>
<DICH_DATA CI_END="0.9288015977278167" CI_START="0.08008186621471892" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.032077046193925346" LOG_CI_START="-1.0964658146831998" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2010-07-07 15:36:09 +0200" MODIFIED_BY="[Empty name]" ORDER="649" O_E="0.0" SE="0.6252272314199782" STUDY_ID="STD-Hsieh-1998" TOTAL_1="60" TOTAL_2="60" VAR="0.3909090909090909" WEIGHT="19.047279413630168"/>
<DICH_DATA CI_END="8.484645216005713" CI_START="0.01478365029820634" EFFECT_SIZE="0.3541666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9286336870835861" LOG_CI_START="-1.8302183190782124" LOG_EFFECT_SIZE="-0.4507923159973133" MODIFIED="2010-07-07 15:36:09 +0200" MODIFIED_BY="[Empty name]" ORDER="656" O_E="0.0" SE="1.6205633249571207" STUDY_ID="STD-Lin-2002" TOTAL_1="47" TOTAL_2="50" VAR="2.626225490196078" WEIGHT="2.5186485175048157"/>
<DICH_DATA CI_END="1.7175402241484234" CI_START="0.024894804563592818" EFFECT_SIZE="0.20677966101694914" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.23490691686471046" LOG_CI_START="-1.6038912787995023" LOG_EFFECT_SIZE="-0.684492180967396" MODIFIED="2010-07-07 15:36:09 +0200" MODIFIED_BY="[Empty name]" ORDER="648" O_E="0.0" SE="1.0801191623310256" STUDY_ID="STD-Hou-2004" TOTAL_1="59" TOTAL_2="61" VAR="1.1666574048346763" WEIGHT="8.513556707607425"/>
<DICH_DATA CI_END="7.51304006704894" CI_START="0.012970738687746532" EFFECT_SIZE="0.31216931216931215" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8758157049387675" LOG_CI_START="-1.8870352900009673" LOG_EFFECT_SIZE="-0.5056097925310999" MODIFIED="2010-07-07 15:36:09 +0200" MODIFIED_BY="[Empty name]" ORDER="653" O_E="0.0" SE="1.6229123507605943" STUDY_ID="STD-Jun-2006" TOTAL_1="62" TOTAL_2="58" VAR="2.633844498251278" WEIGHT="2.6825155060924755"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.08862100999904898" CI_END="1.5601744413681302" CI_START="0.11750367064995605" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.42816611696279744" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.1931731590520105" LOG_CI_START="-0.9299485664295108" LOG_EFFECT_SIZE="-0.3683877036887502" METHOD="MH" MODIFIED="2010-07-07 15:46:58 +0200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9566568659836385" P_Q="0.0" P_Z="0.19853047916148334" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="128" WEIGHT="100.0" Z="1.2857495589230201">
<NAME>Other infections</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.484645216005713" CI_START="0.01478365029820634" EFFECT_SIZE="0.3541666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9286336870835861" LOG_CI_START="-1.8302183190782124" LOG_EFFECT_SIZE="-0.4507923159973133" MODIFIED="2010-07-07 15:36:23 +0200" MODIFIED_BY="[Empty name]" ORDER="657" O_E="0.0" SE="1.6205633249571207" STUDY_ID="STD-Lin-2002" TOTAL_1="47" TOTAL_2="50" VAR="2.626225490196078" WEIGHT="20.768166826258113"/>
<DICH_DATA CI_END="2.427899066052217" CI_START="0.1029696841584531" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.38523062805078434" LOG_CI_START="-0.9872906193787466" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-07-07 15:36:23 +0200" MODIFIED_BY="[Empty name]" ORDER="659" O_E="0.0" SE="0.8062257748298549" STUDY_ID="STD-Hong-2002" TOTAL_1="20" TOTAL_2="20" VAR="0.6499999999999999" WEIGHT="57.11245877220981"/>
<DICH_DATA CI_END="7.51304006704894" CI_START="0.012970738687746532" EFFECT_SIZE="0.31216931216931215" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8758157049387675" LOG_CI_START="-1.8870352900009673" LOG_EFFECT_SIZE="-0.5056097925310999" MODIFIED="2010-07-07 15:36:23 +0200" MODIFIED_BY="[Empty name]" ORDER="658" O_E="0.0" SE="1.6229123507605943" STUDY_ID="STD-Jun-2006" TOTAL_1="62" TOTAL_2="58" VAR="2.633844498251278" WEIGHT="22.11937440153208"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.063124441506678" CI_END="1.5122822073340285" CI_START="0.7600995846036813" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0721404187876387" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="59" I2="0.8937183824162125" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.17963284252208803" LOG_CI_START="-0.1191295048105292" LOG_EFFECT_SIZE="0.030251668855779398" METHOD="MH" MODIFIED="2010-07-07 15:47:07 +0200" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.4223372144215469" P_Q="0.0" P_Z="0.6914274140219885" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="426" TOTAL_2="493" WEIGHT="99.99999999999999" Z="0.39691870116115174">
<NAME>Drop outs before end of study</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.804914146080168" CI_START="0.5264425067842154" EFFECT_SIZE="2.027027027027027" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8923681301929649" LOG_CI_START="-0.2786490515435548" LOG_EFFECT_SIZE="0.3068595393247051" MODIFIED="2010-07-07 15:36:30 +0200" MODIFIED_BY="[Empty name]" ORDER="661" O_E="0.0" SE="0.6878612891805681" STUDY_ID="STD-Rimola-1985" TOTAL_1="74" TOTAL_2="75" VAR="0.4731531531531532" WEIGHT="5.7408749223406845"/>
<DICH_DATA CI_END="2.843872543767492" CI_START="0.22504524733451797" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4539101283520828" LOG_CI_START="-0.6477301543681956" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-07-07 15:36:30 +0200" MODIFIED_BY="[Empty name]" ORDER="665" O_E="0.0" SE="0.6471089552772392" STUDY_ID="STD-Soriano-1992" TOTAL_1="64" TOTAL_2="64" VAR="0.41875" WEIGHT="9.632774362936509"/>
<DICH_DATA CI_END="132.1011207444225" CI_START="0.37092796581794973" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1209065021796567" LOG_CI_START="-0.4307104221511429" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2010-07-07 15:36:30 +0200" MODIFIED_BY="[Empty name]" ORDER="666" O_E="0.0" SE="1.4988324120593923" STUDY_ID="STD-Rolando-1993" TOTAL_1="50" TOTAL_2="50" VAR="2.246498599439776" WEIGHT="0.9632774362936509"/>
<DICH_DATA CI_END="7.701465920161863" CI_START="0.014427267777713661" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8865733979573234" LOG_CI_START="-1.8408159073966481" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-07-07 15:36:30 +0200" MODIFIED_BY="[Empty name]" ORDER="667" O_E="0.0" SE="1.6020819787597222" STUDY_ID="STD-Selby-1994" TOTAL_1="19" TOTAL_2="19" VAR="2.566666666666667" WEIGHT="2.889832308880953"/>
<DICH_DATA CI_END="1.722040057683108" CI_START="0.44148017619695695" EFFECT_SIZE="0.8719211822660099" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.2360432496892908" LOG_CI_START="-0.3550887927921033" LOG_EFFECT_SIZE="-0.05952277155140627" MODIFIED="2010-07-07 15:36:30 +0200" MODIFIED_BY="[Empty name]" ORDER="660" O_E="0.0" SE="0.34723388790437354" STUDY_ID="STD-Blaise-1994" TOTAL_1="58" TOTAL_2="59" VAR="0.12057137290918706" WEIGHT="26.74124028275024"/>
<DICH_DATA CI_END="2.9403480090125766" CI_START="0.7511104902543713" EFFECT_SIZE="1.4861111111111112" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="0.4683987349867707" LOG_CI_START="-0.12429617247888843" LOG_EFFECT_SIZE="0.1720512812539412" MODIFIED="2010-07-07 15:36:30 +0200" MODIFIED_BY="[Empty name]" ORDER="662" O_E="0.0" SE="0.34815192253243726" STUDY_ID="STD-Pauwels-1996" TOTAL_1="40" TOTAL_2="107" VAR="0.1212097611630322" WEIGHT="18.872374262079692"/>
<DICH_DATA CI_END="3.337632500626413" CI_START="0.5294269803861831" EFFECT_SIZE="1.3292978208232447" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5234385157654885" LOG_CI_START="-0.2761939301781066" LOG_EFFECT_SIZE="0.12362229279369093" MODIFIED="2010-07-07 15:36:30 +0200" MODIFIED_BY="[Empty name]" ORDER="664" O_E="0.0" SE="0.4697080569917129" STUDY_ID="STD-Hou-2004" TOTAL_1="59" TOTAL_2="61" VAR="0.22062565880293025" WEIGHT="13.261119372975928"/>
<DICH_DATA CI_END="1.2907483626593148" CI_START="0.2017196266928059" EFFECT_SIZE="0.5102639296187683" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.11084158280818102" LOG_CI_START="-0.6952518442279769" LOG_EFFECT_SIZE="-0.292205130709898" MODIFIED="2010-07-07 15:36:30 +0200" MODIFIED_BY="[Empty name]" ORDER="663" O_E="0.0" SE="0.4735032692678565" STUDY_ID="STD-Jun-2006" TOTAL_1="62" TOTAL_2="58" VAR="0.22420534600734823" WEIGHT="21.89850705174233"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5847446418465885" CI_END="0.977896908104969" CI_START="0.6332679372777249" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7869375819376646" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="145" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-0.009706927013061825" LOG_CI_START="-0.19841249999709268" LOG_EFFECT_SIZE="-0.10405971350507726" METHOD="MH" MODIFIED="2010-07-07 15:47:16 +0200" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.9805311397836415" P_Q="0.0" P_Z="0.030648770102198606" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="588" TOTAL_2="653" WEIGHT="100.0" Z="2.161603258307238">
<NAME>Mortality according to trial sample size</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8028141549180982" CI_END="1.1541708791079035" CI_START="0.43932097627173455" DF="4" EFFECT_SIZE="0.7120754716981131" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="31" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="0.06227011242430476" LOG_CI_START="-0.35721805996805783" LOG_EFFECT_SIZE="-0.14747397377187654" MODIFIED="2010-06-23 16:03:44 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9380704016232675" P_Z="0.168179256588429" STUDIES="5" TAU2="0.0" TOTAL_1="171" TOTAL_2="169" WEIGHT="22.533905224716673" Z="1.3780778399612637">
<NAME>Sample size smaller than 101 patients</NAME>
<DICH_DATA CI_END="1.453646240959568" CI_START="0.35098228665033504" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.1624587295683904" LOG_CI_START="-0.4547148009248664" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="66" O_E="0.0" SE="0.3625307868699863" STUDY_ID="STD-Rolando-1993" TOTAL_1="50" TOTAL_2="50" VAR="0.13142857142857145" WEIGHT="10.00788837326159"/>
<DICH_DATA CI_END="1.8134252939278308" CI_START="0.08823081961840529" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.25849966904069305" LOG_CI_START="-1.0543796863847683" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="67" O_E="0.0" SE="0.7711918322345376" STUDY_ID="STD-Selby-1994" TOTAL_1="19" TOTAL_2="19" VAR="0.5947368421052632" WEIGHT="3.5742458475934247"/>
<DICH_DATA CI_END="2.0054824979214043" CI_START="0.3663427022237784" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.30221887619583887" LOG_CI_START="-0.43611245545706534" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="68" O_E="0.0" SE="0.43369947901195144" STUDY_ID="STD-Zacharof-1997" TOTAL_1="35" TOTAL_2="30" VAR="0.1880952380952381" WEIGHT="6.158700537391747"/>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528007" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-23 14:43:50 +0200" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Hong-2002" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="0.7148491695186849"/>
<DICH_DATA CI_END="4.058163798023074" CI_START="0.12394591057361681" EFFECT_SIZE="0.7092198581560284" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6083295723035174" LOG_CI_START="-0.9067677976142772" LOG_EFFECT_SIZE="-0.14921911265537988" MODIFIED="2010-06-23 14:43:54 +0200" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.8899756949426497" STUDY_ID="STD-Lin-2002" TOTAL_1="47" TOTAL_2="50" VAR="0.7920567375886524" WEIGHT="2.078221296951228"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6059595978626517" CI_END="1.0313966718768601" CI_START="0.6341094417842654" DF="6" EFFECT_SIZE="0.8087140210618244" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="114" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.013425725686318758" LOG_CI_START="-0.19783578019219372" LOG_EFFECT_SIZE="-0.09220502725293746" MODIFIED="2010-06-23 16:03:44 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8564257385605507" P_Z="0.08710852887195472" STUDIES="7" TAU2="0.0" TOTAL_1="417" TOTAL_2="484" WEIGHT="77.46609477528332" Z="1.710851504705407">
<NAME>Sample size larger than 100 patients</NAME>
<DICH_DATA CI_END="1.3429873388139972" CI_START="0.46846430725599986" EFFECT_SIZE="0.7931844888366627" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.12807191832088582" LOG_CI_START="-0.32932349282801177" LOG_EFFECT_SIZE="-0.10062578725356298" ORDER="72" O_E="0.0" SE="0.2686763286526633" STUDY_ID="STD-Rimola-1985" TOTAL_1="74" TOTAL_2="75" VAR="0.07218696957827392" WEIGHT="16.331185053970493"/>
<DICH_DATA CI_END="1.8570415026877929" CI_START="0.17583377203594702" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2688216098177983" LOG_CI_START="-0.7548977071903873" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="73" O_E="0.0" SE="0.6013377943029549" STUDY_ID="STD-Soriano-1992" TOTAL_1="64" TOTAL_2="64" VAR="0.36160714285714285" WEIGHT="5.003944186630795"/>
<DICH_DATA CI_END="1.3759413912904064" CI_START="0.35546226656983415" EFFECT_SIZE="0.6993534482758621" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.1385999353666005" LOG_CI_START="-0.44920649420358616" LOG_EFFECT_SIZE="-0.1553032794184928" ORDER="69" O_E="0.0" SE="0.34528040641828084" STUDY_ID="STD-Blaise-1994" TOTAL_1="58" TOTAL_2="59" VAR="0.1192185590563732" WEIGHT="11.339829560911788"/>
<DICH_DATA CI_END="2.376067966150243" CI_START="0.28511626390864714" EFFECT_SIZE="0.823076923076923" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="0.3758588592476404" LOG_CI_START="-0.5449780084908946" LOG_EFFECT_SIZE="-0.08455957462162715" ORDER="71" O_E="0.0" SE="0.5409041343256248" STUDY_ID="STD-Pauwels-1996" TOTAL_1="40" TOTAL_2="107" VAR="0.29257728253055354" WEIGHT="5.057436301356683"/>
<DICH_DATA CI_END="1.338725780151369" CI_START="0.3896279178343957" EFFECT_SIZE="0.7222222222222222" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" LOG_CI_END="0.1266916267779052" LOG_CI_START="-0.4093499323708438" LOG_EFFECT_SIZE="-0.14132915279646932" ORDER="70" O_E="0.0" SE="0.3148734652924872" STUDY_ID="STD-Hsieh-1998" TOTAL_1="60" TOTAL_2="60" VAR="0.09914529914529915" WEIGHT="12.867285051336328"/>
<DICH_DATA CI_END="2.409299472677698" CI_START="0.6720755898297837" EFFECT_SIZE="1.272490221642764" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.3818907855724282" LOG_CI_START="-0.17258187813700648" LOG_EFFECT_SIZE="0.10465445371771086" MODIFIED="2010-06-23 15:05:48 +0200" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="0.325699987346873" STUDY_ID="STD-Hou-2004" TOTAL_1="59" TOTAL_2="61" VAR="0.10608048175775323" WEIGHT="9.138155217013855"/>
<DICH_DATA CI_END="1.251337369016956" CI_START="0.48566376446343795" EFFECT_SIZE="0.7795698924731183" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="24" LOG_CI_END="0.0973744142094864" LOG_CI_START="-0.31366429817536934" LOG_EFFECT_SIZE="-0.10814494198294143" MODIFIED="2010-06-23 15:57:16 +0200" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="0.2414461743293054" STUDY_ID="STD-Jun-2006" TOTAL_1="62" TOTAL_2="58" VAR="0.05829625509825733" WEIGHT="17.728259404063387"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.275557009117726" CI_END="0.464056143286392" CI_START="0.2964380454593006" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.37089607183037027" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="234" I2="27.98953260143455" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="-0.3334294736596468" LOG_CI_START="-0.5280660588819908" LOG_EFFECT_SIZE="-0.4307477662708188" METHOD="MH" MODIFIED="2010-07-07 15:47:30 +0200" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.1702262334205875" P_Q="0.0" P_Z="4.130310092275301E-18" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="588" TOTAL_2="653" WEIGHT="100.0" Z="8.6751430348765">
<NAME>Bacterial infections according to trial sample size</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.1502195523838" CI_END="0.6206831379335935" CI_START="0.2858924542119252" DF="4" EFFECT_SIZE="0.4212465140411182" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="60" I2="44.057661856460804" ID="CMP-001.11.01" LOG_CI_END="-0.20713005290986009" LOG_CI_START="-0.5437973071721601" LOG_EFFECT_SIZE="-0.37546368004101005" MODIFIED="2010-06-23 16:03:52 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.12815962763802446" P_Z="1.2331246619878191E-5" STUDIES="5" TAU2="0.0" TOTAL_1="171" TOTAL_2="169" WEIGHT="27.77546067246429" Z="4.371647560412326">
<NAME>Sample size smaller than 101 patients</NAME>
<DICH_DATA CI_END="1.045212747193444" CI_START="0.409021793933676" EFFECT_SIZE="0.6538461538461539" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="26" LOG_CI_END="0.01920469765116844" LOG_CI_START="-0.38825355083625657" LOG_EFFECT_SIZE="-0.18452442659254403" ORDER="74" O_E="0.0" SE="0.23934299211237242" STUDY_ID="STD-Rolando-1993" TOTAL_1="50" TOTAL_2="50" VAR="0.05728506787330316" WEIGHT="11.812001473602882"/>
<DICH_DATA CI_END="1.255435388862829" CI_START="0.02212601144128878" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.09879436660498035" LOG_CI_START="-1.6550968673722675" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="75" O_E="0.0" SE="1.0302443927398635" STUDY_ID="STD-Selby-1994" TOTAL_1="19" TOTAL_2="19" VAR="1.06140350877193" WEIGHT="2.725846493908357"/>
<DICH_DATA CI_END="0.5716107095247541" CI_START="0.08033153784875025" EFFECT_SIZE="0.21428571428571427" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.24289964299524938" LOG_CI_START="-1.095113918921902" LOG_EFFECT_SIZE="-0.6690067809585756" ORDER="76" O_E="0.0" SE="0.5005948842080171" STUDY_ID="STD-Zacharof-1997" TOTAL_1="35" TOTAL_2="30" VAR="0.2505952380952381" WEIGHT="7.828071982506051"/>
<DICH_DATA CI_END="0.9022539539810092" CI_START="0.054732612510581626" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.04467120603944865" LOG_CI_START="-1.2617538215112387" LOG_EFFECT_SIZE="-0.6532125137753437" MODIFIED="2010-06-23 14:45:31 +0200" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="0.7149203529842405" STUDY_ID="STD-Hong-2002" TOTAL_1="20" TOTAL_2="20" VAR="0.5111111111111111" WEIGHT="4.088769740862536"/>
<DICH_DATA CI_END="4.058163798023074" CI_START="0.12394591057361681" EFFECT_SIZE="0.7092198581560284" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6083295723035174" LOG_CI_START="-0.9067677976142772" LOG_EFFECT_SIZE="-0.14921911265537988" MODIFIED="2010-06-23 14:45:33 +0200" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.0" SE="0.8899756949426497" STUDY_ID="STD-Lin-2002" TOTAL_1="47" TOTAL_2="50" VAR="0.7920567375886524" WEIGHT="1.3207709815844617"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.004708955466244" CI_END="0.4622245842871831" CI_START="0.26734899260463796" DF="6" EFFECT_SIZE="0.3515327537602662" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="174" I2="14.343336202172997" ID="CMP-001.11.02" LOG_CI_END="-0.3351469594706553" LOG_CI_START="-0.5729214480217334" LOG_EFFECT_SIZE="-0.45403420374619435" MODIFIED="2010-06-23 16:03:52 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.32041212502210825" P_Z="7.145708768544727E-14" STUDIES="7" TAU2="0.0" TOTAL_1="417" TOTAL_2="484" WEIGHT="72.22453932753571" Z="7.485165397806736">
<NAME>Sample size larger than 100 patients</NAME>
<DICH_DATA CI_END="0.8413337434821526" CI_START="0.30523251029461934" EFFECT_SIZE="0.5067567567567568" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="32" LOG_CI_END="-0.0750316924296669" LOG_CI_START="-0.5153692115768477" LOG_EFFECT_SIZE="-0.2952004520032573" ORDER="80" O_E="0.0" SE="0.25865643845292763" STUDY_ID="STD-Rimola-1985" TOTAL_1="74" TOTAL_2="75" VAR="0.06690315315315315" WEIGHT="14.440278518064854"/>
<DICH_DATA CI_END="0.76601958859545" CI_START="0.23977646540936784" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="28" LOG_CI_END="-0.11576012447948708" LOG_CI_START="-0.6201934461097017" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="81" O_E="0.0" SE="0.296306630110801" STUDY_ID="STD-Soriano-1992" TOTAL_1="64" TOTAL_2="64" VAR="0.08779761904761904" WEIGHT="12.720616971572333"/>
<DICH_DATA CI_END="0.5850359155648697" CI_START="0.15918715357909122" EFFECT_SIZE="0.30517241379310345" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="30" LOG_CI_END="-0.2328174716052619" LOG_CI_START="-0.7980919827969994" LOG_EFFECT_SIZE="-0.5154547272011306" ORDER="77" O_E="0.0" SE="0.33204504602798507" STUDY_ID="STD-Blaise-1994" TOTAL_1="58" TOTAL_2="59" VAR="0.11025391259172672" WEIGHT="13.512743303135446"/>
<DICH_DATA CI_END="1.1081131921627243" CI_START="0.22702097871000543" EFFECT_SIZE="0.5015625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="32" LOG_CI_END="0.04458412521265791" LOG_CI_START="-0.6439340083706881" LOG_EFFECT_SIZE="-0.2996749415790151" ORDER="79" O_E="0.0" SE="0.40443895988658574" STUDY_ID="STD-Pauwels-1996" TOTAL_1="40" TOTAL_2="107" VAR="0.1635708722741433" WEIGHT="7.911753995924484"/>
<DICH_DATA CI_END="0.49903266505621147" CI_START="0.09895688099659807" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="27" LOG_CI_END="-0.30187102594101783" LOG_CI_START="-1.0045540016096697" LOG_EFFECT_SIZE="-0.6532125137753437" ORDER="78" O_E="0.0" SE="0.41275945824459354" STUDY_ID="STD-Hsieh-1998" TOTAL_1="60" TOTAL_2="60" VAR="0.17037037037037037" WEIGHT="12.266309222587607"/>
<DICH_DATA CI_END="0.5377484040431961" CI_START="0.031059648934449815" EFFECT_SIZE="0.1292372881355932" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" LOG_CI_END="-0.2694208698596292" LOG_CI_START="-1.5078034573870123" LOG_EFFECT_SIZE="-0.8886121636233207" MODIFIED="2010-06-23 15:07:06 +0200" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.727432062006258" STUDY_ID="STD-Hou-2004" TOTAL_1="59" TOTAL_2="61" VAR="0.5291574048346763" WEIGHT="7.147775250693025"/>
<DICH_DATA CI_END="0.9221801085097353" CI_START="0.04686318810672564" EFFECT_SIZE="0.2078853046594982" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.035184249778319646" LOG_CI_START="-1.3291681696430009" LOG_EFFECT_SIZE="-0.6821762097106603" MODIFIED="2010-06-23 15:58:17 +0200" MODIFIED_BY="[Empty name]" ORDER="142" O_E="0.0" SE="0.7600925598522208" STUDY_ID="STD-Jun-2006" TOTAL_1="62" TOTAL_2="58" VAR="0.5777406995427018" WEIGHT="4.225062065557954"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.402891887212098" CI_END="2.0221261305154044" CI_START="1.0414523071426358" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4511884522551435" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="115" I2="54.55398861942548" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.30580824130365514" LOG_CI_START="0.017639386411428794" LOG_EFFECT_SIZE="0.161723813857542" METHOD="MH" MODIFIED="2010-07-09 14:57:01 +0200" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.03116810418707805" P_Q="0.0" P_Z="0.0278132427587502" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="YEAR" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.11643440637592384" TOTALS="YES" TOTAL_1="426" TOTAL_2="552" WEIGHT="100.00000000000001" Z="2.199910540101832">
<NAME>Mortality sensitivity analysis worst-best case</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7691751305959922" CI_START="0.683788435355088" EFFECT_SIZE="1.099882491186839" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.24777082583613666" LOG_CI_START="-0.16507824852910194" LOG_EFFECT_SIZE="0.04134628865351735" MODIFIED="2010-07-07 15:36:42 +0200" MODIFIED_BY="[Empty name]" ORDER="673" O_E="0.0" SE="0.24250958991801858" STUDY_ID="STD-Rimola-1985" TOTAL_1="74" TOTAL_2="78" VAR="0.05881090120220554" WEIGHT="16.350193151339056"/>
<DICH_DATA CI_END="3.20401390735154" CI_START="0.47383565249974163" EFFECT_SIZE="1.2321428571428572" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.5056943925161087" LOG_CI_START="-0.3243722650539988" LOG_EFFECT_SIZE="0.09066106373105492" MODIFIED="2010-07-07 15:36:42 +0200" MODIFIED_BY="[Empty name]" ORDER="671" O_E="0.0" SE="0.48758526355290355" STUDY_ID="STD-Soriano-1992" TOTAL_1="64" TOTAL_2="69" VAR="0.23773938923395443" WEIGHT="8.09008081141145"/>
<DICH_DATA CI_END="1.7701241393504614" CI_START="0.48710984658713274" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.2480037246354673" LOG_CI_START="-0.31237309137826985" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2010-07-07 15:36:42 +0200" MODIFIED_BY="[Empty name]" ORDER="674" O_E="0.0" SE="0.3291681156364455" STUDY_ID="STD-Rolando-1993" TOTAL_1="50" TOTAL_2="50" VAR="0.10835164835164836" WEIGHT="12.746763277823485"/>
<DICH_DATA CI_END="3.0950901347165254" CI_START="1.057626049080509" EFFECT_SIZE="1.8092672413793103" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="0.4906733009942699" LOG_CI_START="0.024332138844103433" LOG_EFFECT_SIZE="0.2575027199191867" MODIFIED="2010-07-07 15:36:42 +0200" MODIFIED_BY="[Empty name]" ORDER="670" O_E="0.0" SE="0.2739311070729903" STUDY_ID="STD-Blaise-1994" TOTAL_1="58" TOTAL_2="73" VAR="0.07503825142223408" WEIGHT="14.964510655034129"/>
<DICH_DATA CI_END="1.9152556886324799" CI_START="0.0925648306969087" EFFECT_SIZE="0.42105263157894735" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.28222676094150095" LOG_CI_START="-1.0335539888632717" LOG_EFFECT_SIZE="-0.3756636139608854" MODIFIED="2010-07-07 15:36:42 +0200" MODIFIED_BY="[Empty name]" ORDER="675" O_E="0.0" SE="0.7728961256550789" STUDY_ID="STD-Selby-1994" TOTAL_1="19" TOTAL_2="20" VAR="0.5973684210526315" WEIGHT="4.014126195171208"/>
<DICH_DATA CI_END="6.548354529770352" CI_START="1.7295663449463" EFFECT_SIZE="3.3653846153846154" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.816132184202772" LOG_CI_START="0.23793722590021854" LOG_EFFECT_SIZE="0.5270347050514953" MODIFIED="2010-07-07 15:36:42 +0200" MODIFIED_BY="[Empty name]" ORDER="672" O_E="0.0" SE="0.33963458061812307" STUDY_ID="STD-Pauwels-1996" TOTAL_1="40" TOTAL_2="125" VAR="0.11535164835164835" WEIGHT="12.361807664123443"/>
<DICH_DATA CI_END="3.928351127711449" CI_START="1.250537776370165" EFFECT_SIZE="2.2164276401564535" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="13" LOG_CI_END="0.5942102993827816" LOG_CI_START="0.09709681547580437" LOG_EFFECT_SIZE="0.34565355742929293" MODIFIED="2010-07-07 15:36:42 +0200" MODIFIED_BY="[Empty name]" ORDER="668" O_E="0.0" SE="0.2920069211983902" STUDY_ID="STD-Hou-2004" TOTAL_1="59" TOTAL_2="68" VAR="0.08526804202776288" WEIGHT="14.205552041855459"/>
<DICH_DATA CI_END="1.8647137558883213" CI_START="0.7795192427538586" EFFECT_SIZE="1.2056451612903225" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="24" LOG_CI_END="0.2706121746009206" LOG_CI_START="-0.10817315960449382" LOG_EFFECT_SIZE="0.08121950749821336" MODIFIED="2010-07-07 15:36:42 +0200" MODIFIED_BY="[Empty name]" ORDER="669" O_E="0.0" SE="0.2225003803299046" STUDY_ID="STD-Jun-2006" TOTAL_1="62" TOTAL_2="69" VAR="0.0495064192469522" WEIGHT="17.266966203241775"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.314789059820605" CI_END="0.6029251426442188" CI_START="0.3830034027364516" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4805438390283412" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="174" I2="15.812656825824176" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="-0.21973660519756355" LOG_CI_START="-0.41679736758986374" LOG_EFFECT_SIZE="-0.31826698639371365" METHOD="MH" MODIFIED="2010-07-09 14:57:09 +0200" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.3056563635245052" P_Q="0.0" P_Z="2.436416504944597E-10" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="476" TOTAL_2="493" WEIGHT="99.99999999999999" Z="6.330959275981691">
<NAME>Mortality sensitivity analysis best-worst case</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0827703473914385" CI_START="0.3890491881044506" EFFECT_SIZE="0.6490384615384616" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="26" LOG_CI_END="0.03453635372886425" LOG_CI_START="-0.409995486664375" LOG_EFFECT_SIZE="-0.1877295664677554" MODIFIED="2010-07-07 15:36:47 +0200" MODIFIED_BY="[Empty name]" ORDER="679" O_E="0.0" SE="0.2611202035150874" STUDY_ID="STD-Rimola-1985" TOTAL_1="80" TOTAL_2="75" VAR="0.06818376068376068" WEIGHT="15.71569028095334"/>
<DICH_DATA CI_END="0.9227823950719797" CI_START="0.10665968891950128" EFFECT_SIZE="0.3137254901960784" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.03490069958226833" LOG_CI_START="-0.9719996873017549" LOG_EFFECT_SIZE="-0.5034501934420116" MODIFIED="2010-07-07 15:36:47 +0200" MODIFIED_BY="[Empty name]" ORDER="678" O_E="0.0" SE="0.5504565841012279" STUDY_ID="STD-Soriano-1992" TOTAL_1="68" TOTAL_2="64" VAR="0.30300245098039214" WEIGHT="7.239658022781827"/>
<DICH_DATA CI_END="1.375558417582134" CI_START="0.3301058032358578" EFFECT_SIZE="0.6738544474393531" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.13847903885135857" LOG_CI_START="-0.4813468407373751" LOG_EFFECT_SIZE="-0.17143390094300828" MODIFIED="2010-07-07 15:36:47 +0200" MODIFIED_BY="[Empty name]" ORDER="676" O_E="0.0" SE="0.3640887898580092" STUDY_ID="STD-Rolando-1993" TOTAL_1="53" TOTAL_2="50" VAR="0.13256064690026956" WEIGHT="8.436620328661519"/>
<DICH_DATA CI_END="0.5618463088141826" CI_START="0.16999387437568825" EFFECT_SIZE="0.30904761904761907" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="30" LOG_CI_END="-0.2503824679937985" LOG_CI_START="-0.7695667278733015" LOG_EFFECT_SIZE="-0.50997459793355" MODIFIED="2010-07-07 15:36:47 +0200" MODIFIED_BY="[Empty name]" ORDER="681" O_E="0.0" SE="0.30497140425675495" STUDY_ID="STD-Blaise-1994" TOTAL_1="70" TOTAL_2="59" VAR="0.09300755741433707" WEIGHT="19.06476291909031"/>
<DICH_DATA CI_END="1.447629337256831" CI_START="0.07675384040065107" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.16065737581751852" LOG_CI_START="-1.1148998852568435" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-07-07 15:36:47 +0200" MODIFIED_BY="[Empty name]" ORDER="677" O_E="0.0" SE="0.7492686492653552" STUDY_ID="STD-Selby-1994" TOTAL_1="19" TOTAL_2="19" VAR="0.5614035087719298" WEIGHT="3.5133634522323574"/>
<DICH_DATA CI_END="0.7399197057163643" CI_START="0.10304799543344415" EFFECT_SIZE="0.2761290322580645" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="31" LOG_CI_END="-0.13081540629107874" LOG_CI_START="-0.9869604520231601" LOG_EFFECT_SIZE="-0.5588879291571195" MODIFIED="2010-07-07 15:36:47 +0200" MODIFIED_BY="[Empty name]" ORDER="682" O_E="0.0" SE="0.5029038378493503" STUDY_ID="STD-Pauwels-1996" TOTAL_1="50" TOTAL_2="107" VAR="0.2529122701236056" WEIGHT="11.562024099703086"/>
<DICH_DATA CI_END="1.2553520879822786" CI_START="0.41025725449331674" EFFECT_SIZE="0.7176470588235294" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.09876554926133212" LOG_CI_START="-0.38694373066838356" LOG_EFFECT_SIZE="-0.14408909070352569" MODIFIED="2010-07-07 15:36:47 +0200" MODIFIED_BY="[Empty name]" ORDER="680" O_E="0.0" SE="0.2853080353304267" STUDY_ID="STD-Hou-2004" TOTAL_1="68" TOTAL_2="61" VAR="0.081400675024108" WEIGHT="12.3467036047442"/>
<DICH_DATA CI_END="0.7441797217630604" CI_START="0.31921569228551705" EFFECT_SIZE="0.48739495798319327" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="35" LOG_CI_END="-0.12832216829243726" LOG_CI_START="-0.49591576736674964" LOG_EFFECT_SIZE="-0.3121189678295935" MODIFIED="2010-07-07 15:36:47 +0200" MODIFIED_BY="[Empty name]" ORDER="683" O_E="0.0" SE="0.21592629971391294" STUDY_ID="STD-Jun-2006" TOTAL_1="68" TOTAL_2="58" VAR="0.04662416690814256" WEIGHT="22.12117729183336"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.817192590736493" CI_END="7.620388667300684" CI_START="1.433312083223702" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="3.304904712045876" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="18" I2="54.634086089913986" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.8819771224891158" LOG_CI_START="0.15634076211078576" LOG_EFFECT_SIZE="0.5191589422999507" METHOD="MH" MODIFIED="2010-07-09 14:57:18 +0200" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.06583484882751989" P_Q="0.0" P_Z="0.00503907053615799" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="YEAR" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.4881443327987625" TOTALS="YES" TOTAL_1="299" TOTAL_2="409" WEIGHT="100.0" Z="2.804525475072097">
<NAME>Mortality from bacterial infections sensitivity analysis worst-best case</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.860056563091857" CI_START="0.38846432731620884" EFFECT_SIZE="1.054054054054054" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4563746222184699" LOG_CI_START="-0.41064885629946163" LOG_EFFECT_SIZE="0.022862882959504165" MODIFIED="2010-07-07 15:36:53 +0200" MODIFIED_BY="[Empty name]" ORDER="687" O_E="0.0" SE="0.5092938831168694" STUDY_ID="STD-Rimola-1985" TOTAL_1="74" TOTAL_2="78" VAR="0.2593802593802594" WEIGHT="24.304561611938887"/>
<DICH_DATA CI_END="13.405604035050779" CI_START="0.541915862475251" EFFECT_SIZE="2.6953125" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1272863873736747" LOG_CI_START="-0.26606813652286326" LOG_EFFECT_SIZE="0.43060912542540575" MODIFIED="2010-07-07 15:36:53 +0200" MODIFIED_BY="[Empty name]" ORDER="686" O_E="0.0" SE="0.8184633445529566" STUDY_ID="STD-Soriano-1992" TOTAL_1="64" TOTAL_2="69" VAR="0.6698822463768116" WEIGHT="15.68898143943201"/>
<DICH_DATA CI_END="25.49826785201914" CI_START="2.896374745575191" EFFECT_SIZE="8.59375" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="1.4065106789492223" LOG_CI_START="0.461854752071491" LOG_EFFECT_SIZE="0.9341827155103567" MODIFIED="2010-07-07 15:36:53 +0200" MODIFIED_BY="[Empty name]" ORDER="684" O_E="0.0" SE="0.554895567570233" STUDY_ID="STD-Pauwels-1996" TOTAL_1="40" TOTAL_2="125" VAR="0.3079090909090909" WEIGHT="22.82291233976548"/>
<DICH_DATA CI_END="27.45213428498233" CI_START="1.4637370523469015" EFFECT_SIZE="6.338983050847458" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.4385761146206515" LOG_CI_START="0.16546306649602055" LOG_EFFECT_SIZE="0.8020195905583359" MODIFIED="2010-07-07 15:36:53 +0200" MODIFIED_BY="[Empty name]" ORDER="688" O_E="0.0" SE="0.747832906479634" STUDY_ID="STD-Hou-2004" TOTAL_1="59" TOTAL_2="68" VAR="0.559254056013777" WEIGHT="17.346081205693196"/>
<DICH_DATA CI_END="10.693233374813389" CI_START="0.8236509844042615" EFFECT_SIZE="2.967741935483871" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.0291090452007678" LOG_CI_START="-0.08425677817820271" LOG_EFFECT_SIZE="0.4724261335112826" MODIFIED="2010-07-07 15:36:53 +0200" MODIFIED_BY="[Empty name]" ORDER="685" O_E="0.0" SE="0.6539965959025172" STUDY_ID="STD-Jun-2006" TOTAL_1="62" TOTAL_2="69" VAR="0.4277115474520804" WEIGHT="19.837463403170418"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6323504567786302" CI_END="0.3084710262874982" CI_START="0.06458361354719838" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.14114592998829067" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="53" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="-0.5107856216287553" LOG_CI_START="-1.1898776592305325" LOG_EFFECT_SIZE="-0.8503316404296439" METHOD="MH" MODIFIED="2010-07-09 14:57:29 +0200" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.9594018610321586" P_Q="0.0" P_Z="9.183385587823346E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="334" TOTAL_2="365" WEIGHT="100.0" Z="4.9083755893903716">
<NAME>Mortality from bacterial infections sensitivity analysis best-worst case</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.537901128611399" CI_START="0.009668372906467708" EFFECT_SIZE="0.07211538461538461" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="13" LOG_CI_END="-0.2692975444908102" LOG_CI_START="-2.01464660732335" LOG_EFFECT_SIZE="-1.1419720759070804" MODIFIED="2010-07-07 15:37:02 +0200" MODIFIED_BY="[Empty name]" ORDER="690" O_E="0.0" SE="1.025226679125033" STUDY_ID="STD-Rimola-1985" TOTAL_1="80" TOTAL_2="75" VAR="1.0510897435897435" WEIGHT="26.930512880953103"/>
<DICH_DATA CI_END="1.2673383729687144" CI_START="0.019415431051814168" EFFECT_SIZE="0.1568627450980392" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.10289258480725146" LOG_CI_START="-1.711852963019237" LOG_EFFECT_SIZE="-0.8044801891059928" MODIFIED="2010-07-07 15:37:02 +0200" MODIFIED_BY="[Empty name]" ORDER="691" O_E="0.0" SE="1.065990517928619" STUDY_ID="STD-Soriano-1992" TOTAL_1="68" TOTAL_2="64" VAR="1.1363357843137256" WEIGHT="12.405926825404094"/>
<DICH_DATA CI_END="1.1303506185505077" CI_START="0.0206708482651261" EFFECT_SIZE="0.15285714285714286" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="0.05321317630027565" LOG_CI_START="-1.68464170095837" LOG_EFFECT_SIZE="-0.8157142623290472" MODIFIED="2010-07-07 15:37:02 +0200" MODIFIED_BY="[Empty name]" ORDER="689" O_E="0.0" SE="1.0208245574221106" STUDY_ID="STD-Pauwels-1996" TOTAL_1="50" TOTAL_2="107" VAR="1.0420827770360481" WEIGHT="17.89539838059414"/>
<DICH_DATA CI_END="0.7068559850746408" CI_START="0.03763444588401224" EFFECT_SIZE="0.16310160427807488" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.1506690604017061" LOG_CI_START="-1.42441447397772" LOG_EFFECT_SIZE="-0.7875417671897131" MODIFIED="2010-07-07 15:37:02 +0200" MODIFIED_BY="[Empty name]" ORDER="692" O_E="0.0" SE="0.7482043610760358" STUDY_ID="STD-Hou-2004" TOTAL_1="68" TOTAL_2="61" VAR="0.559809765933199" WEIGHT="23.273134044556517"/>
<DICH_DATA CI_END="0.8423545095947893" CI_START="0.04264992079087121" EFFECT_SIZE="0.1895424836601307" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.074505094772961" LOG_CI_START="-1.3700817710643243" LOG_EFFECT_SIZE="-0.7222934329186428" MODIFIED="2010-07-07 15:37:02 +0200" MODIFIED_BY="[Empty name]" ORDER="693" O_E="0.0" SE="0.7610281528615254" STUDY_ID="STD-Jun-2006" TOTAL_1="68" TOTAL_2="58" VAR="0.5791638494478252" WEIGHT="19.495027868492148"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.1209438358314525" CI_END="0.9326313849804805" CI_START="0.6282952455507894" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7654853787203801" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="179" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="-0.03028997372552158" LOG_CI_START="-0.2018362266741119" LOG_EFFECT_SIZE="-0.11606310019981675" METHOD="MH" MODIFIED="2010-07-09 14:57:57 +0200" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.7657465735368463" P_Q="0.0" P_Z="0.007999122347161922" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="426" TOTAL_2="552" WEIGHT="100.0" Z="2.6521068506681567">
<NAME>Bacterial infections sensitivity analysis worst-best case</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1250555350303442" CI_START="0.46676384668902254" EFFECT_SIZE="0.7246621621621622" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="32" LOG_CI_END="0.051173960635781716" LOG_CI_START="-0.3309027897121728" LOG_EFFECT_SIZE="-0.13986441453819554" MODIFIED="2010-07-07 15:37:06 +0200" MODIFIED_BY="[Empty name]" ORDER="697" O_E="0.0" SE="0.22443377446480536" STUDY_ID="STD-Rimola-1985" TOTAL_1="74" TOTAL_2="78" VAR="0.050370519120519125" WEIGHT="20.047973482351654"/>
<DICH_DATA CI_END="1.0274359758744558" CI_START="0.36940891112851004" EFFECT_SIZE="0.6160714285714286" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="28" LOG_CI_END="0.01175476856197394" LOG_CI_START="-0.43249263242782654" LOG_EFFECT_SIZE="-0.21036893193292627" MODIFIED="2010-07-07 15:37:06 +0200" MODIFIED_BY="[Empty name]" ORDER="698" O_E="0.0" SE="0.2609531224015097" STUDY_ID="STD-Soriano-1992" TOTAL_1="64" TOTAL_2="69" VAR="0.06809653209109731" WEIGHT="17.338787876628455"/>
<DICH_DATA CI_END="1.1842407428354211" CI_START="0.499658519529246" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="26" LOG_CI_END="0.07343999854991361" LOG_CI_START="-0.30132670316358706" LOG_EFFECT_SIZE="-0.11394335230683675" MODIFIED="2010-07-07 15:37:06 +0200" MODIFIED_BY="[Empty name]" ORDER="695" O_E="0.0" SE="0.22013981571160285" STUDY_ID="STD-Rolando-1993" TOTAL_1="50" TOTAL_2="50" VAR="0.04846153846153846" WEIGHT="16.72922111534074"/>
<DICH_DATA CI_END="1.365686145605081" CI_START="0.5683749244346603" EFFECT_SIZE="0.8810344827586207" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" LOG_CI_END="0.1353509036697525" LOG_CI_START="-0.24536509052620153" LOG_EFFECT_SIZE="-0.05500709342822453" MODIFIED="2010-07-07 15:37:06 +0200" MODIFIED_BY="[Empty name]" ORDER="699" O_E="0.0" SE="0.2236344595652687" STUDY_ID="STD-Blaise-1994" TOTAL_1="58" TOTAL_2="73" VAR="0.05001237150504981" WEIGHT="17.09268628343681"/>
<DICH_DATA CI_END="1.3248210225625292" CI_START="0.023232346569560296" EFFECT_SIZE="0.17543859649122806" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.12215721097949997" LOG_CI_START="-1.6339069223244829" LOG_EFFECT_SIZE="-0.7558748556724915" MODIFIED="2010-07-07 15:37:06 +0200" MODIFIED_BY="[Empty name]" ORDER="694" O_E="0.0" SE="1.0315207645604128" STUDY_ID="STD-Selby-1994" TOTAL_1="19" TOTAL_2="20" VAR="1.0640350877192983" WEIGHT="3.761600014100284"/>
<DICH_DATA CI_END="1.8051277460582318" CI_START="0.5283140312306104" EFFECT_SIZE="0.9765625" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="32" LOG_CI_END="0.256507941668288" LOG_CI_START="-0.2771078549479119" LOG_EFFECT_SIZE="-0.010299956639811952" MODIFIED="2010-07-07 15:37:06 +0200" MODIFIED_BY="[Empty name]" ORDER="696" O_E="0.0" SE="0.3134485603731496" STUDY_ID="STD-Pauwels-1996" TOTAL_1="40" TOTAL_2="125" VAR="0.09825" WEIGHT="9.982938474422445"/>
<DICH_DATA CI_END="1.5701519723687427" CI_START="0.39986879878965853" EFFECT_SIZE="0.7923728813559322" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.19594168907610784" LOG_CI_START="-0.398082481943323" LOG_EFFECT_SIZE="-0.10107039643360761" MODIFIED="2010-07-07 15:37:06 +0200" MODIFIED_BY="[Empty name]" ORDER="700" O_E="0.0" SE="0.34893273852388346" STUDY_ID="STD-Hou-2004" TOTAL_1="59" TOTAL_2="68" VAR="0.12175405601377684" WEIGHT="9.565345083514027"/>
<DICH_DATA CI_END="2.4052623765569776" CI_START="0.40686215919598545" EFFECT_SIZE="0.989247311827957" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.3811624580385986" LOG_CI_START="-0.3905527004553582" LOG_EFFECT_SIZE="-0.004695121208379844" MODIFIED="2010-07-07 15:37:06 +0200" MODIFIED_BY="[Empty name]" ORDER="701" O_E="0.0" SE="0.4533093041509938" STUDY_ID="STD-Jun-2006" TOTAL_1="62" TOTAL_2="69" VAR="0.2054893252298582" WEIGHT="5.481447670205597"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.674294081865987" CI_END="0.4303123735390404" CI_START="0.16206505172993202" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.26408066396015145" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="237" I2="69.12803558635007" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="-0.3662161656941922" LOG_CI_START="-0.7903106278240705" LOG_EFFECT_SIZE="-0.5782633967591313" METHOD="MH" MODIFIED="2010-07-09 14:58:08 +0200" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.0019420258965996418" P_Q="0.0" P_Z="9.04571259771624E-8" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="YEAR" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.29696538897701513" TOTALS="YES" TOTAL_1="476" TOTAL_2="493" WEIGHT="99.99999999999999" Z="5.344919740444991">
<NAME>Bacterial infections sensitivity analysis best-worst case</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7301630851552576" CI_START="0.26656603457199646" EFFECT_SIZE="0.4411764705882353" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="34" LOG_CI_END="-0.13658012745124304" LOG_CI_START="-0.5741951885219048" LOG_EFFECT_SIZE="-0.3553876579865739" MODIFIED="2010-07-07 15:37:29 +0200" MODIFIED_BY="[Empty name]" ORDER="715" O_E="0.0" SE="0.2570572531023955" STUDY_ID="STD-Rimola-1985" TOTAL_1="80" TOTAL_2="75" VAR="0.06607843137254903" WEIGHT="17.09390784112426"/>
<DICH_DATA CI_END="0.6025845898954566" CI_START="0.1943831939272651" EFFECT_SIZE="0.3422459893048128" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="33" LOG_CI_END="-0.21998197888394133" LOG_CI_START="-0.7113412862212822" LOG_EFFECT_SIZE="-0.46566163255261184" MODIFIED="2010-07-07 15:37:29 +0200" MODIFIED_BY="[Empty name]" ORDER="714" O_E="0.0" SE="0.2886268893977525" STUDY_ID="STD-Soriano-1992" TOTAL_1="68" TOTAL_2="64" VAR="0.08330548128342245" WEIGHT="16.319518776431405"/>
<DICH_DATA CI_END="0.9906084893485568" CI_START="0.38409386536159584" EFFECT_SIZE="0.6168359941944848" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="26" LOG_CI_END="-0.00409795450676768" LOG_CI_START="-0.41556262920786086" LOG_EFFECT_SIZE="-0.20983029185731428" MODIFIED="2010-07-07 15:37:29 +0200" MODIFIED_BY="[Empty name]" ORDER="716" O_E="0.0" SE="0.24169638670241075" STUDY_ID="STD-Rolando-1993" TOTAL_1="53" TOTAL_2="50" VAR="0.05841714334500128" WEIGHT="17.46241596849768"/>
<DICH_DATA CI_END="0.3229972629444152" CI_START="0.09202138532138915" EFFECT_SIZE="0.1724025974025974" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="44" LOG_CI_END="-0.4908011578335211" LOG_CI_START="-1.0361112330044293" LOG_EFFECT_SIZE="-0.7634561954189752" MODIFIED="2010-07-07 15:37:29 +0200" MODIFIED_BY="[Empty name]" ORDER="713" O_E="0.0" SE="0.3203178374837978" STUDY_ID="STD-Blaise-1994" TOTAL_1="70" TOTAL_2="59" VAR="0.10260351701029667" WEIGHT="15.531332679681004"/>
<DICH_DATA CI_END="1.0518551021841926" CI_START="0.019402067093583768" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.021955917901392338" LOG_CI_START="-1.7121519979299062" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2010-07-07 15:37:29 +0200" MODIFIED_BY="[Empty name]" ORDER="717" O_E="0.0" SE="1.0186235737319287" STUDY_ID="STD-Selby-1994" TOTAL_1="19" TOTAL_2="19" VAR="1.037593984962406" WEIGHT="4.650102294831896"/>
<DICH_DATA CI_END="0.5587441712534678" CI_START="0.11802582182120744" EFFECT_SIZE="0.2568" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="50" LOG_CI_END="-0.25278699433993357" LOG_CI_START="-0.9280229668664352" LOG_EFFECT_SIZE="-0.5904049806031844" MODIFIED="2010-07-07 15:37:29 +0200" MODIFIED_BY="[Empty name]" ORDER="710" O_E="0.0" SE="0.39663695273403776" STUDY_ID="STD-Pauwels-1996" TOTAL_1="50" TOTAL_2="107" VAR="0.1573208722741433" WEIGHT="13.660632373634868"/>
<DICH_DATA CI_END="0.31726245003614395" CI_START="0.0191790676124298" EFFECT_SIZE="0.07800511508951406" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="23" LOG_CI_END="-0.49858132628320295" LOG_CI_START="-1.7171725098149588" LOG_EFFECT_SIZE="-1.107876918049081" MODIFIED="2010-07-07 15:37:29 +0200" MODIFIED_BY="[Empty name]" ORDER="712" O_E="0.0" SE="0.7158064933301969" STUDY_ID="STD-Hou-2004" TOTAL_1="68" TOTAL_2="61" VAR="0.5123789358936732" WEIGHT="7.667734753482888"/>
<DICH_DATA CI_END="0.3496060076626173" CI_START="0.020809386411377234" EFFECT_SIZE="0.08529411764705883" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="20" LOG_CI_END="-0.45642111301616367" LOG_CI_START="-1.6817407252704344" LOG_EFFECT_SIZE="-1.069080919143299" MODIFIED="2010-07-07 15:37:29 +0200" MODIFIED_BY="[Empty name]" ORDER="711" O_E="0.0" SE="0.7197588056680613" STUDY_ID="STD-Jun-2006" TOTAL_1="68" TOTAL_2="58" VAR="0.5180527383367141" WEIGHT="7.614355312315989"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.584744641846588" CI_END="0.9778969081049691" CI_START="0.633267937277725" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7869375819376647" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="145" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="-0.009706927013061776" LOG_CI_START="-0.19841249999709262" LOG_EFFECT_SIZE="-0.1040597135050772" METHOD="MH" MODIFIED="2010-07-09 14:39:10 +0200" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.9805311397836415" P_Q="0.0" P_Z="0.0306487701021987" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="588" TOTAL_2="653" WEIGHT="100.0" Z="2.161603258307237">
<NAME>Mortality according to the antibiotic used</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.204553009052643" CI_END="1.2684783538250703" CI_START="0.6087521347354116" DF="4" EFFECT_SIZE="0.8787427984095644" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="47" I2="0.0" ID="CMP-001.18.01" LOG_CI_END="0.10328306052539891" LOG_CI_START="-0.21555950281684272" LOG_EFFECT_SIZE="-0.056138221145721895" MODIFIED="2010-06-23 15:08:38 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6981958285478191" P_Z="0.4900829307727743" STUDIES="5" TAU2="0.0" TOTAL_1="238" TOTAL_2="235" WEIGHT="33.882934161891406" Z="0.6901769352773406">
<NAME>Quinolones</NAME>
<DICH_DATA CI_END="1.8570415026877929" CI_START="0.17583377203594702" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2688216098177983" LOG_CI_START="-0.7548977071903873" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="83" O_E="0.0" SE="0.6013377943029549" STUDY_ID="STD-Soriano-1992" TOTAL_1="64" TOTAL_2="64" VAR="0.36160714285714285" WEIGHT="5.003944186630795"/>
<DICH_DATA CI_END="2.0054824979214043" CI_START="0.3663427022237784" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.30221887619583887" LOG_CI_START="-0.43611245545706534" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="84" O_E="0.0" SE="0.43369947901195144" STUDY_ID="STD-Zacharof-1997" TOTAL_1="35" TOTAL_2="30" VAR="0.1880952380952381" WEIGHT="6.158700537391747"/>
<DICH_DATA CI_END="1.338725780151369" CI_START="0.3896279178343957" EFFECT_SIZE="0.7222222222222222" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" LOG_CI_END="0.1266916267779052" LOG_CI_START="-0.4093499323708438" LOG_EFFECT_SIZE="-0.14132915279646932" ORDER="82" O_E="0.0" SE="0.3148734652924872" STUDY_ID="STD-Hsieh-1998" TOTAL_1="60" TOTAL_2="60" VAR="0.09914529914529915" WEIGHT="12.867285051336328"/>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528007" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-23 14:26:47 +0200" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Hong-2002" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="0.7148491695186849"/>
<DICH_DATA CI_END="2.409299472677698" CI_START="0.6720755898297837" EFFECT_SIZE="1.272490221642764" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.3818907855724282" LOG_CI_START="-0.17258187813700648" LOG_EFFECT_SIZE="0.10465445371771086" MODIFIED="2010-06-23 15:08:38 +0200" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.325699987346873" STUDY_ID="STD-Hou-2004" TOTAL_1="59" TOTAL_2="61" VAR="0.10608048175775323" WEIGHT="9.138155217013855"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.06485614509539596" CI_END="1.3065485862681823" CI_START="0.4163078552179066" DF="1" EFFECT_SIZE="0.7375136877965689" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="29" I2="0.0" ID="CMP-001.18.02" LOG_CI_END="0.11612556435483244" LOG_CI_START="-0.38058539443245015" LOG_EFFECT_SIZE="-0.13222991503880888" MODIFIED="2010-07-09 14:39:10 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7989789993021998" P_Z="0.2967038823710947" STUDIES="2" TAU2="0.0" TOTAL_1="98" TOTAL_2="166" WEIGHT="16.39726586226847" Z="1.0435278971400546">
<NAME>Quinolones + beta-lactams</NAME>
<DICH_DATA CI_END="1.3759413912904064" CI_START="0.35546226656983415" EFFECT_SIZE="0.6993534482758621" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.1385999353666005" LOG_CI_START="-0.44920649420358616" LOG_EFFECT_SIZE="-0.1553032794184928" ORDER="85" O_E="0.0" SE="0.34528040641828084" STUDY_ID="STD-Blaise-1994" TOTAL_1="58" TOTAL_2="59" VAR="0.1192185590563732" WEIGHT="11.339829560911788"/>
<DICH_DATA CI_END="2.376067966150243" CI_START="0.28511626390864714" EFFECT_SIZE="0.823076923076923" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="0.3758588592476404" LOG_CI_START="-0.5449780084908946" LOG_EFFECT_SIZE="-0.08455957462162715" ORDER="86" O_E="0.0" SE="0.5409041343256248" STUDY_ID="STD-Pauwels-1996" TOTAL_1="40" TOTAL_2="107" VAR="0.29257728253055354" WEIGHT="5.057436301356683"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6951365291930369" CI_END="1.111160727002887" CI_START="0.46045698096889054" DF="2" EFFECT_SIZE="0.7152913488411187" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="32" I2="0.0" ID="CMP-001.18.03" LOG_CI_END="0.045776883244906606" LOG_CI_START="-0.3368109383239048" LOG_EFFECT_SIZE="-0.14551702753949908" MODIFIED="2010-06-23 15:59:57 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.706403879676623" P_Z="0.13597671332946368" STUDIES="3" TAU2="0.0" TOTAL_1="128" TOTAL_2="127" WEIGHT="23.38072654860804" Z="1.4909420375444153">
<NAME>Cephalosporins </NAME>
<DICH_DATA CI_END="1.8134252939278308" CI_START="0.08823081961840529" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.25849966904069305" LOG_CI_START="-1.0543796863847683" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2010-06-23 14:51:06 +0200" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.7711918322345376" STUDY_ID="STD-Selby-1994" TOTAL_1="19" TOTAL_2="19" VAR="0.5947368421052632" WEIGHT="3.5742458475934247"/>
<DICH_DATA CI_END="4.058163798023074" CI_START="0.12394591057361681" EFFECT_SIZE="0.7092198581560284" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6083295723035174" LOG_CI_START="-0.9067677976142772" LOG_EFFECT_SIZE="-0.14921911265537988" MODIFIED="2010-06-23 14:49:35 +0200" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.8899756949426497" STUDY_ID="STD-Lin-2002" TOTAL_1="47" TOTAL_2="50" VAR="0.7920567375886524" WEIGHT="2.078221296951228"/>
<DICH_DATA CI_END="1.251337369016956" CI_START="0.48566376446343795" EFFECT_SIZE="0.7795698924731183" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="24" LOG_CI_END="0.0973744142094864" LOG_CI_START="-0.31366429817536934" LOG_EFFECT_SIZE="-0.10814494198294143" MODIFIED="2010-06-23 15:59:57 +0200" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="0.2414461743293054" STUDY_ID="STD-Jun-2006" TOTAL_1="62" TOTAL_2="58" VAR="0.05829625509825733" WEIGHT="17.728259404063387"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.053953164424824354" CI_END="1.1651764270102933" CI_START="0.4999098193032782" DF="1" EFFECT_SIZE="0.7632058287795993" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="37" I2="0.0" ID="CMP-001.18.04" LOG_CI_END="0.06639168971900863" LOG_CI_START="-0.30110833268660175" LOG_EFFECT_SIZE="-0.11735832148379657" MODIFIED="2010-06-23 14:51:53 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8163219412217587" P_Z="0.21064313280447455" STUDIES="2" TAU2="0.0" TOTAL_1="124" TOTAL_2="125" WEIGHT="26.339073427232083" Z="1.2517990169831514">
<NAME>Other antibiotics</NAME>
<DICH_DATA CI_END="1.3429873388139972" CI_START="0.46846430725599986" EFFECT_SIZE="0.7931844888366627" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.12807191832088582" LOG_CI_START="-0.32932349282801177" LOG_EFFECT_SIZE="-0.10062578725356298" ORDER="87" O_E="0.0" SE="0.2686763286526633" STUDY_ID="STD-Rimola-1985" TOTAL_1="74" TOTAL_2="75" VAR="0.07218696957827392" WEIGHT="16.331185053970493"/>
<DICH_DATA CI_END="1.453646240959568" CI_START="0.35098228665033504" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.1624587295683904" LOG_CI_START="-0.4547148009248664" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="88" O_E="0.0" SE="0.3625307868699863" STUDY_ID="STD-Rolando-1993" TOTAL_1="50" TOTAL_2="50" VAR="0.13142857142857145" WEIGHT="10.00788837326159"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.4263788904827037" CI_END="0.9735100628767254" CI_START="0.1869715200307698" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4266364450223535" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="-0.01165955495109196" LOG_CI_START="-0.7282245412466496" LOG_EFFECT_SIZE="-0.3699420480988707" METHOD="MH" MODIFIED="2010-07-09 15:28:47 +0200" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.7875394396154639" P_Q="0.0" P_Z="0.04299619861237234" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="346" TOTAL_2="415" WEIGHT="100.0" Z="2.023746916212577">
<NAME>Mortality from bacterial infections according to the antibiotic used</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.21701148978456242" CI_END="3.3384192411431743" CI_START="0.175165263636854" DF="1" EFFECT_SIZE="0.7647058823529411" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-001.19.01" LOG_CI_END="0.523540874788431" LOG_CI_START="-0.7565520129313055" LOG_EFFECT_SIZE="-0.11650556907143719" MODIFIED="2010-06-28 16:02:14 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6413265246528748" P_Z="0.7212670977336915" STUDIES="2" TAU2="0.0" TOTAL_1="123" TOTAL_2="125" WEIGHT="21.30234293008514" Z="0.3567658590543701">
<NAME>Quinolones</NAME>
<DICH_DATA CI_END="5.377224246500977" CI_START="0.04649238873805159" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.730558148247107" LOG_CI_START="-1.3326181395750694" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-06-28 16:02:14 +0200" MODIFIED_BY="[Empty name]" ORDER="515" O_E="0.0" SE="1.2119199643540823" STUDY_ID="STD-Soriano-1992" TOTAL_1="64" TOTAL_2="64" VAR="1.46875" WEIGHT="10.740677107605952"/>
<DICH_DATA CI_END="7.101799877745542" CI_START="0.15051757634100574" EFFECT_SIZE="1.0338983050847457" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8513684301149411" LOG_CI_START="-0.8224127833776955" LOG_EFFECT_SIZE="0.014477823368622805" MODIFIED="2010-06-28 16:01:10 +0200" MODIFIED_BY="[Empty name]" ORDER="511" O_E="0.0" SE="0.9831873701562059" STUDY_ID="STD-Hou-2004" TOTAL_1="59" TOTAL_2="61" VAR="0.9666574048346763" WEIGHT="10.561665822479187"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.804577450335183" CI_START="0.07704722115029666" DF="0" EFFECT_SIZE="0.66875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-001.19.02" LOG_CI_END="0.7637706103507295" LOG_CI_START="-1.11324302029216" LOG_EFFECT_SIZE="-0.17473620497071518" MODIFIED="2010-07-09 14:39:20 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7151737011327385" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="107" WEIGHT="11.690532906237772" Z="0.36491654929592604">
<NAME>Quinolones + beta lactam</NAME>
<DICH_DATA CI_END="5.804577450335185" CI_START="0.07704722115029662" EFFECT_SIZE="0.66875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.7637706103507297" LOG_CI_START="-1.1132430202921602" LOG_EFFECT_SIZE="-0.17473620497071518" MODIFIED="2010-06-28 16:01:49 +0200" MODIFIED_BY="[Empty name]" ORDER="513" O_E="0.0" SE="1.1025670980069544" STUDY_ID="STD-Pauwels-1996" TOTAL_1="40" TOTAL_2="107" VAR="1.2156542056074768" WEIGHT="11.690532906237772"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3748386368437687" CI_END="1.9524191019055452" CI_START="0.10061815191066115" DF="1" EFFECT_SIZE="0.4432254525507405" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-001.19.03" LOG_CI_END="0.2905730480172586" LOG_CI_START="-0.9973236637780388" LOG_EFFECT_SIZE="-0.35337530788039023" MODIFIED="2010-06-28 16:02:29 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5403788345814269" P_Z="0.28212564168491494" STUDIES="2" TAU2="0.0" TOTAL_1="109" TOTAL_2="108" WEIGHT="29.667052071463107" Z="1.0755565568699155">
<NAME>Cephalosporins</NAME>
<DICH_DATA CI_END="4.313972048844031" CI_START="0.010467441487503393" EFFECT_SIZE="0.2125" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6348773268879621" LOG_CI_START="-1.9801594581153013" LOG_EFFECT_SIZE="-0.6726410656136697" MODIFIED="2010-06-28 16:02:29 +0200" MODIFIED_BY="[Empty name]" ORDER="516" O_E="0.0" SE="1.5360855521517711" STUDY_ID="STD-Lin-2002" TOTAL_1="47" TOTAL_2="50" VAR="2.3595588235294116" WEIGHT="13.019002554673882"/>
<DICH_DATA CI_END="3.5996908730919825" CI_START="0.10805002783649102" EFFECT_SIZE="0.6236559139784946" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5562652069132014" LOG_CI_START="-0.9663751168951972" LOG_EFFECT_SIZE="-0.20505495499099782" MODIFIED="2010-06-28 16:01:27 +0200" MODIFIED_BY="[Empty name]" ORDER="512" O_E="0.0" SE="0.8944064633962144" STUDY_ID="STD-Jun-2006" TOTAL_1="62" TOTAL_2="58" VAR="0.7999629217649239" WEIGHT="16.648049516789225"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1480284022923046" CI_START="0.018260403698457977" DF="0" EFFECT_SIZE="0.14478764478764478" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" ID="CMP-001.19.04" LOG_CI_END="0.059952632666690105" LOG_CI_START="-1.738489625373756" LOG_EFFECT_SIZE="-0.8392684963535331" MODIFIED="2010-06-28 16:01:59 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.06735620804464247" STUDIES="1" TAU2="0.0" TOTAL_1="74" TOTAL_2="75" WEIGHT="37.34007209221398" Z="1.8292897854883665">
<NAME>Others</NAME>
<DICH_DATA CI_END="1.1480284022923046" CI_START="0.018260403698457977" EFFECT_SIZE="0.14478764478764478" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.059952632666690105" LOG_CI_START="-1.738489625373756" LOG_EFFECT_SIZE="-0.8392684963535331" MODIFIED="2010-06-28 16:01:59 +0200" MODIFIED_BY="[Empty name]" ORDER="514" O_E="0.0" SE="1.0564138848057119" STUDY_ID="STD-Rimola-1985" TOTAL_1="74" TOTAL_2="75" VAR="1.1160102960102958" WEIGHT="37.34007209221398"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.304623845674648" CI_END="0.4489919827677634" CI_START="0.2859923324440569" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3583409890040971" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="237" I2="32.53447547078419" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="-0.34776141372007613" LOG_CI_START="-0.5436456103040839" LOG_EFFECT_SIZE="-0.4457035120120801" METHOD="MH" MODIFIED="2010-07-09 15:29:07 +0200" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.13019337063505254" P_Q="0.0" P_Z="4.697694846930419E-19" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="588" TOTAL_2="653" WEIGHT="100.00000000000001" Z="8.919176192470964">
<NAME>Bacterial infections according to the antibiotic used</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.024848497781951" CI_END="0.39217228547178307" CI_START="0.17948722650744667" DF="4" EFFECT_SIZE="0.2653109794795854" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="96" I2="0.6173772204256862" ID="CMP-001.20.01" LOG_CI_END="-0.4065231008568126" LOG_CI_START="-0.7459664532401058" LOG_EFFECT_SIZE="-0.5762447770484592" MODIFIED="2010-06-28 16:06:44 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4026536385806144" P_Z="2.8419513130528355E-11" STUDIES="5" TAU2="0.0" TOTAL_1="238" TOTAL_2="235" WEIGHT="43.382265639309736" Z="6.65453603002939">
<NAME>Quinolones</NAME>
<DICH_DATA CI_END="0.76601958859545" CI_START="0.23977646540936784" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="28" LOG_CI_END="-0.11576012447948708" LOG_CI_START="-0.6201934461097017" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2010-06-28 16:06:23 +0200" MODIFIED_BY="[Empty name]" ORDER="524" O_E="0.0" SE="0.296306630110801" STUDY_ID="STD-Soriano-1992" TOTAL_1="64" TOTAL_2="64" VAR="0.08779761904761904" WEIGHT="12.527351935193103"/>
<DICH_DATA CI_END="0.5716107095247541" CI_START="0.08033153784875025" EFFECT_SIZE="0.21428571428571427" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="16" LOG_CI_END="-0.24289964299524938" LOG_CI_START="-1.095113918921902" LOG_EFFECT_SIZE="-0.6690067809585756" MODIFIED="2010-06-28 16:06:44 +0200" MODIFIED_BY="[Empty name]" ORDER="525" O_E="0.0" SE="0.5005948842080171" STUDY_ID="STD-Zacharof-1997" TOTAL_1="35" TOTAL_2="30" VAR="0.2505952380952381" WEIGHT="7.709139652426524"/>
<DICH_DATA CI_END="0.49903266505621147" CI_START="0.09895688099659807" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="27" LOG_CI_END="-0.30187102594101783" LOG_CI_START="-1.0045540016096697" LOG_EFFECT_SIZE="-0.6532125137753437" MODIFIED="2010-06-28 16:05:10 +0200" MODIFIED_BY="[Empty name]" ORDER="520" O_E="0.0" SE="0.41275945824459354" STUDY_ID="STD-Hsieh-1998" TOTAL_1="60" TOTAL_2="60" VAR="0.17037037037037037" WEIGHT="12.079946508936205"/>
<DICH_DATA CI_END="0.9022539539810092" CI_START="0.054732612510581626" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.04467120603944865" LOG_CI_START="-1.2617538215112387" LOG_EFFECT_SIZE="-0.6532125137753437" MODIFIED="2010-06-28 16:04:40 +0200" MODIFIED_BY="[Empty name]" ORDER="518" O_E="0.0" SE="0.7149203529842405" STUDY_ID="STD-Hong-2002" TOTAL_1="20" TOTAL_2="20" VAR="0.5111111111111111" WEIGHT="4.026648836312068"/>
<DICH_DATA CI_END="0.5377484040431961" CI_START="0.031059648934449815" EFFECT_SIZE="0.1292372881355932" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" LOG_CI_END="-0.2694208698596292" LOG_CI_START="-1.5078034573870123" LOG_EFFECT_SIZE="-0.8886121636233207" MODIFIED="2010-06-28 16:04:56 +0200" MODIFIED_BY="[Empty name]" ORDER="519" O_E="0.0" SE="0.727432062006258" STUDY_ID="STD-Hou-2004" TOTAL_1="59" TOTAL_2="61" VAR="0.5291574048346763" WEIGHT="7.039178706441838"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9041593088975792" CI_END="0.6226679031411223" CI_START="0.22910218027038073" DF="1" EFFECT_SIZE="0.3776964047936085" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="62" I2="0.0" ID="CMP-001.20.02" LOG_CI_END="-0.20574352041632676" LOG_CI_START="-0.6399707777905681" LOG_EFFECT_SIZE="-0.42285714910344746" MODIFIED="2010-07-09 14:39:37 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.34166901457722887" P_Z="1.3492781271145016E-4" STUDIES="2" TAU2="0.0" TOTAL_1="98" TOTAL_2="166" WEIGHT="21.098993728033236" Z="3.8172858510065737">
<NAME>Quinolones + beta-lactams</NAME>
<DICH_DATA CI_END="0.5850359155648697" CI_START="0.15918715357909122" EFFECT_SIZE="0.30517241379310345" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="30" LOG_CI_END="-0.2328174716052619" LOG_CI_START="-0.7980919827969994" LOG_EFFECT_SIZE="-0.5154547272011306" MODIFIED="2010-06-28 16:04:27 +0200" MODIFIED_BY="[Empty name]" ORDER="517" O_E="0.0" SE="0.33204504602798507" STUDY_ID="STD-Blaise-1994" TOTAL_1="58" TOTAL_2="59" VAR="0.11025391259172672" WEIGHT="13.307443447641024"/>
<DICH_DATA CI_END="1.1081131921627243" CI_START="0.22702097871000543" EFFECT_SIZE="0.5015625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="32" LOG_CI_END="0.04458412521265791" LOG_CI_START="-0.6439340083706881" LOG_EFFECT_SIZE="-0.2996749415790151" MODIFIED="2010-06-28 16:05:45 +0200" MODIFIED_BY="[Empty name]" ORDER="522" O_E="0.0" SE="0.40443895988658574" STUDY_ID="STD-Pauwels-1996" TOTAL_1="40" TOTAL_2="107" VAR="0.1635708722741433" WEIGHT="7.791550280392212"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.33454979852403327" CI_END="0.4812721597594055" CI_START="0.052946414467014646" DF="2" EFFECT_SIZE="0.1596296815822696" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="21" I2="0.0" ID="CMP-001.20.03" LOG_CI_END="-0.3176092603101119" LOG_CI_START="-1.276163444997763" LOG_EFFECT_SIZE="-0.7968863526539374" MODIFIED="2010-06-28 16:13:56 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8459670500270875" P_Z="0.001118842144961839" STUDIES="3" TAU2="0.0" TOTAL_1="128" TOTAL_2="127" WEIGHT="9.665312981167926" Z="3.2588007562288066">
<NAME>Cephalosporins</NAME>
<DICH_DATA CI_END="1.255435388862829" CI_START="0.02212601144128878" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.09879436660498035" LOG_CI_START="-1.6550968673722675" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2010-06-28 16:07:17 +0200" MODIFIED_BY="[Empty name]" ORDER="528" O_E="0.0" SE="1.0302443927398635" STUDY_ID="STD-Selby-1994" TOTAL_1="19" TOTAL_2="19" VAR="1.06140350877193" WEIGHT="2.684432557541379"/>
<DICH_DATA CI_END="1.4119668128919467" CI_START="0.004730931759912724" EFFECT_SIZE="0.08173076923076923" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.1498244891043975" LOG_CI_START="-2.3250533162733724" LOG_EFFECT_SIZE="-1.0876144135844876" MODIFIED="2010-06-28 16:06:55 +0200" MODIFIED_BY="[Empty name]" ORDER="526" O_E="0.0" SE="1.4537554737216178" STUDY_ID="STD-Lin-2002" TOTAL_1="47" TOTAL_2="50" VAR="2.1134049773755654" WEIGHT="2.820009959437408"/>
<DICH_DATA CI_END="0.9221801085097353" CI_START="0.04686318810672564" EFFECT_SIZE="0.2078853046594982" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.035184249778319646" LOG_CI_START="-1.3291681696430009" LOG_EFFECT_SIZE="-0.6821762097106603" MODIFIED="2010-06-28 16:05:31 +0200" MODIFIED_BY="[Empty name]" ORDER="521" O_E="0.0" SE="0.7600925598522208" STUDY_ID="STD-Jun-2006" TOTAL_1="62" TOTAL_2="58" VAR="0.5777406995427018" WEIGHT="4.160870464189138"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5297996054081533" CI_END="0.8096800772920392" CI_START="0.4054174845613461" DF="1" EFFECT_SIZE="0.572938443670151" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="58" I2="0.0" ID="CMP-001.20.04" LOG_CI_END="-0.09168654669217847" LOG_CI_START="-0.39209752529084857" LOG_EFFECT_SIZE="-0.24189203599151352" MODIFIED="2010-06-28 16:13:58 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.46669119728468933" P_Z="0.001597622032367852" STUDIES="2" TAU2="0.0" TOTAL_1="124" TOTAL_2="125" WEIGHT="25.85342765148912" Z="3.1563405631975923">
<NAME>Others</NAME>
<DICH_DATA CI_END="0.8413337434821526" CI_START="0.30523251029461934" EFFECT_SIZE="0.5067567567567568" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="32" LOG_CI_END="-0.0750316924296669" LOG_CI_START="-0.5153692115768477" LOG_EFFECT_SIZE="-0.2952004520032573" MODIFIED="2010-06-28 16:06:08 +0200" MODIFIED_BY="[Empty name]" ORDER="523" O_E="0.0" SE="0.25865643845292763" STUDY_ID="STD-Rimola-1985" TOTAL_1="74" TOTAL_2="75" VAR="0.06690315315315315" WEIGHT="14.220886568809812"/>
<DICH_DATA CI_END="1.045212747193444" CI_START="0.409021793933676" EFFECT_SIZE="0.6538461538461539" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="26" LOG_CI_END="0.01920469765116844" LOG_CI_START="-0.38825355083625657" LOG_EFFECT_SIZE="-0.18452442659254403" MODIFIED="2010-06-28 16:07:05 +0200" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="0.23934299211237242" STUDY_ID="STD-Rolando-1993" TOTAL_1="50" TOTAL_2="50" VAR="0.05728506787330316" WEIGHT="11.632541082679309"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4221670172031409" CI_END="0.7359330805704861" CI_START="0.3805162822808705" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5291828793774319" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="63" I2="0.0" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="-0.1331616748748487" LOG_CI_START="-0.4196267550473053" LOG_EFFECT_SIZE="-0.276394214961077" METHOD="MH" MODIFIED="2010-07-09 15:29:28 +0200" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.49111185292090076" P_Q="0.0" P_Z="1.5549813545905964E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="141" TOTAL_2="139" WEIGHT="100.0" Z="3.7821203654756586">
<NAME>Rebleeding</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-06-29 15:26:24 +0200" MODIFIED_BY="[Empty name]" ORDER="371" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Hong-2002" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.7782101167315175"/>
<DICH_DATA CI_END="0.819226070037441" CI_START="0.25774298043277105" EFFECT_SIZE="0.4595103578154426" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="27" LOG_CI_END="-0.08659623569777097" LOG_CI_START="-0.5888131537877083" LOG_EFFECT_SIZE="-0.3377046947427396" MODIFIED="2010-06-29 15:26:41 +0200" MODIFIED_BY="[Empty name]" ORDER="369" O_E="0.0" SE="0.2950047036998676" STUDY_ID="STD-Hou-2004" TOTAL_1="59" TOTAL_2="61" VAR="0.08702777520504666" WEIGHT="41.32295719844358"/>
<DICH_DATA CI_END="0.8155533004803686" CI_START="0.36513532135467974" EFFECT_SIZE="0.5456989247311828" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="36" LOG_CI_END="-0.08854765038327833" LOG_CI_START="-0.43754615355409093" LOG_EFFECT_SIZE="-0.26304690196868463" MODIFIED="2010-06-29 15:27:02 +0200" MODIFIED_BY="[Empty name]" ORDER="370" O_E="0.0" SE="0.20500344833298792" STUDY_ID="STD-Jun-2006" TOTAL_1="62" TOTAL_2="58" VAR="0.04202641382841605" WEIGHT="57.89883268482491"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.6894125839915324" CI_END="0.498051307589229" CI_START="0.11964902928040932" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.24411340701585774" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="34" I2="25.634318367333965" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="-0.30272591536256627" LOG_CI_START="-0.9220908204928493" LOG_EFFECT_SIZE="-0.6124083679277077" METHOD="MH" MODIFIED="2010-07-09 15:29:42 +0200" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.2606164326160759" P_Q="0.0" P_Z="1.0623112994055961E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="141" TOTAL_2="139" WEIGHT="100.0" Z="3.875900410330094">
<NAME>Early rebleeding (up to 7 days)</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="69.5152908317231" CI_START="0.12946791838627933" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.84208034406391" LOG_CI_START="-0.8878378346245852" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-06-29 15:27:52 +0200" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Hong-2002" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="1.4416146083613646"/>
<DICH_DATA CI_END="0.6018645368882226" CI_START="0.0787172063913163" EFFECT_SIZE="0.21766280107047278" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="19" LOG_CI_END="-0.2205012454565515" LOG_CI_START="-1.103930327055936" LOG_EFFECT_SIZE="-0.6622157862562438" MODIFIED="2010-06-29 15:28:47 +0200" MODIFIED_BY="[Empty name]" ORDER="373" O_E="0.0" SE="0.5189306155759599" STUDY_ID="STD-Hou-2004" TOTAL_1="59" TOTAL_2="61" VAR="0.2692889837820447" WEIGHT="53.86833253243633"/>
<DICH_DATA CI_END="0.6130111432304767" CI_START="0.05710369754317916" EFFECT_SIZE="0.1870967741935484" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="15" LOG_CI_END="-0.21253163086572693" LOG_CI_START="-1.243335769676944" LOG_EFFECT_SIZE="-0.7279337002713354" MODIFIED="2010-06-29 15:29:02 +0200" MODIFIED_BY="[Empty name]" ORDER="372" O_E="0.0" SE="0.6054994537004891" STUDY_ID="STD-Jun-2006" TOTAL_1="62" TOTAL_2="58" VAR="0.36662958843159066" WEIGHT="44.690052859202304"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="20.467347929053375" CI_END="0.25721501160736726" CI_START="-1.843500372022094" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7931426802073633" ESTIMABLE="YES" I2="70.68501487931904" I2_Q="50.41629115362121" ID="CMP-001.23" MODIFIED="2010-07-09 15:30:05 +0200" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.002285672988801002" P_Q="0.15556794470449176" P_Z="0.1388728137387455" Q="2.016791448776491" RANDOM="YES" SCALE="19.4" SORT_BY="YEAR" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.7846454012146568" TOTALS="YES" TOTAL_1="351" TOTAL_2="418" UNITS="" WEIGHT="100.0" Z="1.4800016222304209">
<NAME>Days of hospitalisation</NAME>
<GROUP_LABEL_1>Antibiotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="13.527498766856855" CI_END="0.9993495556913529" CI_START="-1.5468986985278481" DF="1" EFFECT_SIZE="-0.2737745714182477" ESTIMABLE="YES" I2="92.60765040725741" ID="CMP-001.23.01" MODIFIED="2010-06-30 11:11:23 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.3509494243456608E-4" P_Z="0.6734092340827464" STUDIES="2" TAU2="0.7825346459413254" TOTAL_1="98" TOTAL_2="166" WEIGHT="67.89637074913479" Z="0.421473671291488">
<NAME>Intensive care unit</NAME>
<CONT_DATA CI_END="0.9989038600177664" CI_START="-0.1989038600177675" EFFECT_SIZE="0.39999999999999947" ESTIMABLE="YES" MEAN_1="7.1" MEAN_2="6.7" MODIFIED="2010-06-30 11:04:47 +0200" MODIFIED_BY="[Empty name]" ORDER="191" SD_1="2.0" SD_2="1.2" SE="0.3055688087851839" STUDY_ID="STD-Blaise-1994" TOTAL_1="58" TOTAL_2="59" WEIGHT="32.70958154562502"/>
<CONT_DATA CI_END="-0.5518185284527989" CI_START="-1.248181471547202" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="7.4" MODIFIED="2010-06-30 11:05:29 +0200" MODIFIED_BY="[Empty name]" ORDER="192" SD_1="0.9" SD_2="1.1" SE="0.1776468722352107" STUDY_ID="STD-Pauwels-1996" TOTAL_1="40" TOTAL_2="107" WEIGHT="35.18678920350977"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.923057713420028" CI_END="-0.02258942453376034" CI_START="-3.7983672027884285" DF="4" EFFECT_SIZE="-1.9104783136610946" ESTIMABLE="YES" I2="18.749682964386448" ID="CMP-001.23.02" MODIFIED="2010-06-30 11:11:49 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2952838131103107" P_Z="0.04732100152987649" STUDIES="5" TAU2="0.9001966379564543" TOTAL_1="253" TOTAL_2="252" WEIGHT="32.10362925086521" Z="1.9834158194296179">
<NAME>Full-lenght</NAME>
<CONT_DATA CI_END="2.5945153389593507" CI_START="-4.394515338959351" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="13.5" MEAN_2="14.4" MODIFIED="2010-06-30 11:09:29 +0200" MODIFIED_BY="[Empty name]" ORDER="194" SD_1="9.2" SD_2="10.9" SE="1.782948751366679" STUDY_ID="STD-Soriano-1992" TOTAL_1="64" TOTAL_2="64" WEIGHT="7.245923359232724"/>
<CONT_DATA CI_END="-1.5261184885481685" CI_START="-12.473881511451832" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="19.0" MEAN_2="26.0" MODIFIED="2010-06-30 11:07:31 +0200" MODIFIED_BY="[Empty name]" ORDER="193" SD_1="12.0" SD_2="18.0" SE="2.7928480087537886" STUDY_ID="STD-Hsieh-1998" TOTAL_1="60" TOTAL_2="60" WEIGHT="3.3454604299669883"/>
<CONT_DATA CI_END="4.206555782020752" CI_START="-18.20655578202075" EFFECT_SIZE="-6.999999999999998" ESTIMABLE="YES" MEAN_1="13.4" MEAN_2="20.4" MODIFIED="2010-06-30 11:06:31 +0200" MODIFIED_BY="[Empty name]" ORDER="196" SD_1="9.6" SD_2="23.7" SE="5.717735565763775" STUDY_ID="STD-Hong-2002" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.8578865118535371"/>
<CONT_DATA CI_END="1.0682747037057996" CI_START="-3.4682747037058017" EFFECT_SIZE="-1.200000000000001" ESTIMABLE="YES" MEAN_1="10.2" MEAN_2="11.4" MODIFIED="2010-06-30 11:08:57 +0200" MODIFIED_BY="[Empty name]" ORDER="195" SD_1="2.4" SD_2="7.8" SE="1.1573042778324816" STUDY_ID="STD-Lin-2002" TOTAL_1="47" TOTAL_2="50" WEIGHT="13.521473881251215"/>
<CONT_DATA CI_END="2.3288707002007376" CI_START="-4.72887070020074" EFFECT_SIZE="-1.200000000000001" ESTIMABLE="YES" MEAN_1="13.6" MEAN_2="14.8" MODIFIED="2010-06-30 11:08:21 +0200" MODIFIED_BY="[Empty name]" ORDER="197" SD_1="9.7" SD_2="10.0" SE="1.8004773189895429" STUDY_ID="STD-Jun-2006" TOTAL_1="62" TOTAL_2="58" WEIGHT="7.132885068560749"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-08-04 18:02:03 +0200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-08-04 11:41:50 +0200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-08-04 11:41:50 +0200" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAAEZCAMAAAC0DjydAAADAFBMVEUAAADAAAAAwAAAAMDg4ADAAMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdCQkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYAAJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkAmcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwzAP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8zzAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBmMzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNmzGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZM5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZzMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zMM//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP//2b//5n//8z///80TKWtAAAK60lEQVR42u2d63KsKhCF3amp4uX6X16Vl6MqJznJeOGu4Dje+NbJ2TMioLLsBpQ13XWgNfzrFI3QFswHbdAc4BzOAZwDOAdwDuAcwDk4Hx5NXKWBaOfZWxucn9ad7XdeX/h2+nMA5wDOAZwDOAd35VyiLwv5doGkDigicLsB56LP2o46PlWtIX073z5Y0GBJv/8OhiZjYp8yGdqUMZf/r4DYmt2SyUzDlnO0OBeYQfVzONF9E+v+q3Yda5+o+/Tn/27GXP5ph+7CkpLK5FepvcMM6RpiN7Hzv6aUhCvVMz42la5n9uuZgtFR9eyhBN43sHNZHqhJ/O3vPtHL+WfSsseV+TsUvM659lpZZxpawt2D09VFg69UWs6tiN57itCab38aTu/cxbMz6RIf0e5cfp81yUwKZcmbFN1NYOUY7pf2p7vuXbbdcj6eI6ux2W3GZH7XIYiTsctnGrfs0bowF759DhvoWGqbtyb/RtQZ3p9/TTybE6+ZEFz0ae38AmBtlLM2yjzaul7Q8V4NzgGcAzgHdwCahubG7WgaWnGNaBrozwGcAzgHcA7gHMD5H8YVNZLdLa/WPrMPTcMBnBcIIN74bhxNw+G+XSLNQlaJEAgXYq3DZMH93ji/sDByAXs8hwtlCzklQpcWLnhpVvLQax7i/BpNwzF2bgUQoTtfXPOc0kjo3N6svIJFkPvbuawafhXUWKiNgPL9Oc/qDVYrEfRMcQg+3rc7AoiEPUq1h5Dl4sJdcKYxnKNnWFAiRLqGKG0snjpAMGYEGTSy1pn3546mgWev+Pab4vukdcH524Cm4fqdE4BzAOcAzkF7Yzg0DQ1qGhYu87/7t8APvp3+HMA5gHMA5wDOAZy/ASLjgub4l0CJ07DlxPVEeP44tB6/Rbt8ylkpczPfLpHcwUvAwm9j55El+2EfvARM/B6c+1xauYOkE3Dtt+rPC/0AYK4G7sJ5JnwLZn6//nzqu32Fw5SAb8/jhpqGBN2G9+c/t/39diZqbdp5AqyNIk4D43YA5wDOAZyDawNNQ3PjduI03Ocq5h8soWmgPwdwDuAcwDmAc3BZzosXCUtJkQ1rk6oaidOwgHvOz9E0VHAu/Y+rduO/z99nfqaJ/Tpa019iv6DcTRsaXMbf1E9U4xXR87XZHP3CV5sl8wHVy1ATPn//PvuP8W9K+4x3+9+Um6YWqnGLfC7W5h78M3GY4KCf09VM6D5ugccs/s2icxojuAMSoRHcgAjVRjQbVyGRPPMtoVVLnZW27h1s258XjeOKx3dSU++wmnn6ce/Rt4c9OtiY82SIlBXWb8dc2W+Z0sPQwX6AF+fnBdEQ8iZZbKypiZhk5mjil45T3TAO3AK1dp4Kl+Ds6ByXqm2uIJTCc1eyGq/Ic8MrIoldjnrBd+rRB5qGJdStdb5qSxren/8QpwE7vztYG4WmgXE7gHMA5wDOwbWBpqG5cTuahlau8QvfTn8O4BzAOYBzAOegSc7HOArzeeKkeLtyfR1xGmqx3fx8eTlF4YoL/fqh0TTs6dufYRJkjJkgrtmNERTSe3svIMN/nVONV6mNxzBtCXEajrJza2KDlVlj679pdyPa2/9pxzodY3XyT/EY3Io64jQcYueDVRY1t55P7oVP6fw6U1EoxsC179ufz+pIYxHCghx1IddLYwc435j+vDX7IgRd5A0g8ezz87ypS+qr+NtTtx6bupQdmTtkXzsPlGSBqiG3d1RBhxmDrVgn4bpxNA0FuNpaZ1n1GMDw/vyLOA3Y+d3B2ig0DYzbAZwDOAdwDq4NNA3NjdvRNFz4TKoifhKngf4cwDmAcwDnAM4BnC+iVgCRUzpkV+OgaZjBQfPzzQQQ6drQNJzWt5cKIAaVgy9mcLyBE4EFAz+tnVt7LBFA6KSYwakgVEpg4ifkXLJhGwodeLicOlI94NpP3J/XBdJaEEBM62Gh/Ky+PWWx60Z/Y1QHBm8XmZ+vN/UgdoOjioDa89p5kQDC2m4Q9MGNGzGEc8C3L6GRtc68PydOA779/vjmTFrjHE3D6cbtAM4BnAM4B4zhlufnEI2m4bBHI4cBTQP9OYBzAOcAzgGcg4Y5n/nd3owsQbIbs4nJXe76GZY857Hn/FzvVj+ahl19u0zxFrzIClP4BS/agqdqsEEaXH2CH93BD9PQ+REdBAM/yM6neAteLAU/SMOkRXDzddoXJqSiOwTKhsis0TQcMobTJS5dFxRPRmrQ/i4b0SEsh2s/pD+XFwvOjO/8rcSiWSg/hnP9WsFRphBvBFuukoHB2+Hz8xdNfdnSdXAz7DVHwM6TQ7lAfjAM00I6vHy9iTqBG8QpqMV15s4Wvr0Ol9c0FJFreH9+I00D9tygnReBtVHEaWDcDuAcwDmAc3BtoGlobtxOnIbNvd9JH9GgaaA/B3AO4BzAOYBzAOdZLIVnkOI93tIY4jRUYdf5uXg/47kdiNNwAd/uqR08kYMfsCGx7fySr8yIJcBJ7Hw0Sleg0HkahkCfEAZw8Gx3RvOAiZ+Gcz38wrorUJj9+XadUTbki2ivHwHH2/nYn0vFOK58XBcNHcBJxnBLtOvEcCxbG533hebns9Ys/pdQsiAFlo6Zn60/9yUJw64wTEOfZPOmtl3NQ6fx7UU4yVrnN1NkeH9OnAbs/PZgbRSaBsbtAM4BnAM4B3AO4BzAOYBzAOfvhzm4/LkqwM6xcwDn4H7gvVoraO292qs3tnnVME5QAb6d/hzAOWAMB+40oH20cqH9OM78/Vs6HprKPD+ritpxk1p3bDvuUsVn0O+yZ507aCOcm/7Kn3/FlI+tpYat8qLedGHNsW1x05WegQmuNHtQ+vOl+d36WZJRm92smx7t0RyV1UyY1fSb8MFA/bFV8Rmo4gtui3Nl/v5M8bh1dO2/n7VFu6nkymNH9aw6g1SZxuxcdVNvV+niVxRVLx/71TNIl2muP69pMfOiZ369W1GvjxDiMozhCjrT9fPDreaZPJNZPz/vx8Fl1+zMjmuLRhP8tRWompNPzc8TZQzP4dpzX/j29gDncA7gHMA5gHNwPTzeN/UH54JKcM5M/d7Tcnw7/TmAcwDnAM7BPeZqM7O2s4zoObG3cR5a//dZT/frNCf2z9/8wbcDOAeX4Nyk+60+0RR0dFEeY2yqWeofq8/sBE+Skydm4ks2O7dYMefqebzU0GR2Meacukrls6lbPPw3c42lDmuxet9unnfb+BGkjzeiGW9p42U1bk4T3Ly5iiuaeKwhdapmf9NXwYlE9mqGkzLGOoH3t9ij4gLUKJ6yGjh756aEVUb5e9xtZcuZQMrXizbWLeWe/qIaN5GPrbwZ/RZwT9B4bbBPi33U3LVq0Qv9CWWe/wcZVLYTSPm6teSk/aY6bsqcdrgq/K4Su97YYo8VHnS8GlV+4apglFFdcWl/euDYYJW7eneLPdYaU4WzHLIuKK2MI67fiHTlVXwhvLfFPlbaj5m5sYOb2xSPbc0qo0zMKEzJFPNA777QOG9uscdKv2MdysBw3sOEWf2cykw7+z2m+sYNDu3WOJyqOpb0qLGcMzX7t5ijXTLZSHvfamlU+pahbiI1fN5+mncs4fN2VXpdm7XeUkXT/i1+Q0i9gXRz17V5XmOZDWcTFS22xW8OvIGf+y7HVG+6yoq60px/n7XFvs56Yj8Xuu0el7IyTmwL8C61PcA5nAM4B3AO4BxcD+5cDTFyc5wjRca3AzgHcA7gHMA5gHMA5wCAnfA/oCoXjLRIM8cAAAAASUVORK5CYII=</FILE>
</FIGURE>
<FIGURE FILENAME="Mortality 12 trials corrected.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-08-04 18:01:32 +0200" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>O&#8217;Brien-Fleming monitoring boundaries for assessing statistical significance for overall mortality. The solid blue curve presents the cumulative meta-analysis test-score and the inward sloping red curves present the adjusted threshold for statistical significance - the two-sided O'Brien-Fleming boundaries. </P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Bacterial mortality corrected.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2010-08-04 18:01:52 +0200" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>O&#8217;Brien-Fleming monitoring boundaries for assessing statistical significance for mortality from bacterial infections. The solid blue curve presents the cumulative meta-analysis test-score and the inward sloping red curves present the adjusted threshold for statistical significance - the two-sided O'Brien-Fleming boundaries. </P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Bacterial infection corrected.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2010-08-04 18:02:03 +0200" MODIFIED_BY="[Empty name]" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>O&#8217;Brien-Fleming monitoring boundaries for assessing statistical significance for bacterial infections. The solid blue curve presents the cumulative meta-analysis test-score and the inward sloping red curves present the adjusted threshold for statistical significance - the two-sided O'Brien-Fleming boundaries. </P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-07-28 12:28:50 +0200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-07-28 12:28:50 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-06-24 16:02:50 +0200" MODIFIED_BY="[Empty name]">Search Strategies</TITLE>
<APPENDIX_BODY MODIFIED="2010-07-28 12:28:50 +0200" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Time span</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search strategy</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Hepato-Biliary Group Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>June 2010</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(antibiotic* OR antibacteri*) AND (bleed* OR hemorr* or haemorr*) AND cirrho*</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cochrane Central Register of Controlled<BR/>Trials (CENTRAL) in The Cochrane Library</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 2, 2010</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 MeSH Descriptor antibiotic-prophylaxis explode all trees in MeSH products<BR/>#2 antibiotic* in All Fields in all products<BR/>#3 antibacteri* NEAR prophyl* in All Fields in all products<BR/>#4 (#1 OR #2 OR #3)<BR/>#5 MeSH descriptor Gastrointestinal Hemorrhage explode all trees in MeSH products<BR/>#6 bleed* in All Fields in all products<BR/>#7 haemorr* in All Fields in all products<BR/>#8 hemorr* in All Fields in all products<BR/>#9 (#5 OR #6 OR #7 OR #8)<BR/>#10 MeSH Descriptor Liver Cirrhosis explode all tress in MeSH products<BR/>#11 cirrho* in All Fields in all products<BR/>#12 (#10 OR #11)<BR/>#13 (#4 AND #9 AND #12)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1950 to June 2010</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 explode antibiotic-prophylaxis /All subheadings<BR/>#2 antibiotic* prophyl*<BR/>#3 antibiotic* pre<BR/>*#4 #1 or #2 or #3<BR/>#5 explode liver-cirrhosis /All subheadings<BR/>#6 liver cirrho*<BR/>#7 hepatic cirrho*<BR/>#8 liver fibro*<BR/>#9 #5 or #6 or #7 or #8<BR/>#10 explode gastrointestinal-hemorrhage /All subheadings<BR/>#11 gastr* hemorrhage<BR/>#12 gastr* haemorrhage<BR/>#13 gastr* bleeding<BR/>#14 #10 or #11 or #12 or #13<BR/>#15 random* or blind* or placebo* or meta-analysis<BR/>#16 #4 and #9 and #14 and #15</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1980 to June 2010</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 explode &#8220;antibiotic-prophylaxis&#8221;/all subheadings<BR/>#2 antibiotic*<BR/>#3 antibacteri* prophy*<BR/>#4 #1 or #2 or #3<BR/>#5 explode &#8220;gastrointestinal-hemorrhage&#8221;/all subheadings<BR/>#6 hemorr*<BR/>#7 haemorr*<BR/>#8 bleed*<BR/>#9 #5 or #6 or #7 or #8<BR/>#10 explode &#8220;liver-cirrhosis&#8221;/all subheadings<BR/>#11 cirrho*<BR/>#12 #10 or #11<BR/>#13 #4 and #9 and #12<BR/>#14 random* or blind* or placebo* or meta-analysis<BR/>#13 #13 and #14</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Science Citation Index EXPANDED<BR/>(http://apps.isiknowledge.com)</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1945 to June 2010</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 TS=(antibiotic* OR antibacteri* prophyl*)<BR/>#2 TS=(bleed* or hemorr* or haemorr*)<BR/>#3 TS=(cirrho*)<BR/>#4 #3 AND #2 AND #1<BR/>#5 TS=(random* or blind* or placebo* or meta-analysis)<BR/>#6 #5 AND #4</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>